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Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia with an estimated 
prevalence ranging from 4.4% in persons aged 65 years to 22% at ages 90 and 
older [1]. Age is the most important risk factor for AD but also other factors like 
genetic factors (see below) play an important role. AD is clinically characterized by 
insidious onset and progressive impairment of memory and other cognitive functions 
[2]. Classically, abundant neurofibrillary tangles (NFT) (Fig. 1), composed of the 
hyperphosphorylated microtubule-associated protein (MAP) tau and accumulation 
of extracellular senile plaques made out of β-amyloid deposition (Aβ) (Fig. 1),  are 
known as the key neuropathological features of AD [3]. 
Accumulation of extracellular senile plaques made out of Aβ as a central event in 
AD is formulated as ‘the amyloid hypothesis’. The basis of this theory originates 
from genetic studies where it has been found that mutations in the amyloid precursor 
protein (APP) and presenilin 1 and 2 (PS1, PS2) cause rare, early onset (before the 
age of 60 to 65) autosomal-dominant inherited familial AD (FAD) [4-7]. Mutations 
in all of these three genes can cause altered production of Aβ via the amyloidogenic 
pathway (Fig. 2) [8] and therefore have provided insight into the underlying molecular 
mechanisms operating in AD. In the amyloidogenic pathway proteolytic processing 
of APP by β-site APP cleaving enzyme (BACE1) followed by γ-secretase (which 
includes PS1, PS2, Nicastrin, anterior pharynx-defective 1 (APH-1), and presenilin 
enhancer 2 (PEN2) [9]) generates an APP intracellular domain (AICD) [10] and Aβ 
peptides which accumulate into senile plaques as seen in AD [11] (Fig. 2). Multiple 
studies have shown that deposition of Aβ is neurotoxic and/or neuroinflammatory and 
Figure 1. Image shows the two main pathological hallmarks in Alzheimer’s disease. (A), Extracellular deposits of 
Aβ plaques and (B) tangles, the intracellular aggregates composed of a hyperphosphorylated form of the microtubule-
associated protein tau. Figure adapted from Blennow et al. [114].
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is therefore believed to be one of the causes of synaptic dysfunction and subsequent 
neuronal cell death, thereby contributing to memory loss and other symptoms [12]. 
However, paradoxically, a neuroprotective role for Aβ is also currently debated and 
compatible with a promising new theory: the “two hit hypothesis”, which will be 
discussed later.
While the fully penetrant mutations in APP, PS1, and PS2 were identified as causal 
factors in FAD, late-onset Alzheimer's disease (LOAD, above the age of 65) shows 
less-obvious or no apparent familial aggregation. Therefore, susceptibility for LOAD 
is likely caused by an array of risk alleles and/or environmental factors, which may 
act through various pathways eventually leading to e.g. defects in the production, 
deposition, and removal of Aβ (Fig 3). Understanding of how these risk alleles, 
Figure 2. Amyloidogenic and the non-amyloidogenic pathway. In the non-amyloidogenic pathway, APP is cleaved within 
the Aβ domain (light pink) by the γ-secretases ADAM9, 10 or 17. Two fragments are released, the larger ectodomain 
(sAPPβ) and the smaller carboxy-terminal fragment (C83). APP molecules that are not cleaved by the non-amyloidogenic 
pathway become a substrate for γ-secretase (β-site APP cleaving enzyme 1; BACE1), releasing an ectodomain (sAPPβ), 
and retaining the last 99 amino acids of APP (known as C99) within the membrane. The first amino acid of C99 is the 
first amino acid of Aβ. C99 is subsequently cleaved 38–43 amino acids from the amino terminus to release Aβ, by the 
γ-secretase complex, which is made up of presenilin 1 or 2, nicastrin, anterior pharynx defective and presenilin enhancer 2. 
LRRTM3 promotes APP processing via BACE1 through a mechanism currently unknown. STOX1A has been shown to 
operate upstream of LRRTM3. AICD, APP intracellular domain; APH-1, anterior pharynx defective; PEN2, presenilin 
enhancer 2; LRRTM3, Leucine-rich repeat transmembrane 3; STOX1A, Storkheadbox 1A. Figure adapted from Laferla 
et al. [115]
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environmental factors and their underlying pathways operate in LOAD could also help 
explain the presence of the second key hallmark in LOAD, the NFT. Interestingly, as 
for Aβ, the “two hit hypothesis”, which will be discussed later, has also provided insight 
in a possible underlying mechanism, which explains NFT formation in LOAD. 
In conclusion, research has been primarily focusing on the understanding of the genetic 
etiology of LOAD, such as Apolipoprotein E gene (APOE), and its pathological 
hallmarks; Aβ deposition and the NFT. In the next chapter is it discussed how 
hyperphosphorylated tau proteins, the main constituents of NFT, also play a central 
role in AD and other neurodegenerative diseases. 
 
Tau protein and neurodegeneration
Senile plaques composed of Aβ are not the only pathological features found in 
early onset FAD and LOAD. A second key pathological feature in AD (but also in 
several other neurodegenerative diseases as shown below) are paired helical filaments 
(PHF) and straight filaments (SF) accumulated as intra-neuronal NFT (Fig. 1) and 
as neuropil threads or dystrophic neurites in dendrites and axons. Eventually these 
neurons die, leaving behind extracellular NFTs or so called “ghost tangles” [13, 14]. 
The number of NFT directly correlates with the presence and the degree of dementia 
in AD [15-17] and therefore NFT count is also used to diagnose the progression 
of AD. According to the Braak-staging system six histopathological stages can be 
discriminated [18].  The transentorhinal stages I-II: clinically silent cases; limbic 
stages III-IV: incipient Alzheimer's disease; neocortical stages V-VI: fully developed 
Alzheimer's disease [18].
The major component of NFT consists of the hyper-phosphorylated microtubule-
associated protein (MAP) tau [19-22]. The main importance of normal tau protein in 
the binding and stabilization of microtubules was first described in the mid 1970s [23, 
Figure 3. Scheme of contribution and interaction pattern of known and putative AD genes. (A) Known early onset risk 
AD genes where mutations lead to altered production of Aβ. (B) Simplified model showing an array of risk alleles and/
or non-genetic environmental factors which may act through various pathways eventually leading to e.g. defects in the 
production, deposition and removal of Aβ. Figure adapted from Bertram et al. [102].
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24] but new functions of tau in maintaining neuronal cell shape and axonal transport 
are emerging rapidly [25]. Tau is a phospho-protein and therefore its activity is 
regulated through phosphorylation. However, when hyper-phosphorylated as seen in 
NFT, tau has been shown to reduce its ability to promote microtubule assembly [26], 
a process, which has also been found to be impaired in brain extracts from AD cases 
[27]. Furthermore, studies in transgenic mouse models have shown that the abnormal 
hyper-phosphorylation of tau is an early change that precedes neuronal cell loss and 
the formation of NFT inclusions [28, 29]. Therefore, for the last decades there has been 
a tremendous increase of interest in the physiological and pathological role of tau and 
its hyper-phosphorylation in neurodegenerative diseases, in particular the activities of 
protein kinases and protein phosphatases, which regulate the phosphorylation status 
of tau protein. 
NFT are not exclusively found in AD but also in other neurodegenerative disorders 
including Pick’s disease, progressive supranuclear palsy (PSP), corticobasal 
degeneration, argyrophilic grain disease, and hereditary frontotemporal dementia 
and parkinsonism linked to chromosome 17 (FTDP-17), collectively referred as 
tauopathies [30]. In the latter group of disorders NFT are not exclusively neuronal, 
but are also found in glial cells such as oligodendrocytes and astrocytes [30-32]. 
The relevance of tau in neurodegeneration is emphasized by studies where multiple 
mutations in the tau gene identified from FTDP-17 patients have provided evidence 
that tau abnormalities alone are sufficient to cause neurodegeneration [33-35]. 
Subsequently, today more than 35 pathogenic mutations in the tau gene have been 
identified from FTDP-17 patients and related neurodegenerative diseases [36-
40]. These mutations can be classified into two groups. The first group consists of 
mutations, which are associated with the direct impairment in the ability of tau to 
bind and promote the polymerization and stability of microtubules [41]. The second 
group of mutations have been shown to affect alternative splicing of tau exon 10 
via splicing cis-elements, splicing enhancers, or via destabilization of the stem loop 
structure of tau pre-mRNA [42]. The loss in binding ability of tau to microtubules 
is shared in both groups and is believed to produce an increase in the levels of free 
tau proteins in the neuronal cytoplasm. Subsequently, the free tau proteins are hyper-
phosphorylated at residues that make tau more fibrillogenic, which increases NFT 
formation and consequently leads to neurodegeneration [30, 43]. While the second 
group of mutations by itself are sufficient to trigger neurodegeneration in FTDP-17 
patients, there is an increasing interest in understanding the underlying mechanisms 
that regulate alternative splicing of tau exon 10. 
Tau exon 10 splicing
Molecular cloning has identified six tau isoforms in human brain tissue that are 
produced from the tau gene by alternative mRNA splicing [44]. They differ from each 
other by the presence of either three (3R-tau) or four (4R-tau) microtubule binding 
repeat sequences in the carboxy-terminal (C-terminal) part of the molecule and 
the absence or presence of one or two inserts (29 or 58 amino acids) in the amino-
terminal (N-terminal) part [45]. Not surprisingly, it has been shown that 4R-tau has a 
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greater microtubule binding affinity than 3R-tau and therefore promotes microtubule 
assembly better [46, 47]. The presence of 3R-tau or 4R-tau depends on exclusion 
(3R-tau) or inclusion (4R-tau) of tau exon 10 and is developmentally (and cell type-
specifically) regulated. In fetal brain >95% of tau mRNA consists of 3R-tau and in 
adult human brain, the ratio of 3R-tau to 4R-tau isoforms is about 1 [46, 48]. The 
shift from abundant 3R tau to an equal ratio between 3R and 4R tau isoforms is 
potentially associated with a switch from a more dynamic to a more stable microtubule 
network necessary for the development of the brain [49, 50]. Several tauopathies show 
de-regulation of 3R-tau and 4R-tau isoform expression altering the 3R/4R tau ratio. 
This includes corticobasal degeneration and progressive supranuclear palsy (PSP) 
which mainly show 4R-tau pathology [51], while in Pick’s disease there is abundant 
3R-tau pathology [52-54]. There is still a debate on whether tau isoform patterns are 
specific for LOAD. Currently, several studies have failed to show a direct correlation 
between the 4R/3R ratio and tau pathology in LOAD patients [55-57], yet another 
study demonstrated that in the temporal cortex of many LOAD brains, production of 
4R-tau is significantly elevated [58]. Nevertheless, it is becoming clear that abnormal 
splicing of tau exon 10, is probably one of the mechanisms by which tau accumulates 
and aggregates into NFT in tauopathic brains. 
Summarized, a combination of two major hallmarks (Aβ and NFT) characterizes 
LOAD pathology. In the last decade it became clear that these hallmarks are the result 
of other pathological changes, which occured very early in the disease progression of 
LOAD [59]. Specifically, both oxidative stress [60, 61] and cell cycle markers [62] in 
LOAD neurons are found to precede Aβ and NFT pathology. Together these findings 
have led to a very promising new hypothesis which can be seen as a cause rather than 
a consequence for the typical hallmarks seen (Aβ and tau) LOAD pathology [60, 63, 
64]. The next chapters will discuss this theory, which is based on abnormal neuronal 
cell cycle re-entry.
The cell cycle and Alzheimer’s disease
The eukaryotic cell cycle can be distinguished into two main stages, the interphase 
and M (mitotic) stage. Additionally, when cells are in a non-dividing quiescent state, 
they reside in the G0 phase of the cell cycle. The interphase consists of 3 major 
phases (the G1, S, and G2 phase) where the cells are prepared for cell division. The M 
phase sequentially progresses into the prophase, metaphase, anaphase, and telophase, 
immediately followed by cytokinesis which eventually results in two identical daughter 
cells [65]. The transition into each of the G1, S and G2/M phases is driven by the 
tightly regulated activation of cyclin dependant kinases (CDKs) upon phosphorylation 
at specific residues. The phosphorylation of CDKs induces conformational changes 
which enhances the binding towards their activating binding partners cyclins [65-67].
In general, during the G1 phase, the start of the cell cycle is initiated by activation of 
CDK4/CDK6 bound to cyclin D by mitogenic signals, such as extracellular growth 
factors or intercellular contacts. Furthermore, the activated CDK4/CDK6/cyclinD 
complex also controls re-entry of resting (G0) cells into the G1 phase of the cell cycle 
[68]. G1 to S phase progression is then controlled by CDK2 bound to S-phase cyclins 
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[69] (E- and A-type) and G2 to M phase is triggered by CDK1 associated with 
mitotic cyclins [70] (A- and B-type). Only in complex with these cyclins, the CDKs 
can form an active kinase. 
Cyclins, in contrast to fairly stable protein expression levels of CDKs, are differentially 
expressed throughout the cell cycle and degraded at specific phases by ubiquitin-
mediated cyclin proteolysis. Reversely, in G1 phase, CDK activity is negatively 
regulated by specific CDK inhibitors (CDKIs). These CDKIs consists of two groups, 
the INK4 family which includes p15 (INK4b), p16 (INK4a), p18 (INK4c), p19 
(INK4d), and the Cip/Kip family which includes p21 (Waf1, Cip1), p27 (Cip2), and 
p57 (Kip2) [65, 66]. During S and G2 phase, CDK1, which is less sensitive to CDK 
inhibitors (CDKIs), is kept inactive by Wee1/Myt kinases [71-73]. 
When CDKs are active they are capable of phosphorylating target proteins on CDK 
consensus sites which in turn may regulate expression of cell cycle associated genes 
such as cyclins [65, 66]. Three CDKs target proteins have been shown to be forkhead 
transcription factors, FOXM1  [74] , FOXO1 [75],  and FOXK2 [76], all shown to be 
regulated by CDK1 [74-76].
Cell division in most of our body cells is driven by the repeated cycling of G1, S, G2, 
and the M phase, this in contrast to most neurons in the adult brain, which in general 
are thought to reside in the quiescent state of the cell cycle (G0). However, during 
early development of the central nervous system (CNS) there is a well-regulated 
pattern of regular cell division. The process begins with a few hundred of ectodermal 
cells, which rapidly develop into as many as hundred billion of neurons in the adult 
CNS. This process of neurogenesis has been shown to take place in a tightly packed 
layer of nuclei lining the lumen of the neural tube (the ventricular zone, VZ) and later 
in the closely opposed region known as the subventricular zone (SVZ) [77]. When the 
neurons emigrate from the VZ and SVZ they lose their capacity to divide and become 
mature differentiated non-dividing cells (G0) not capable of re-entering the cell cycle 
[77]. However, as increasing evidence indicates, neurons in AD patients appear to 
have emerged from this post-mitotic state showing an activated cell cycle phenotype 
rather than a silent one [64].
Interestingly, while markers of each stage of the cell cycle (G1, S, G2, and M –phase) 
are found in AD neurons, there is no actual evidence which has shown the completion 
of a successful mitosis [64]. Furthermore, in contrast to the highly organized nature 
of a regular cell cycle, a highly un-organized nature of the cell cycle is observed in 
affected neurons in AD [64]. A prominent example is that the expression of most of 
these cell cycle markers are found in the cytoplasm rather than in the nucleus where 
they act [78]. In conclusion, it seems that post-mitotic neuronal cells in AD can re-
enter the cell cycle, however, being an abortive and de-regulated cell cycle [64]. 
Recently, a hypothesis has been developed explaining why neuronal cell cycle re-
entry in LOAD avoids apoptosis to gain an “immortality” analogous to tumor cells 
[60, 63]. Normally, a mitotic stimulus in post-mitotic neurons leads to cell cycle re-
entry resulting in apoptosis and cell death before mitosis can even occur. In contrast, 
the hypothesis explains why a neuronal cell cycle re-entry in LOAD initially avoids 
apoptosis to gain an “immortality” analogous to tumor cells [60, 63]. This steady state 
of “immortal” LOAD neurons mirrors the pathological hallmarks seen in AD (Aβ 
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and NFT). 
The above hypothesis, the “two hit hypothesis”, was proposed [60] by its similarities 
with the “two hit hypothesis” in cancer [79] and helps explain why a healthy neuron 
becomes a LOAD neuron. The reason for the differences in pathological outcomes 
between cancer and LOAD has been suggested to lie in their alternative usage of the 
MAPK pathway [80]. 
The “two hit hypothesis” in LOAD
In the “two hit hypothesis” it is suggested that a combination of both oxidative stress 
and cell cycle aberration is necessary for a normal neuron to become a LOAD neuron 
[60, 63, 64]. The sequence of events can begin with either one, leading to the other. This 
results in an “immortal” neuronal cell that can survive for decades. This “immortality” 
of a LOAD neuron compared to a normal neuron can be explained by the findings 
that excessive oxidative stress inhibits downstream propagation of caspase-mediated 
apoptotic signals [81]. Also, evidence for deregulated apoptotic signalling in LOAD 
has been found by Raina et al. [82, 83]. Together, this suggests that a combination of 
the two hits might produce a neuron, which has activated its cell cycle machinery but 
fails to progress through the cell cycle or divide. While such cell may normally die, 
the avoidance of apoptosis would initially prevent cell death and causes the neuron 
to remain in a “steady state” of partial cell cycle progression. This “steady state” of 
partial cell cycle progression in which neurons can remain for decades, could result 
in the excessive phosphorylation of tau proteins by e.g. activated mitotic kinases and 
therefore initiate the formation of NFT. Accordingly, overexpression of the myc 
oncogene, which forces post-mitotic neurons to re-enter the cell cycle, results in tau 
changes similar to those seen in LOAD neurons [84, 85]. 
The “two hit hypothesis” also gives a new meaning to the role for Aβ in LOAD 
pathology. While it is generally believed that Aβ aggregation and deposition is toxic 
and therefore causes neuronal cell death, there is currently a debate on whether this 
is actually true. This debate has arisen from the finding that Aβ has anti-oxidative 
properties [86, 87]. Because of this feature it has been suggested that Aβ actually has a 
protective effect shielding neurons from oxidative damage [88, 89]. In the view of the 
“two hit hypothesis” this would mean that in response to the accumulation of oxidative 
damage in LOAD neurons, production of Aβ could be induced to neutralize future 
free radicals and therefore actually tries to protect the neuron from oxidative damage. 
Taking into account that Aβ itself has been found to be mitogenic [90], the production 
of Aβ in response to excessive oxidative damage could initiate neuronal cell cycle 
re-entry. Furthermore, Aβ itself and/or the excessive amounts of oxidative damage 
can also cause deregulated expression of transcription factors. An example for this 
is the transcription factor SP1 which was found to be regulated by oxidative stress 
[91]. Upregulation of SP1 can regulate the expression of several AD-related proteins, 
including APP [92]. 
The induction of cell cycle proteins itself can in turn also control expression of 
transcription factors. E.g. aberrant expression of the mitotic kinase CDK1 and its 
binding partner cyclin B1 have been found in degenerating neurons of AD [78]. 
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Active CDK1 has been shown to regulate transcription factor activity [74-76]. CDK1 
dependent activation of brain specific transcription factors could initiate transcriptional 
programs, which drive the cell cycle machinery itself and therefore could results in 
a positive feedback loop. Large amounts of cell cycle dependent kinases could then 
phosphorylate tau resulting in NFT formation. 
Together, eventually, after several of the above events, the accumulation of excessive 
Aβ deposition and hyperphosphorylation of tau (as a result of accumulated active 
mitotic kinases) does become toxic to the cells and finally leads to successful apoptosis 
and neuronal death. 
In conclusion, the “two hit hypothesis” explains why a combination of oxidative stress 
and neuronal cell cycle abnormalities can result in the typical pathological hallmarks 
seen in LOAD. Because these events seem to appear very early in the disease 
progression of LOAD [59] and precede formation of Aβ and NFT’s, insight into 
exact mechanisms that induce and mediate these cell cycle events might eventually 
enable the prevention or even reversal of the disease. 
STOX1, a transcription factor related to the family of forkhead 
transcription factors
Shown above, one of the factors that may contribute to the production of Aβ is 
the abnormal regulation of gene transcription. This may be the result of oxidative 
damage, which induces the expression of transcription factors, as shown for SP1. The 
cell cycle machinery itself is also capable of regulating the activity of transcription 
factors, and when activated can drive expression of cell cycle regulatory proteins itself 
[74-76]. Abnormal activation of transcription factors may therefore potentially cause 
transcription of genes that are directly or indirectly involved in the production of Aβ 
and formation of NFT. This feature makes them interesting targets for therapeutic 
intervention.
Recently, transcription factor STOX1 has been found to be associated with LOAD. 
Paradoxically, STOX1 was initially discovered as a gene associated with Pre-eclampsia 
which is a pregnancy-associated disease occurring in 5–8% of pregnancies which 
threatens the lives of both mother and fetus [93]. Genome wide linkage studies 
have shown that linkage for pre-eclampsia in Dutch females resides in a region on 
Figure 4. Transcriptional organization of STOX1. By differential donor splice site use, exon 3 skipping and alternative 
use of exon 5, six different transcripts are generated (A–F) that encode three different proteins; STOX1A, STOX1B and 
STOX1C. Identical colors in exons indicate identical protein sequences. Exon 1 contains the bihelical NLS (gray). Exon 2 
and first part of exon 3 contain the DNA-binding winged helix domain (green). The blue box in exon 3 contains the nuclear 
export sequence. Figure adapted from van Dijk et al. [95].
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chromosome 10q22 [94, 95]. In-depth analysis of this region resulted in the discovery 
of STOX1, the Dutch pre-eclampsia susceptibility gene [95]. 
The STOX1 gene contains a winged helix domain structurally and functionally similar 
to that of the forkhead family of transcription factors and expresses 3 isoforms; 
STOX1A, STOX1B, and STOX1C. STOX1A (the full length isoform) and STOX1B 
express the complete winged helix domain while STOX1C expresses only part of it 
(Fig. 4). Furthermore, only STOX1A contains both a nuclear localization (NLS) and 
a nuclear export signal (NES, Fig. 4). In the forkhead family of transcription factors, 
these dual control sequences, among other factors, regulate nuclear-cytoplasmic 
shuttling [96]. Therefore the main focus of research lies with STOX1A as this isoform 
contains all the regulatory domains for its functioning. For several transcription 
factors of the forkhead family nucleo-cytoplasmic shuttling is regulated by Akt (also 
known as Protein Kinase B, PKB) phosphorylation, in turn influencing their activity 
[97-100]. A recent study elucidates the functional similarities of STOX1A with 
members of the forkhead transcription factor family [101]. In this study it was shown 
that STOX1A, when phosphorylated by Akt, is inhibited from entering the nucleus 
and is subsequently degraded by ubiquitin-mediated proteolysis [101]. Besides the 
inactivation of STOX1A through degradation, exclusion from the nucleus prevents 
the ability of STOX1A to bind to DNA and therefore loses its transcriptional 
activity. In contrast, when STOX1A is located in the nucleus it can perform its 
transcriptional activity through specific binding to target genes, which in turn can be 
expressed or suppressed. In conclusion, STOX1A, identified as a susceptibility gene 
for pre-eclampsia, shows several similarities with members of the family of forkhead 
transcription factors. Interestingly, one of its target genes LRRTM3 is involved in 
LOAD pathology.
STOX1A and Alzheimer’s disease
It becomes clear that LOAD is a multi-factorial and heterogeneous disease which 
involves many potential risk genes. With the exception of APOE as a confirmed risk 
gene for LOAD, there are several hundreds of other potential risk genes described 
[102]. These genes reside on several different chromosomal loci with potential 
linkage for LOAD as discovered by genomic screening. These include loci on 
chromosomes 9 [103], 10 [103-106], and 12 [103, 107] (Fig. 3B). The leucine-rich 
repeat transmembrane 3 (LRRTM3) gene mapping to the locus on chromosome 10 
(10q22) has previously been shown to be linked to LOAD [104, 105, 108]. A detailed 
study of this gene showed that LRRTM3 promotes APP processing via BACE1 and 
therefore increases the production of Aβ via the amyloidogenic pathway [108] (Fig 
2). In a recent study it was found that STOX1A is expressed abundantly in the brain 
and the expression level correlates with the severity of LOAD [109]. Interestingly, it 
was also shown that LRRTM3 is selectively transactivated by STOX1A. This resulted 
in increased APP processing via BACE1, thereby enhancing the production of the 
Aβ peptide. Together, it was shown for the first time that STOX1A is functionally 
involved in LOAD by acting upstream in the amyloidogenic pathway consequently 
1                                           1 · Introduction
             21
effecting the production of Aβ [109].
However, Aβ depositions in the brain without a second key pathological hallmark 
(the NFT as mentioned above) are not sufficient to produce LOAD clinically. In 
fact, several normal aged individuals have been shown to have similar amounts of 
Aβ plaques in the brain as typical cases of AD [15, 16, 110-112]. This elucidates 
the importance of the simultaneous deregulation and interplay between different 
pathways, their associated risk genes and their outcomes, which results in the typical 
LOAD pathology (Aβ deposition and NFT). 
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Aims and outline
Previous studies have established a direct link between STOX1A, LRRTM3 and 
the amyloidogenic pathway, which plays a central role in LOAD pathology [3], 
[109]. However LRRTM3 alone cannot account for all the aspects associated with 
LOAD.  It becomes clear that LOAD is a multi-factorial and heterogeneous disease, 
which involves many potential risk genes. These genes may act through a variety of 
transcriptional networks, which results in its classical pathological outcomes (NFT 
and Aβ). Most likely these changes are preceded by a combination of oxidative 
stress, which increases with age, and cell cycle aberration as explained by the “two hit 
hypothesis”. 
While transcription factors like STOX1A regulate several hundreds of target genes 
and STOX1A is expressed abundantly in the brain and is associated with LOAD, 
the main objective of this thesis is the search and exploration of target genes that 
STOX1A directly or indirectly regulates. Discovery of such genes, pathways, and 
their associated biological functions could further unravel how STOX1A operates in 
transcriptional networks in the normal brain as well as in neurodegenerative diseases 
like LOAD. 
In the future, better knowledge of these transcriptional networks could elucidate the 
molecular mechanisms involved in LOAD, and may help design disease-modifying 
drugs.
In an initial study to search for direct STOX1A target genes we used chromatin 
immunoprecipitation shotgun cloning (ChIP-shotgun cloning) in a neuronal cell 
model overexpressing STOX1A. With the use of this procedure it is described in 
Chapter 2 how this resulted in the discovery of contactin-associated protein-like 2 
(CNTNAP2) as a direct gene target of STOX1A. Additionally, we used a relatively 
new technique called ChIP-sequencing (ChIP-Seq) to discover direct STOX1A 
target genes on a genome-wide scale. This technique, which involves Massively 
Parallel Sequencing (MPS), led to the discovery of several other potential directly 
regulated STOX1A target genes. One of the validated target genes was found to be 
transactivated by STOX1A in a cell type specific manner. This gene, serine/arginine-
rich splicing factor 7 (SFRS7), has previously been shown to modulate splicing of tau 
at exon 10. The in-depth functional and pathological consequences for STOX1A as an 
upstream target gene for SFRS7 are discussed in Chapter 3. 
While previous results already suggested a potential link between STOX1A and 
regulation of the cell cycle [109] and STOX1A is structurally and functionally similar 
to the family of forkhead transcription factors, of which several have been described 
to function in the cell cycle, we investigated a potential role for STOX1A in cell cycle 
regulation. The involvement of STOX1A in cell cycle events is explored in Chapter 4.
NFT, the second key hallmark of LOAD consists of hyper-phosphorylated tau 
protein. Interestingly, a near identical tau phosphorylation pattern, as found in NFT 
of LOAD, is suggested to be driven by kinases associated with the cell cycle machinery 
[62]. More specifically, Okadaic acid induced overexpression of cyclin B1 (CCNB1) 
has been shown to induce tau phosphorylation in vivo [113]. Therefore, with the 
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knowledge that STOX1A directly regulates CCNB1 expression during the cell cycle 
(Chapter 4), we speculated that STOX1A might, at least through activation of cell 
cycle related kinases, induce phosphorylation of tau proteins. A correlation between 
STOX1A expression and tau phosphorylation was tested and described in Chapter 5.
Together, these results have provided evidence for several direct (SFRS7, CNTNAP2, 
Integrin alpha-9 (ITGA9), CCNB1) and (in)direct (cyclin A1 (CCNA1), cyclin C1 
(CCNC1), cyclin E (CCNE), MAPT) downstream STOX1A target genes. The study 
of these STOX1A target genes has resulted in better understanding of its potential 
biological function. To expand this knowledge and to see how STOX1A operates on 
a genome wide level we also performed a transcriptome analysis with the use of MPS. 
In this study, genome-wide differential RNA expression effectuated by STOX1A 
overexpression in neuronal cells was investigated. The applied technique (RNA-seq) 
and its outcomes are described in Chapter 6.
1Introduction · 1
24
Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland 
JR, Dartigues JF, Jagger C, Martinez-Lage J et al: Prevalence of dementia and major 
subtypes in Europe: A collaborative study of population-based cohorts. Neurologic 
Diseases in the Elderly Research Group. Neurology 2000, 54(11 Suppl 5):S4-9.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical 
diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group 
under the auspices of Department of Health and Human Services Task Force on 
Alzheimer's Disease. Neurology 1984, 34(7):939-944.
Castellani RJ, Rolston RK, Smith MA: Alzheimer disease. Dis Mon 2010, 56(9):484-
546.
Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-
Pelfrey C, Lieberburg I, Selkoe DJ: Mutation of the beta-amyloid precursor protein 
in familial Alzheimer's disease increases beta-protein production. Nature 1992, 
360(6405):672-674.
Cai XD, Golde TE, Younkin SG: Release of excess amyloid beta protein from a mutant 
amyloid beta protein precursor. Science (New York, NY 1993, 259(5094):514-516.
Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy 
J, Hutton M, Kukull W et al: Secreted amyloid beta-protein similar to that in the 
senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 
and APP mutations linked to familial Alzheimer's disease. Nature medicine 1996, 
2(8):864-870.
Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, 
Harigaya Y, Yager D et al: Increased amyloid-beta42(43) in brains of mice expressing 
mutant presenilin 1. Nature 1996, 383(6602):710-713.
Tanzi RE, Bertram L: Twenty years of the Alzheimer's disease amyloid hypothesis: a 
genetic perspective. Cell 2005, 120(4):545-555.
Kaether C, Haass C, Steiner H: Assembly, trafficking and function of gamma-
secretase. Neuro-degenerative diseases 2006, 3(4-5):275-283.
Passer B, Pellegrini L, Russo C, Siegel RM, Lenardo MJ, Schettini G, Bachmann M, 
Tabaton M, D'Adamio L: Generation of an apoptotic intracellular peptide by gamma-
secretase cleavage of Alzheimer's amyloid beta protein precursor. J Alzheimers Dis 
2000, 2(3-4):289-301.
Haass C, Steiner H: Alzheimer disease gamma-secretase: a complex story of GxGD-
type presenilin proteases. Trends in cell biology 2002, 12(12):556-562.
Selkoe DJ: Alzheimer's disease is a synaptic failure. Science (New York, NY 2002, 
298(5594):789-791.
Bondareff W, Harrington C, Wischik CM, Hauser DL, Roth M: 
Immunohistochemical staging of neurofibrillary degeneration in Alzheimer's disease. 
Journal of neuropathology and experimental neurology 1994, 53(2):158-164.
Braak E, Braak H, Mandelkow EM: A sequence of cytoskeleton changes related to 
the formation of neurofibrillary tangles and neuropil threads. Acta neuropathologica 
1994, 87(6):554-567.
Alafuzoff I, Iqbal K, Friden H, Adolfsson R, Winblad B: Histopathological criteria 
for progressive dementia disorders: clinical-pathological correlation and classification 
by multivariate data analysis. Acta neuropathologica 1987, 74(3):209-225.
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT: Neurofibrillary tangles 
but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 
1992, 42(3 Pt 1):631-639.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
References
1                                           1 · Introduction
             25
Tomlinson BE, Blessed G, Roth M: Observations on the brains of demented old 
people. Journal of the neurological sciences 1970, 11(3):205-242.
Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta 
neuropathologica 1991, 82(4):239-259.
Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM: 
Microtubule-associated protein tau. A component of Alzheimer paired helical 
filaments. The Journal of biological chemistry 1986, 261(13):6084-6089.
Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI: 
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in 
Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences 
of the United States of America 1986, 83(13):4913-4917.
Kosik KS, Joachim CL, Selkoe DJ: Microtubule-associated protein tau (tau) is 
a major antigenic component of paired helical filaments in Alzheimer disease. 
Proceedings of the National Academy of Sciences of the United States of America 
1986, 83(11):4044-4048.
Wood JG, Mirra SS, Pollock NJ, Binder LI: Neurofibrillary tangles of Alzheimer 
disease share antigenic determinants with the axonal microtubule-associated protein 
tau (tau). Proceedings of the National Academy of Sciences of the United States of 
America 1986, 83(11):4040-4043.
Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW: A protein factor essential 
for microtubule assembly. Proceedings of the National Academy of Sciences of the 
United States of America 1975, 72(5):1858-1862.
Cleveland DW, Hwo SY, Kirschner MW: Physical and chemical properties of 
purified tau factor and the role of tau in microtubule assembly. Journal of molecular 
biology 1977, 116(2):227-247.
Morris M, Maeda S, Vossel K, Mucke L: The many faces of tau. Neuron 2011, 
70(3):410-426.
Yoshida H, Ihara Y: Tau in paired helical filaments is functionally distinct from fetal 
tau: assembly incompetence of paired helical filament-tau. Journal of neurochemistry 
1993, 61(3):1183-1186.
Iqbal K, Grundke-Iqbal I, Zaidi T, Merz PA, Wen GY, Shaikh SS, Wisniewski HM, 
Alafuzoff I, Winblad B: Defective brain microtubule assembly in Alzheimer's disease. 
Lancet 1986, 2(8504):421-426.
Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, 
Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X et al: Neurofibrillary tangles, 
amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) 
tau protein. Nature genetics 2000, 25(4):402-405.
Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer 
M, Craxton M, Emson PC et al: Abundant tau filaments and nonapoptotic 
neurodegeneration in transgenic mice expressing human P301S tau protein. J 
Neurosci 2002, 22(21):9340-9351.
Lee VM, Goedert M, Trojanowski JQ: Neurodegenerative tauopathies. Annual 
review of neuroscience 2001, 24:1121-1159.
Higuchi M, Zhang B, Forman MS, Yoshiyama Y, Trojanowski JQ, Lee VM: Axonal 
degeneration induced by targeted expression of mutant human tau in oligodendrocytes 
of transgenic mice that model glial tauopathies. J Neurosci 2005, 25(41):9434-9443.
Forman MS, Lal D, Zhang B, Dabir DV, Swanson E, Lee VM, Trojanowski JQ: 
Transgenic mouse model of tau pathology in astrocytes leading to nervous system 
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
1Introduction · 1
26
degeneration. J Neurosci 2005, 25(14):3539-3550.
Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-
Brown S, Chakraverty S, Isaacs A, Grover A et al: Association of missense and 
5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 
393(6686):702-705.
Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis 
A, Wiederholt WC, Raskind M, Schellenberg GD: Tau is a candidate gene for 
chromosome 17 frontotemporal dementia. Annals of neurology 1998, 43(6):815-825.
Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B: Mutation 
in the tau gene in familial multiple system tauopathy with presenile dementia. 
Proceedings of the National Academy of Sciences of the United States of America 
1998, 95(13):7737-7741.
Wilhelmsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG: Localization of 
disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. American 
journal of human genetics 1994, 55(6):1159-1165.
Wijker M, Wszolek ZK, Wolters EC, Rooimans MA, Pals G, Pfeiffer RF, Lynch 
T, Rodnitzky RL, Wilhelmsen KC, Arwert F: Localization of the gene for rapidly 
progressive autosomal dominant parkinsonism and dementia with pallido-ponto-
nigral degeneration to chromosome 17q21. Human molecular genetics 1996, 
5(1):151-154.
Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D'Amato CJ, Gilman S: 
Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus 
conference. Conference Participants. Annals of neurology 1997, 41(6):706-715.
Lendon CL, Lynch T, Norton J, McKeel DW, Jr., Busfield F, Craddock N, 
Chakraverty S, Gopalakrishnan G, Shears SD, Grimmett W et al: Hereditary 
dysphasic disinhibition dementia: a frontotemporal dementia linked to 17q21-22. 
Neurology 1998, 50(6):1546-1555.
Bird TD, Wijsman EM, Nochlin D, Leehey M, Sumi SM, Payami H, Poorkaj P, 
Nemens E, Rafkind M, Schellenberg GD: Chromosome 17 and hereditary dementia: 
linkage studies in three non-Alzheimer families and kindreds with late-onset FAD. 
Neurology 1997, 48(4):949-954.
Delobel P, Flament S, Hamdane M, Jakes R, Rousseau A, Delacourte A, Vilain JP, 
Goedert M, Buee L: Functional characterization of FTDP-17 tau gene mutations 
through their effects on Xenopus oocyte maturation. The Journal of biological 
chemistry 2002, 277(11):9199-9205.
Zhou J, Yu Q, Zou T: Alternative splicing of exon 10 in the tau gene as a target for 
treatment of tauopathies. BMC neuroscience 2008, 9 Suppl 2:S10.
Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR: Tau protein isoforms, 
phosphorylation and role in neurodegenerative disorders. Brain research 2000, 
33(1):95-130.
Goedert M, Spillantini MG, Crowther RA: Tau proteins and neurofibrillary 
degeneration. Brain pathology (Zurich, Switzerland) 1991, 1(4):279-286.
Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA: Multiple 
isoforms of human microtubule-associated protein tau: sequences and localization in 
neurofibrillary tangles of Alzheimer's disease. Neuron 1989, 3(4):519-526.
Goedert M, Jakes R: Expression of separate isoforms of human tau protein: 
correlation with the tau pattern in brain and effects on tubulin polymerization. The 
EMBO journal 1990, 9(13):4225-4230.
Butner KA, Kirschner MW: Tau protein binds to microtubules through a flexible 
array of distributed weak sites. The Journal of cell biology 1991, 115(3):717-730.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
1                                           1 · Introduction
             27
Gao QS, Memmott J, Lafyatis R, Stamm S, Screaton G, Andreadis A: Complex 
regulation of tau exon 10, whose missplicing causes frontotemporal dementia. Journal 
of neurochemistry 2000, 74(2):490-500.
Goode BL, Feinstein SC: Identification of a novel microtubule binding and assembly 
domain in the developmentally regulated inter-repeat region of tau. The Journal of 
cell biology 1994, 124(5):769-782.
Bullmann T, de Silva R, Holzer M, Mori H, Arendt T: Expression of embryonic tau 
protein isoforms persist during adult neurogenesis in the hippocampus. Hippocampus 
2007, 17(2):98-102.
Sergeant N, Wattez A, Delacourte A: Neurofibrillary degeneration in progressive 
supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively 
"exon 10" isoforms. Journal of neurochemistry 1999, 72(3):1243-1249.
Delacourte A, Robitaille Y, Sergeant N, Buee L, Hof PR, Wattez A, Laroche-
Cholette A, Mathieu J, Chagnon P, Gauvreau D: Specific pathological Tau protein 
variants characterize Pick's disease. Journal of neuropathology and experimental 
neurology 1996, 55(2):159-168.
Sergeant N, David JP, Lefranc D, Vermersch P, Wattez A, Delacourte A: Different 
distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's 
diseases. FEBS letters 1997, 412(3):578-582.
Chambers CB, Lee JM, Troncoso JC, Reich S, Muma NA: Overexpression of four-
repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's 
disease. Annals of neurology 1999, 46(3):325-332.
Connell JW, Rodriguez-Martin T, Gibb GM, Kahn NM, Grierson AJ, Hanger DP, 
Revesz T, Lantos PL, Anderton BH, Gallo JM: Quantitative analysis of tau isoform 
transcripts in sporadic tauopathies. Brain Res Mol Brain Res 2005, 137(1-2):104-
109.
Boutajangout A, Boom A, Leroy K, Brion JP: Expression of tau mRNA and soluble 
tau isoforms in affected and non-affected brain areas in Alzheimer's disease. FEBS 
letters 2004, 576(1-2):183-189.
Ingelsson M, Ramasamy K, Cantuti-Castelvetri I, Skoglund L, Matsui T, Orne J, 
Kowa H, Raju S, Vanderburg CR, Augustinack JC et al: No alteration in tau exon 10 
alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. Acta 
neuropathologica 2006, 112(4):439-449.
Glatz DC, Rujescu D, Tang Y, Berendt FJ, Hartmann AM, Faltraco F, Rosenberg C, 
Hulette C, Jellinger K, Hampel H et al: The alternative splicing of tau exon 10 and 
its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's 
disease. Journal of neurochemistry 2006, 96(3):635-644.
Yang Y, Varvel NH, Lamb BT, Herrup K: Ectopic cell cycle events link human 
Alzheimer's disease and amyloid precursor protein transgenic mouse models. J 
Neurosci 2006, 26(3):775-784.
Zhu X, Lee HG, Perry G, Smith MA: Alzheimer disease, the two-hit hypothesis: an 
update. Biochimica et biophysica acta 2007, 1772(4):494-502.
Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA: 
Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. 
Journal of neuropathology and experimental neurology 2000, 59(11):1011-1017.
Vincent I, Zheng JH, Dickson DW, Kress Y, Davies P: Mitotic phosphoepitopes 
precede paired helical filaments in Alzheimer's disease. Neurobiology of aging 1998, 
19(4):287-296.
Zhu X, Raina AK, Perry G, Smith MA: Alzheimer's disease: the two-hit hypothesis. 
Lancet neurology 2004, 3(4):219-226.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
1Introduction · 1
28
Bonda DJ, Lee HP, Kudo W, Zhu X, Smith MA, Lee HG: Pathological implications 
of cell cycle re-entry in Alzheimer disease. Expert reviews in molecular medicine 
2010, 12:e19.
Vermeulen K, Van Bockstaele DR, Berneman ZN: The cell cycle: a review of 
regulation, deregulation and therapeutic targets in cancer. Cell proliferation 2003, 
36(3):131-149.
Hochegger H, Takeda S, Hunt T: Cyclin-dependent kinases and cell-cycle transitions: 
does one fit all? Nature reviews 2008, 9(11):910-916.
Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP: 
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 
complex. Nature 1995, 376(6538):313-320.
Sherr CJ: G1 phase progression: cycling on cue. Cell 1994, 79(4):551-555.
Woo RA, Poon RY: Cyclin-dependent kinases and S phase control in mammalian 
cells. Cell cycle (Georgetown, Tex 2003, 2(4):316-324.
Porter LA, Donoghue DJ: Cyclin B1 and CDK1: nuclear localization and upstream 
regulators. Progress in cell cycle research 2003, 5:335-347.
L L Parker, P J Sylvestre, M J Byrnes, 3rd, F Liu, H Piwnica-Worms. Identification of 
a 95-kDa WEE1-like tyrosine kinase in HeLa cells. Proc Natl Acad Sci U S A. 1995 
October 10; 92(21): 9638–9642.
Mueller PR, Coleman TR, Kumagai A, Dunphy WG. Myt1: a membrane-associated 
inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. 
Science. 1995 Oct 6;270(5233):86-90.
King RW, Deshaies RJ, Peters JM, Kirschner MW: How proteolysis drives the cell 
cycle. Science (New York, NY 1996, 274(5293):1652-1659.
Major ML, Lepe R, Costa RH: Forkhead box M1B transcriptional activity requires 
binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of 
p300/CBP coactivators. Molecular and cellular biology 2004, 24(7):2649-2661.
Yuan Z, Becker EB, Merlo P, Yamada T, DiBacco S, Konishi Y, Schaefer EM, Bonni 
A: Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. Science 
(New York, NY 2008, 319(5870):1665-1668.
Marais A, Ji Z, Child ES, Krause E, Mann DJ, Sharrocks AD: Cell cycle-dependent 
regulation of the forkhead transcription factor FOXK2 by CDK.cyclin complexes. 
The Journal of biological chemistry 2010, 285(46):35728-35739.
Dehay C, Kennedy H: Cell-cycle control and cortical development. Nat Rev Neurosci 
2007, 8(6):438-450.
Vincent I, Jicha G, Rosado M, Dickson DW: Aberrant expression of mitotic cdc2/
cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J Neurosci 
1997, 17(10):3588-3598.
Knudson AG, Jr.: Mutation and cancer: statistical study of retinoblastoma. 
Proceedings of the National Academy of Sciences of the United States of America 
1971, 68(4):820-823.
Kim EK, Choi EJ: Pathological roles of MAPK signaling pathways in human 
diseases. Biochimica et biophysica acta 2010, 1802(4):396-405.
Hampton MB, Fadeel B, Orrenius S: Redox regulation of the caspases during 
apoptosis. Annals of the New York Academy of Sciences 1998, 854:328-335.
Raina AK, Zhu X, Rottkamp CA, Monteiro M, Takeda A, Smith MA: Cyclin' 
toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer 
disease. Journal of neuroscience research 2000, 61(2):128-133.
Raina AK, Hochman A, Zhu X, Rottkamp CA, Nunomura A, Siedlak SL, Boux H, 
Castellani RJ, Perry G, Smith MA: Abortive apoptosis in Alzheimer's disease. Acta 
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
1                                           1 · Introduction
             29
neuropathologica 2001, 101(4):305-310.
Lee HG, Casadesus G, Nunomura A, Zhu X, Castellani RJ, Richardson SL, Perry 
G, Felsher DW, Petersen RB, Smith MA: The neuronal expression of MYC causes a 
neurodegenerative phenotype in a novel transgenic mouse. The American journal of 
pathology 2009, 174(3):891-897.
Repetto E, Yoon IS, Zheng H, Kang DE: Presenilin 1 regulates epidermal growth 
factor receptor turnover and signaling in the endosomal-lysosomal pathway. The 
Journal of biological chemistry 2007, 282(43):31504-31516.
Hayashi T, Shishido N, Nakayama K, Nunomura A, Smith MA, Perry G, Nakamura 
M: Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to 
amyloid-beta peptide. Free radical biology & medicine 2007, 43(11):1552-1559.
Nakamura M, Shishido N, Nunomura A, Smith MA, Perry G, Hayashi Y, Nakayama 
K, Hayashi T: Three histidine residues of amyloid-beta peptide control the redox 
activity of copper and iron. Biochemistry 2007, 46(44):12737-12743.
Moreira PI, Santos MS, Oliveira CR, Shenk JC, Nunomura A, Smith MA, Zhu X, 
Perry G: Alzheimer disease and the role of free radicals in the pathogenesis of the 
disease. CNS & neurological disorders drug targets 2008, 7(1):3-10.
Castellani RJ, Lee HG, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, Zhu 
X, Perry G, Smith MA: Reexamining Alzheimer's disease: evidence for a protective 
role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis 2009, 
18(2):447-452.
Schubert D, Cole G, Saitoh T, Oltersdorf T: Amyloid beta protein precursor is a 
mitogen. Biochemical and biophysical research communications 1989, 162(1):83-88.
Santpere G, Nieto M, Puig B, Ferrer I: Abnormal Sp1 transcription factor expression 
in Alzheimer disease and tauopathies. Neuroscience letters 2006, 397(1-2):30-34.
Citron BA, Dennis JS, Zeitlin RS, Echeverria V: Transcription factor Sp1 dysregulation 
in Alzheimer's disease. Journal of neuroscience research 2008, 86(11):2499-2504.
Redman CW, Sargent IL: Latest advances in understanding preeclampsia. Science 
(New York, NY 2005, 308(5728):1592-1594.
Lachmeijer AM, Arngrimsson R, Bastiaans EJ, Frigge ML, Pals G, Sigurdardottir 
S, Stefansson H, Palsson B, Nicolae D, Kong A et al: A genome-wide scan for 
preeclampsia in the Netherlands. Eur J Hum Genet 2001, 9(10):758-764.
van Dijk M, Mulders J, Poutsma A, Konst AA, Lachmeijer AM, Dekker GA, 
Blankenstein MA, Oudejans CB: Maternal segregation of the Dutch preeclampsia 
locus at 10q22 with a new member of the winged helix gene family. Nature genetics 
2005, 37(5):514-519.
Zhao X, Gan L, Pan H, Kan D, Majeski M, Adam SA, Unterman TG: Multiple 
elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of 
phosphorylation- and 14-3-3-dependent and -independent mechanisms. The 
Biochemical journal 2004, 378(Pt 3):839-849.
Janes SM, Ofstad TA, Campbell DH, Watt FM, Prowse DM: Transient activation 
of FOXN1 in keratinocytes induces a transcriptional programme that promotes 
terminal differentiation: contrasting roles of FOXN1 and Akt. Journal of cell science 
2004, 117(Pt 18):4157-4168.
Wolfrum C, Besser D, Luca E, Stoffel M: Insulin regulates the activity of forkhead 
transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and 
nuclear/cytosolic localization. Proceedings of the National Academy of Sciences of 
the United States of America 2003, 100(20):11624-11629.
Dahle MK, Gronning LM, Cederberg A, Blomhoff HK, Miura N, Enerback S, 
Tasken KA, Tasken K: Mechanisms of FOXC2- and FOXD1-mediated regulation 
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
1Introduction · 1
30
of the RI alpha subunit of cAMP-dependent protein kinase include release of 
transcriptional repression and activation by protein kinase B alpha and cAMP. The 
Journal of biological chemistry 2002, 277(25):22902-22908.
Aoki M, Jiang H, Vogt PK: Proteasomal degradation of the FoxO1 transcriptional 
regulator in cells transformed by the P3k and Akt oncoproteins. Proceedings of the 
National Academy of Sciences of the United States of America 2004, 101(37):13613-
13617.
van Dijk M, van Bezu J, van Abel D, Dunk C, Blankenstein MA, Oudejans CB, 
Lye SJ: The STOX1 genotype associated with pre-eclampsia leads to a reduction 
of trophoblast invasion by alpha-T-catenin upregulation. Human molecular genetics 
2010, 19(13):2658-2667.
Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE: Systematic meta-
analyses of Alzheimer disease genetic association studies: the AlzGene database. 
Nature genetics 2007, 39(1):17-23.
Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, 
Collins JS, Harrell LE, Go RC et al: Results of a high-resolution genome screen of 
437 Alzheimer's disease families. Human molecular genetics 2003, 12(1):23-32.
Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth 
J, DeVrieze FW, Crook R et al: Susceptibility locus for Alzheimer's disease on 
chromosome 10. Science (New York, NY 2000, 290(5500):2304-2305.
Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson 
J, Ronald J, Blangero J, Hutton M, Younkin SG: Linkage of plasma Abeta42 to a 
quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. 
Science (New York, NY 2000, 290(5500):2303-2304.
Myers A, Wavrant De-Vrieze F, Holmans P, Hamshere M, Crook R, Compton D, 
Marshall H, Meyer D, Shears S, Booth J et al: Full genome screen for Alzheimer 
disease: stage II analysis. American journal of medical genetics 2002, 114(2):235-244.
Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA, 
Menold MM, Conneally PM, Small GW, Vance JM et al: Complete genomic screen 
in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 
12. Jama 1997, 278(15):1237-1241.
Majercak J, Ray WJ, Espeseth A, Simon A, Shi XP, Wolffe C, Getty K, Marine S, 
Stec E, Ferrer M et al: LRRTM3 promotes processing of amyloid-precursor protein 
by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. 
Proceedings of the National Academy of Sciences of the United States of America 
2006, 103(47):17967-17972.
van Dijk M, van Bezu J, Poutsma A, Veerhuis R, Rozemuller AJ, Scheper W, 
Blankenstein MA, Oudejans CB: The pre-eclampsia gene STOX1 controls a 
conserved pathway in placenta and brain upregulated in late-onset Alzheimer's 
disease. J Alzheimers Dis 2010, 19(2):673-679.
Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SH: Alzheimer's disease. A 
double-labeling immunohistochemical study of senile plaques. The American journal 
of pathology 1988, 132(1):86-101.
Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, Yen SH, 
Aronson MK: Identification of normal and pathological aging in prospectively 
studied nondemented elderly humans. Neurobiology of aging 1992, 13(1):179-189.
Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing X, Peck A: 
Clinical, pathological, and neurochemical changes in dementia: a subgroup with 
preserved mental status and numerous neocortical plaques. Annals of neurology 
1988, 23(2):138-144.
100
101
102
103
104
105
106
107
108
109
110
111
112
1                                           1 · Introduction
             31
Chen B, Cheng M, Hong DJ, Sun FY, Zhu CQ: Okadaic acid induced cyclin 
B1 expression and mitotic catastrophe in rat cortex. Neuroscience letters 2006, 
406(3):178-182.
Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet 2006, 
368(9533):387-403.
LaFerla FM, Green KN, Oddo S: Intracellular amyloid-beta in Alzheimer's disease. 
Nat Rev Neurosci 2007, 8(7):499-509.
113
114
115
2
Chapter 2
Direct downregulation of CNTNAP2 by STOX1A is 
associated with Alzheimer’s disease
Daan van Abel 1, Omar Michel1, Rob Veerhuis2, Marlies Jacobs3, Marie van Dijk1, Cees BM Oudejans1
1Department of Clinical Chemistry, 2 The Alzheimer Center, 3 Department of Pathology, 
1,2,3VU University Medical Center, Amsterdam, The Netherlands.
Accepted in the Journal of Alzheimer’s Disease, 2012 
2STOX1A Negatively Regulates CNTNAP2 · 2
34
Abstract
STOX1A is a transcription factor which is functionally and structurally similar to 
the forkhead box protein family. STOX1A has been shown to be associated with pre-
eclampsia, a pregnancy associated disease, and to have potential implications in Late 
Onset Alzheimer’s Disease (LOAD). However, the exact function of STOX1A and its 
target genes are still largely unknown. Therefore, in this study we performed chromatin 
immunoprecipitation coupled to shotgun cloning to discover novel STOX1A target 
genes. Our results show that CNTNAP2, a member of the neurexin family, is directly 
downregulated by STOX1A. Additionally, we show that CNTNAP2 expression is 
downregulated in the hippocampus of Alzheimer’s disease patients where STOX1A 
expression has been shown to be upregulated. 
In conclusion these results further indicate the potential involvement of STOX1A 
and its target genes in the etiology of Alzheimer’s disease.
2        2 · STOX1A Negatively Regulates CNTNAP2
             35
Introduction
Forkhead box proteins, characterized by a DNA binding motif termed the winged 
helix domain [1], are a family of transcription factors that play a role in the regulation 
of genes involved in multiple disease associated pathways [2]. Previously, we found 
that Storkhead box 1 (STOX1), a transcription factor structurally and functionally 
related to the forkhead box protein family, is a susceptibility gene for pre-eclampsia, 
a hypertensive disorder of pregnancy [3]. In addition to STOX1 as a pre-eclampsia 
susceptibility gene, a recent study performed in our lab showed that STOX1, 
which resides on chromosome 10q22, is also functionally important in Late Onset 
Alzheimer’s Disease (LOAD) [4]. LOAD is a disease with progressive and insidious 
neurodegeneration of the central nervous system (CNS) resulting in memory loss and 
impairments in behaviour, language and visual-spatial skills involving elderly patients 
(> 65 years) of both sexes [5].
Interestingly, while both syndromes (pre-eclampsia and LOAD) lack shared clinical 
features, both share multiple susceptibility loci which exceed the threshold for 
significant linkage found on chromosomes 2, 9, 10, and 12 [7-14]. Furthermore, these 
loci are situated at positions near or at 2p12, 2p25, 9p13, 10q22, and 12q22 for which 
at least 10q22 is subject to a parent-of-origin effect with maternal segregation in 
both syndromes [9, 15]. These (epi)genetic similarities led us to suggest that these 
chromosomal regions are subject to evolutionary conserved, genetic pressures. A 
recent study performed by us suggests that chromosomal region 10q22 also shares 
a functional overlap [4]. In the former study, it was found in our lab that STOX1A 
expression in the brain correlates with the severity of LOAD and transactivates the 
neuronal leucine-rich repeat transmembrane 3 (LRRTM3) gene [4]. The LRRTM3 
gene resides within the large intron of the α-T catenin-encoding CTNNA3 gene on 
10q21-22 and has been confirmed as a functional and positional candidate gene for 
LOAD [6]. 
LRRTM3 has been shown to promote amyloid-β precursor protein (AβPP) processing 
via Beta-secretase 1 (BACE1) resulting in enhanced production of amyloid β (Aβ) [6]. 
Aggregation of Aβ in the brain is one of the key pathological hallmarks of LOAD [5]. 
Transcription factors like STOX1A are likely to regulate several hundreds of target 
genes, but the exact function of STOX1A and its target genes is still largely unknown. 
As STOX1A is highly expressed in the brain [4] we started a search for STOX1A 
downstream target genes to further explore the fundamental role of STOX1A in 
neuronal pathways. In this study we used STOX1A chromatin immunoprecipitation 
followed by random shotgun cloning (ChIP-shotgun cloning) in the neuroblastoma 
cell-line SK-N-SH, a cellular model for neuronal function. This approach resulted 
in the identification of the neurexin family member Contactin Associated Protein-
like 2 (CNTNAP2) gene as a direct target for STOX1A in SK-N-SH cells. Here we 
describe that STOX1A directly and negatively regulates CNTNAP2 expression in 
neuroblastoma SK-N-SH cells. Furthermore, our results show that downregulation 
of CNTNAP2 expression in the hippocampus is associated with LOAD pathology. 
Therefore, this study describes a second STOX1A target gene with potential 
implication in LOAD pathology. 
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Figure 1. STOX1A binds to a region in intron 1 of the CNTNAP2 gene resulting in decreased CNTNAP2 mRNA and 
protein levels. (A) Results show a mean 376 fold (mean ΔΔCt is −8,56) enrichment for CNTNAP2 in STOX1A stimu-
lated ChIP DNA compared with their negative controls (ChIP sample vs ChIP blocked sample). Bar is mean ± SEM. 
Asterisks indicates P<0.05 (one sample t-test with theoretical mean 0). (B) Expression of STOX1A protein was confirmed 
with an anti-Halotag specific antibody by western blot using total cell protein extracts obtained from STOX1A (left lane) 
and MOCK (right lane) transfected SK-N-SH cells. A specific band representing STOX1A-halotag protein was observed 
at its expected size of 150 kD. Halotag protein (MOCK) was detected at its expected size of 34 kD. Westernblot image is a 
representative of at least 3 independent experiments. (C) Quantitative RT-PCR data shows a mean 1,78 fold (mean ΔΔCt 
is 0,835) decreased mRNA expression for CNTNAP2. Bars are mean ± SEM. * indicate P<0.05 (one sample t-test with 
theoretical mean 0). (D) Endogenous CNTNAP2 protein was determined with a CNTNAP2 specific antibody by western 
blot using total cell protein extracts obtained from STOX1A and MOCK transfected SK-N-SH cells. Westernblot image 
is a representative of at least 3 independent experiments.
Results
ChIP-shotgun cloning identifies a STOX1A DNA binding region associated with 
CNTNAP2.
By using the ChIP-shotgun cloning procedure 283 potential STOX1A binding regions 
were found (Supplementary Table 1) and 42 background regions (Supplementary 
Table 2). We focused on regions for which multiple hits were positioned within a gene 
(Supplementary Table 1, highlighted in grey). Validation was done using Q-PCR with 
probes and primers specific for the obtained regions (Supplementary Table 3). Results 
show significant enrichment for the region located in intron 1 of the CNTNAP2 gene 
(Fig. 1A) in STOX1A ChIP DNA compared to the negative controls. A small but 
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Diagnosis1 Patient ID Gender Age (Years) Braak score Brain weigth (grams) PMD (hrs:min)2
Non demented control  08/83 Female 80 1A 1227 6:58
Non demented control  08/315 Male 80 1A 1350 8:10
Non demented control  04/184 Female 81 1B 1164 6:40
Non demented control  09/039 Male 78 10 1145 17:40
Non demented control  04/57 Male 80 0A 1285 6:30
Alzheimer's disease  08/078 Male 78 5C 1300 6:35
Alzheimer's disease  10/016 Male 77 5C 1208 5:39
Alzheimer's disease  08/132 Male 77 6C 1340 6:35
Alzheimer's disease  05/54 Female 81 5C 1061 6:15
Table 1. Demographics of the cases included in this study.
1Clinical diagnosis with neuropathological conformation
2PMD, post mortem delay time (hours:minutes)
significant enrichment was found for a region associated with the Integrin alpha-9 
(ITGA9) (Supplementary Fig. 1) gene. No significant enrichment was found for the 
other obtained regions (Data not shown).
To test the effect of STOX1A on CNTNAP2 mRNA levels we transiently transfected 
SK-N-SH cells with STOX1A or MOCK (negative control) constructs. Transient 
overexpression of STOX1A and MOCK (Halotag) protein was confirmed on 
westernblot (Fig. 1B) and significantly decreased levels of both mRNA (Fig. 1C) and 
protein levels (Fig. 1D) were seen for CNTNAP2 in STOX1A compared to MOCK 
transfected SK-N-SH cells. 
Knockdown of endogenous STOX1A resulted in a significant increase in CNTNAP2 
mRNA expression (Supplementary Fig. 2). However, this effect was not seen on a 
protein level (Data not shown).
CNTNAP2 expression levels are altered in LOAD patients versus non-demented 
controls
As our results show that CNTNAP2 is directly downregulated by STOX1A and given 
that STOX1A expression correlates with the severity of LOAD, we speculated that 
CNTNAP2 expression levels in affected brain regions are reduced in LOAD. First, we 
tested STOX1A mRNA expression levels in hippocampus tissue of LOAD patients 
(Table 1). Consistent with previous results from our lab [4] STOX1A mRNA levels 
were significantly increased in the hippocampus of LOAD (Braak stage 5/6) compared 
to non-demented controls (Braak 0/1, Fig. 2A). As hypothesized, CNTNAP2 mRNA 
levels were significantly decreased in the LOAD samples compared to non-demented 
controls (Fig. 2B). Furthermore, we tested mRNA expression levels of FOXP2, 
a member of the forkhead transcription factor family previously shown to directly 
downregulate CNTNAP2 expression [18]. However, we did not find a significant 
increase of FOXP2 mRNA expression in the hippocampus of LOAD (Braak stage 
5/6) compared to non-demented controls (Braak 0/1, Fig. 2C).
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Figure 2. Expression analysis of STOX1A, CNTNAP2 and FOXP2 in patients with LOAD. (A) Quantitative RT-
PCR showing a significant increased mRNA expression for STOX1A (lower ΔCt) and (B) a significant decreased mRNA 
expression for CNTNAP2 (higher ΔCt) in advanced stages of LOAD (Braak 5/6,) compared to non-demented controls 
(Braak 0/1). (C) No significant changes in FOXP2 mRNA expression levels were found in advanced stages of LOAD 
(Braak 5/6) compared to non-demented controls (Braak 0/1). P-values were calculated using a two-tailed unpaired t-test, 
* indicate P<0.05.
Discussion
In this study we searched for target genes of STOX1A, a transcription factor which 
has been shown to be functionally involved in LOAD [4]. With the use of chromatin 
immunoprecipitation followed by shotgun cloning we identified CNTNAP2 to be 
directly and negatively regulated by STOX1A in the neuroblastoma cell-line SK-
N-SH. Knockdown of endogenous STOX1A by siRNA increases mRNA levels 
of CNTNAP2 in these cells. However, increased levels of CNTNAP2 mRNA did 
not result in increased CNTNAP2 protein levels indicating that other mechanisms 
counteract the effect of STOX1A siRNA knockdown on CNTNAP2 mRNA 
translation like miRNAs. Additional experiments are necessary to reveal the 
mechanisms that regulate CNTNAP2 mRNA translation under these conditions.
Interestingly, we show that CNTNAP2 is downregulated in the hippocampus of 
LOAD patients, where STOX1A mRNA levels were upregulated. This suggests that 
the reduction of CNTNAP2 expression in LOAD patients is directly associated with 
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increased expression of STOX1A. Differential expression of CNTNAP2 has, to our 
knowledge, not yet been associated with AD. We can therefore only speculate on the 
role of CNTNAP2 in AD pathology.
CNTNAP2 is a gene involved in neural-glial interactions and clustering of ion 
channels in myelinated axons [19, 20]. A recessive nonsense mutation in the 
CNTNAP2 gene has been found to be associated with autism, focal epilepsy, mental 
retardation, hyperactivity and cortical dysplasia [21-24]. Therefore, much effort has 
been made unravelling the function of CNTNAP2. Currently, several studies have 
shown that at the juxtaparanodal regions of myelinated axons of the CNS (central 
nervous system) and PNS (peripheral nervous system) CNTNAP2 is important for 
the clustering of Shaker-like K+ channels and neural-glia interactions [19, 20, 25]. 
While the mechanisms and function of this clustering remain unclear there are several 
studies which elucidate the importance of ion channel clustering at the juxtaparanodal 
region in myelinated axons. 
In one of the studies performed it was shown that disrupted juxtaparanodal regions 
in myelinated axons are linked to cognitive abnormalities in transient axonal 
glycoprotein-1 (TAG-1) deficient mice [26]. These mice show reduced CNTNAP2 
expression levels suggesting that disrupted CNTNAP2 expression is associated with 
cognitive abnormalities as observed in these mice [26]. 
Another suggested function for molecular organization at the nodes of Ranvier in 
myelinated axons was recently proposed in a study where re-myelinated lesions of 
multiple sclerose (MS) patients were analysed. In this study it has been suggested 
that during myelin repair the aggregation of nodal, paranodal and juxtaparanodal 
constituents, in particular ion channels, precede re-myelination [27].  This indicates 
that defects in domain organization surrounding the nodes of Ranvier in myelinated 
axons could aggravate re-myelination failure in de-myelinated MS lesions [27] and 
therefore may contribute to neurodegeneration. Re-myelination defects have previously 
also been associated with AD [28], suggesting that defects in domain organization at 
the nodes of Ranvier of myelinated axons could also be associated with proper re-
myelination in AD. Another study elucidating the role of domain organisation at 
the nodes of Ranvier in myelinated axons showed that in the grey matter of triple-
transgenic AD (3xTg-AD) mice the levels of myelin-associated proteins, including 
ion channels, are significantly lower than controls [29]. A recent study performed by 
Strauss and collaborators [21] shows that patients diagnosed with cortical dysplasia–
focal epilepsy (CDFE) syndrome have a single-base deletion resulting in a premature 
stop codon in the CNTNAP2 gene and is  therefore predicted to yield a non-functional 
protein. Histopathological inspection of brain regions from these patients showed that 
several neurons have intense neurofilament tangle staining [21]. As neurofilament 
tangles are one of the constituents of neurofibrillary tangles (NFT) in AD [30], the 
findings of Straus and collaborators indicates that disruption of CNTNAP2 could 
directly contribute to NFT formation also seen in AD.
In conclusion, several studies indicate that defects in proper domain organization at 
the nodes of Ranvier in myelinated axons is important for proper axonal functioning 
and when compromised is associated with neurdegeneration. While speculative, 
decreased levels of CNTNAP2 by upregulated STOX1A expression in LOAD could 
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therefore contribute to neurodegeneration and cognitive decline. 
Another member of the forkhead family of transcription factors, FOXP2, has also 
been shown to directly downregulate CNTNAP2 [18]. Although a possible outcome 
for FOXP2 overexpression in LOAD is unclear we speculated that decreased levels of 
CNTNAP2 expression in the hippocampus of LOAD, as found in this study, could in 
part also be the result of upregulated FOXP2 expression as also shown for STOX1A. 
However, we did not find upregulated expression of FOXP2 in the hippocampus 
of LOAD patients. Therefore it is unlikely that FOXP2 contributes to reduced 
CNTNAP2 expression levels in the hippocampus of LOAD patients. 
Nevertheless, our results indicate a potential role for CNTNAP2 in AD pathology, a 
gene which we found to be directly regulated by STOX1A. As both CNTNAP2 and 
STOX1A are deregulated in LOAD, in the future, it would therefore be nice to see 
if genetic variants in STOX1 or CNTNAP2 are associated with AD pathology. This 
could indicate that these genes are capable of influencing AD disease progression by 
itself which elucidates their role in AD pathology. It does not seem, however, that the 
predominant pre-eclampsia STOX1 mutation Y153H [3] is involved in the pathology 
of LOAD.
In this study we primarily focussed on the link between STOX1A, CNTNAP2 and 
LOAD. However, other genes associated with the obtained STOX1A ChIP-regions 
could be of great significance as well. For example, the EPB41L3 gene has been shown 
to be required for the proper domain clustering of Kv1 channels by CNTNAP2 at the 
juxtaparanodal axonal membrane [31]. Furthermore, as for CNTNAP2, other genes 
associated with ASD are also found in the list of obtained ChIP-cloning fragment, 
these include neurexin 3 (NRXN3), and CNTNAP5 [32, 33]. As shown for CNTNAP2 
these potential STOX1A target genes could also have implications in LOAD. Their 
association with ASD also suggest a role for STOX1A as an upstream regulator in 
ASD. Additional experiments are therefore needed to validate these genes as direct 
targets for STOX1A. 
Besides CNTNAP2, we also validated ITGA9 as a direct target gene. ITGA9 has 
been shown to be involved in axon regeneration [34]. Exploration of STOX1A as an 
upstream regulator of the ITGA9 gene could possibly reveal a function for STOX1A 
in axon regeneration. Together, we show dat our data can be very informative in the 
exploration of the biological role of STOX1A in neuronal signalling.
Materials and Methods
Human tissues
Human brain specimens of Alzheimer’s disease cases (Braak stages 6, n = 4) and non-
demented control cases (Braak stages 1, n = 5) were matched for age and were obtained 
at autopsy through the Netherlands Brain Bank (http://www.brainbank.nl). Clinical 
diagnosis was neuropathologically confirmed on formalin-fixed, paraffin-embedded 
tissue from different sites. Staging of AD was neuropathologically evaluated according 
to Braak and Braak [16]. Demographics of the cases included in this study are listed 
in Table 1.
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Cell culture and transfection
SK-N-SH human neuroblastoma cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). All reagents for cell culture were purchased 
from Invitrogen Life Technologies, Inc. (Burlington, Canada). SK-N-SH cells were 
cultured at 37 ºC in a humidified atmosphere of 5% CO2 in Iscove’s Modified 
Dulbecco’s Medium (IMDM) supplemented with 10% fetal calf serum and 100 U/
ml penicillin, and 100 g/ml streptomycin. Cells were subcultured in medium every 
2–3 days following harvesting by trypsinization (HBSS containing 5% trypsin). The 
ORF (Open Reading Frame) of the STOX1A gene was subcloned into the pFN21A 
HaloTag® CMV Flexi® vector according to the manufacturers protocol (Promega) 
and transfected into SK-N-SH cells. For transfection the calcium phosphate method 
was used [17]. Briefly, at the time of transfection, cells were at 70% confluence. By 
vortexing 2X HEBS (HEPES-buffered saline) with a solution of 2.5 M CaCl2 and 
20 µg of plasmid DNA a co-precipitate of DNA and CaPO4 was allowed to form. 
After incubation for 30 min at room temperature, the precipitate was added to the 
cells and the medium was changed after 24 hours. Cells were harvested 48 hours post-
transfection for further analysis. RNA was isolated as described in the Quantitative 
PCR and RT-PCR section. 
Knockdown of STOX1A was performed by transfecting 4 siRNA’s against STOX1A 
and control siRNA (Qiagen) in SK-N-SH cells with Lipofectamine™ RNAiMAX 
(Invitrogen) according to the manufactures protocol. Cells were harvested 48 hours 
post-transfection and RNA was isolated as described in the Quantitative PCR and 
RT-PCR section.
Chromatin immunoprecipitation cloning (ChIP-cloning)
Transiently STOX1A-transfected SK-N-SH cells were treated with formaldehyde 
to create protein-DNA crosslinks. Cytoplasmic lysis was performed to reduce 
competition of cytoplasmic STOX1A-Halotag proteins against nuclear STOX1A-
Halotag proteins with the Halotag resin. Nuclear lysate was subsequently fragmented 
by sonication (Ranging from 200 till 1000 bp). The nuclear lysates were split into 
two equal parts of which one was treated with Halotag blocking ligand to function 
as a negative control. Both the samples and controls were treated using Halotag resin 
according to the Halo-ChIP system protocol in the presence of proteinase inhibitors. 
After reversal of crosslinks the DNA was purified using the MinElute PCR Purification 
Kit (QIAGEN). DNA was then blunt ended according to the Zero Blunt® PCR 
Cloning Kit (Invitrogen). At least 4 experimental and 4 control samples were combined 
and concentrated using the MinElute PCR Purification Kit (QIAGEN). Both pooled 
experimental and control samples were then cloned into the pCR®-Blunt vector and 
subsequently transformed into One Shot® TOP10 Competent Cells according to 
the Zero Blunt® PCR Cloning Kit (Invitrogen). The amount of positive clones on 
the experimental plate were visually inspected and compared to the control plate. 
The amount of colonies present on the experimental plate compared to the amount 
of positive colonies on the control plate was used as an indication of ChIP DNA 
enrichment. Colonies of experimental and control plates were selected and inserts 
were PCR amplified using the M13 Forward and M13 revered primers present in the 
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backbone of the pCR®-Blunt vector. PCR amplified inserts were then analysed by 
DNA sequencing using the M13 Forward primer and Big Dye Terminators followed 
by separation on an ABI3130xl Genetic Analyser (Applied biosystems). To determine 
the positions of the obtained DNA sequences we used the function BLAT on the 
University of California, Santa Cruz, Genome Server (http://genome.ucsc.edu/), 
which enabled identification of putative STOX1A binding regions. Sequences for 
both the experimental and controls that were positioned in repeat masked regions 
were rejected. This resulted in a list of 283 experimental (Supplementary Table 1) and 
42 background (Supplementary Table 2) sequences.
Quantitative PCR and RT-PCR
Standard quantitative PCR was performed on an ABI7300 (Applied Biosystems) 
using a probe and primers specific for the region in intron 1 of the CNTNAP2 gene 
obtained in the ChIP-shotgun cloning procedure. Probe and primer characteristics 
were: CNTNAP2_forward 5’ AGCAGAAGGAGTTGAAATGC 3’, CNTNAP2_
reversed 5’ GCTGTCATTTGGCAGTAGC 3’ and 5’-FAM 3’-TAMRA labeled 
probe: 5’ GCAGATAGGGGGATCGCAGC 3’. Reactions were performed in the 
presence of 1M betaine and ROX reference dye, and corrected for input using the 
non-intron-spanning Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene 
expression assay (Applied Biosystems). Input ChIP DNA was obtained from at least 
four independent ChIP experiments.
RNA isolation from transfected SK-N-SH cells was performed using the RNeasy 
kit (Qiagen) including on-column DNase treatment. For isolation of RNA from the 
hippocampal region of non-demented controls and brains with advanced LOAD 
we cut between 10-20 cryostat sections (30 µm each) from each patient sample (see 
human tissues section for details) and immediately mixed them with 1 ml RNABee. 
After addition with 100 µl of chloroform the samples were mixed and centrifuged for 
15 min. The aqueous phase was collected and further treated using the RNeasy kit 
(Qiagen) including on-column DNase treatment. Quantitative RT-PCR using gene 
expression assays (Applied Biosystems) for FOXP2 and CNTNAP2 were performed 
on an ABI7300.
Probe and primer characteristics for STOX1A were: STOX1A_
forward 5’ TTCTCCACGGACACAGAGT 3’, STOX1A_reversed 5’ 
TATGCTTGCCTTTAGACAAT  3’ and 5’-FAM 3’-TAMRA labelled probe: 5’ 
AGAGCAGTCAACCACTCACATCTAAT 3’. Normalization was done with gene 
expression assays for PBGD (Applied Biosystems). Data of transfected cells was 
obtained from at least four transfections, each RNA sample was measured in triplicate. 
Western blot
Protein lysates from transfected cells were obtained by directly scraping cells into 
Loading Buffer including β-mercaptoethanol. Lysates were separated by SDS-
polyacrylamide gel electrophoresis, and electroblotted onto a PVDF-membrane. An 
antibody recognizing the Halotag (Promega) or CNTNAP2 (Sigma) protein, were used 
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in combination with goat anti-rabbit horseradish peroxidase-conjugated secondary 
antibody (DAKO). Protein bands were detected by an enhanced-chemiluminescence 
assay (GE Healthcare) on a LAS3000.
Data analysis
For Real-time PCR data, a threshold cycle number, Ct, was measured as the PCR cycle 
at which the amount of amplified target reaches the threshold value. Quantification 
was determined by the 2-ΔΔCt method as described in Applied Biosystems “Guide to 
Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative 
PCR”, Section VII,  Relative Quantitation of Gene Expression Experimental Design 
and Analysis” http://www3.appliedbiosystems.com/cms/groups/mcb_support/
documents/generaldocuments/cms_042380.pdf ). Statistical analysis of the obtained 
data was carried out with the GraphPad Prism program. Significance in Figure 1 
(and supplementary figures 1 and 2) was calculated with a one sample t-test with 
a theoretical mean of 0. Significance in Figure 2 was calculated using a two-tailed 
unpaired t-test. * indicate P<0.05, ** indicate P<0.01, *** indicate P<0.001. Bars are 
mean ± SEM.
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Supplementary Figure 1. STOX1A binds to a region associated with the ITGA9 gene. Results show 
a mean 13,01 fold (mean ΔΔCt is -3,68) enrichment for ITGA9 in STOX1A stimulated ChIP DNA 
compared with their negative controls (ChIP sample vs ChIP blocked sample). Bar is mean ± SEM. * 
indicates P<0.05 (one sample t-test with theoretical mean 0). N = 4, each sample was measured in triplicate.
Supplementary Figure 2. The effect of STOX1A knockdown in the SK-N-SH neuroblastoma cell line. CNTNAP2 
mRNA expression was determined with quantitative RT-PCR showing a mean 1,47 fold (mean ΔΔCt is −0,55) increased 
mRNA expression in STOX1A siRNA treated cells compared to their negative controls. Bars are mean ± SEM. * indicate 
P<0.05, (one sample t-test with theoretical mean 0). N = 3, each sample was measured in triplicate.
Supplementary Figures
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Supplementary Tables
Supplementary table 1. Potential STOX1A bound regions
MYSM1 chr1:58,902,181-58,902,644
xxxxx chr1:162,133,367-162,133,546
RGL1 chr1:182,073,027-182,073,110
xxxxx chr1:182,870,028-182,870,153
FRAMEF1 chr1:12,777,496-12,777,702
ZNF643 chr1:40,700,479-40,700,705
xxxxx chr1:48298098-48298375
xxxxx chr1:212,005,122-212,005,281
xxxxx chr1:2,739,405-2,739,863
TXNDC12 chr1:52,279,845-52,280,060
xxxxx chr1:45,051,096-45,051,370
xxxxx chr1:164,189,403-164,189,739
FAF1 chr1:50,684,369-50,684,727
xxxxx chr1:236,957,151-236,957,324
xxxxx chr1:224,817,464-224,817,746
FHL3 chr1:38,235,576-38,235,860
xxxxx chr1:17,085,952-17,086,077
TPR chr1:184,582,115-184,582,224
xxxxx chr1:82,504,749-82,504,935
LRRC39 chr1:100,392,174-100,392,316
xxxxx chr1:101,982,873-101,983,032
DISC1 chr1:229,959,153-229,959,250
KIFAP3 chr1:168,302,270-168,302,439
LPHN2 chr1:81,971,383-81,971,440
SOAT1 chr1:177,550,174-177,550,289
xxxxx chr1:213,141,291-213,141,450
xxxxx chr1:101,982,876-101,983,033
TNNI3 chr1:74,455,977-74,456,278
AJAP1 chr1:4,618,989-4,619,194
CNTNAP5 chr2:125,010,676-125,010,957
xxxxx chr2:117,292,001-117,292,194
SPAG16 chr2:213,882,301-213,882,408
SRBD1 chr2:45,681,047-45,681,207
PDE11A chr2:178,248,305-178,248,538
LYPD6B chr2:149,630,000-149,630,142
LASS6 chr2:169,249,759-169,249,951
xxxxx chr2:200,637,796-200,637,935
xxxxx chr2:237,852,825-237,853,018
xxxxx chr2:60,383,098-60,383,510
xxxxx chr2:207,796,446-207,796,680
RBKS chr2:27,949,403-27,949,575
MYT1L chr2:1,983,497-1,983,860
xxxxx chr2:200,637,798-200,637,941
xxxxx chr2:16,235,887-16,235,993
xxxxx chr2:237,701,531-237,701,651
xxxxx chr2:218,072,300-218,072,480
xxxxx chr2:46,945,733-46,945,881
TRIB2 chr2:12,790,297-12,790,516
MCM6 chr2:136,343,733-136,343,896
xxxxx chr2:206,557,679-206,557,796
PARD3B chr2:206,084,100-206,084,223
xxxxx chr2:184,682,478-184,682,659
CALPN14 chr2:31,304,515-31,304,578
xxxxx chr2:10,931,500-10,931,734
ARHGAP15 chr2:143,885,565-143,885,783
PID1 chr2:229,789,533-229,789,714
xxxxx chr2:100,451,915-100,452,270
xxxxx chr2:22,569,048-22,569,122
xxxxx chr3:96,505,565-96,505,871
ATP1B3 chr3:143,127,532-143,127,806
ITGA9 chr3:37,521,134-37,521,554
ITGA9 chr3:37,657,387-37,657,815
SYNPR chr3:63,449,413-63,449,652
CHCHD6 chr3:128,031,745-128,032,036
xxxxx chr3:153,876,686-153,876,866
LRRC31 chr3:171,060,733-171,061,151
ATG7 chr3:11,404,044-11,404,281
xxxxx chr3:48,231,365-48,231,500
xxxxx chr3:82,035,149-82,035,231
PTPRG chr3:61,948,314-61,948,398
xxxxx chr3:121,884,506-121,884,712
STOX2 chr4:185,166,123-185,166,226
PDLIM5/ LIM chr4:95,797,508-95,797,576
xxxxx chr4:155,896,136-155,896,232
KLHL2 chr4:166,374,387-166,374,694
xxxxx chr4:128,025,611-128,025,921
xxxxx chr4:125,450,510-125,450,651
xxxxx chr4:83,096,158-83,096,266
AFAP1 chr4:7,932,035-7,932,327
xxxxx chr4:130,494,411-130,494,649
xxxxx chr4:15,274,370-15,274,506
FAT4 chr4:126,585,285-126,585,425
xxxxx chr4:92,436,821-92,436,984
xxxxx chr4:124,600,860-124,601,134
xxxxx chr4:164,518,031-164,518,101
xxxxx chr5:56,809,248-56,809,454
NPY6R chr5:137,171,620-137,171,807
xxxxx chr5:169,690,749-169,690,805
ADAMTS2 chr5:178,516,263-178,516,283
SYNPO chr5:149,995,911-149,996,156
SLIT3 chr5:168,246,847-168,247,249
FGF1 chr5:141,974,074-141,974,299
SIL1 chr5:138,439,577-138,439,972
xxxxx chr5:32,230,619-32,230,983
xxxxx chr5:102,034,014-102,034,104
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PDGFRB chr5:149,475,700-149,475,898
PCDHB8 chr5:140,538,103-140,538,183
EPB41L4A chr5:111,529,800-111,529,855
xxxxx chr5:129,690,195-129,690,308
SGCD chr5:156,029,167-156,029,257
PPIL6 chr6:109,819,265-109,819,298
CDYL chr6:4,883,236-4,883,476
SYNE1 chr6:152,990,411-152,990,527
xxxxx chr6:83,260,962-83,261,259
xxxxx chr6:147,830,995-147,831,173
STK38 chr6:36,620,136-36,620,226
xxxxx chr6:8,242,299-8,242,471
xxxxx chr6:54,450,535-54,450,707
SIM1 chr6:100,992,438-100,992,669
xxxxx chr6:36,996,589-36,996,746
xxxxx chr7:51,781,850-51,782,017
WBSCR17 chr7:70,420,433-70,420,562
TRIP6 chr7:100,308,057-100,308,083
SHFM1 chr7:96,174,558-96,174,681
PRKAR2B chr7:106,571,369-106,571,786
xxxxx chr7:10,423,780-10,428,759
RAPGEF5 chr7:22,183,342-22,183,419
PRKAG2 chr7:151,097,816-151,097,986
RBM33 chr7:155,163,305-155,163,414
SFRP4 chr7:37,920,251-37,920,821
xxxxx chr7:152,956,629-152,956,704
xxxxx chr7:105,759,453-105,759,875
HDAC9 chr7:18,622,899-18,623,151
xxxxx chr7:39,538,023-39,538,116
xxxxx chr7:49,130,485-49,130,817
xxxxx chr7:12,665,243-12,665,439
xxxxx chr7:66,627,376-66,627,724
xxxxx chr7:30,580,476-30,581,032
xxxxx chr7:6,499,724-6,499,973
PTPRZ1 chr7:121,472,887-121,472,970
CNTNAP2 chr7:145,644,227-145,644,441
CNTNAP2 chr7:145,592,668-145,593,046
CNTNAP2 chr7:146,726,641-146,726,934
PTN,pleiotropchr7:136,628,461-136,628,641
xxxxx chr7:113,201,150-113,201,427
xxxxx chr7:41,192,107-41,192,453
PPP1R3A chr7:113,321,925-113,322,033
METTL2B chr7:127,915,177-127,915,379
Clip2 chr7:73,430,008-73,430,095
cd36, CD36 achr7:80,094,620-80,094,715
CREB5 chr7:28,587,758-28,587,874
TBRG4 chr7:45,114,664-45,114,929
xxxxx chr8:136,497,678-136,497,757
xxxxx chr8:6,965,228-6,965,372
xxxxx chr8:103,758,969-103,759,081
xxxxx chr8:117,280,844-117,280,979
RNF19A chr8:101,381,201-101,381,264
PXDNL chr8:52,452,013-52,452,188
xxxxx chr8:36,230,991-36,231,338
FNTA chr8:43,039,447-43,039,533
MCPH1 chr8:6,422,973-6,423,451
xxxxx chr8:82,306,564-82,306,700
BMP1 chr8:22,104,029-22,104,330
xxxxx chr8:69,838,325-69,838,582
xkr4 chr8:56,313,512-56,313,665
MELK chr9:36,633,263-36,633,520
Mob1 homolochr9:27,337,545-27,337,643
xxxxx chr9:137,334,963-137,335,146
xxxxx chr9:101,294,560-101,294,759
xxxxx chr9:137,157,069-137,157,416
xxxxx chr9:35,027,329-35,027,531
xxxxx chr9:101,294,562-101,294,759
NBIF chr9:14,186,532-14,186,687
JAK2 chr9:4,988,437-4,988,721
KIF24 chr9:34,312,083-34,312,329
xxxxx chr10:60,832,406-60,832,533
xxxxx chr10:8,394,225-9,474,224
xxxxx chr10:52,344,134-52,344,297
SGMS1 chr10:51,776,710-51,776,860
SLC16A9 chr10:61,127,290-61,127,889
KCNMA1 chr10:78,854,843-78,855,109
CDH23 chr10:72,915,506-72,915,595
DNMBP chr10:101,728,540-101,728,850
xxxxx chr10:9,964,445-9,964,576
LIPA chr10:90,977,426-90,977,840
C10ORF59 chr10:90,219,610-90,220,000
DOCK1 chr10:129,098,906-129,098,938
xxxxx chr10:133,460,102-133,460,527
xxxxx chr11:27,290,596-27,290,678
xxxxx chr11:33,768,551-33,768,833
xxxxx chr11:85,458,174-85,458,289
xxxxx chr11:85,458,171-85,458,288
xxxxx chr11:14,628,192-14,628,280
xxxxx chr11:3,505,213-3,505,432
PAAF1 chr11:73,299,129-73,299,320
INHBC chr12:56,120,212-56,120,294
YAF2 chr12:40,881,285-40,881,405
xxxxx chr12:33,375,084-33,375,283
xxxxx chr12:56,455,254-56,455,401
TSPAN9 chr12:3,219,732-3,219,910
xxxxx chr12:705,818-705,977
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RILPL1 chr12:122,539,659-122,539,819
CSAD chr12:51,839,344-51,839,463
GRIP1 chr12:65,123,998-65,124,199
GRIP1 chr12:65,123,998-65,124,190
xxxxx chr13:59,845,125-59,845,301
EDNRB chr13:77,386,662-77,386,792
GPC6 chr13:92,972,084-92,972,541
xxxxx chr13:58,880,578-58,880,666
xxxxx chr13:94,155,143-94,155,253
SLC15A1 chr13:98,177,474-98,177,590
SPATA13 chr13:23,746,178-23,746,348
xxxxx chr13:94,155,151-94,155,253
RB1 chr13:47,875,341-47,875,455
EML1 chr14:99,344,718-99,344,886
xxxxx chr14:63,884,162-63,884,305
xxxxx chr14:70,226,446-70,226,738
NRXN3 chr14:77,859,932-77,860,231
PLEK2 chr14:66,935,921-66,936,043
SFTA3 chr14:36,020,863-36,021,048
MAP3K9 chr14:70,272,501-70,272,563
xxxxx chr14:73,925,445-73,925,725
FOXN3 chr14:89,139,656-89,139,788
xxxxx chr15:19,542,031-19,542,234
xxxxx chr15:40,818,789-40,818,892
AKAP13 chr15:84,010,618-84,010,896
xxxxx chr15:82,611,783-82,611,922
BNC1 chr15:81,732,821-81,733,055
LRRC49 chr15:69,093,804-69,094,064
xxxxx chr15:99,878,885-99,879,341
xxxxx chr15:99,878,882-99,879,342
COX4NB chr16:84,383,552-84,383,681
xxxxx chr16:72,436,596-72,436,785
xxxxx chr16:5,554,482-5,554,580
IMMA BolA-li chr16:30,018,957-30,018,988
GCSH chr16:79,685,641-79,685,719
ZCCHC14 chr16:86,022,913-86,023,162
xxxxx chr16:83,956,243-83,956,474
WWOX chr16:77,452,146-77,452,327
FBXO31 chr16:85,962,723-85,962,930
SIAH1 chr16:46,985,440-46,985,778
NTAN1 / PDXchr16:15,040,004-15,040
FBXO31 chr16:85,962,723-85,962,930
CDYL2 chr16:79,224,798-79,225,011
ABCC11 chr16:46,818,452-46,818,695
xxxxx chr16:9,563,950-9,564,093
xxxxx chr16:72,859,536-72,859,639
A2BP1 chr16:6,105,879-6,106,056
NFAT chr16:68,230,694-68,230,926
RAB11FIP4 chr17:26,743,776-26,743,890
xxxxx chr17:61,725,796-61,725,967
ACCN1 chr17:28,620,319-28,620,611
ACCN1 chr17:29,476,644-29,476,863
xxxxx chr17:49,247,593-49,247,934
ITGB4 chr17:71,263,928-71,264,144
xxxxx chr17:59,751,311-59,751,797
AXIN2 chr17:60,975,238-60,975,884
ZNF232 chr17:4,954,122-4,954,251
xxxxx chr17:4,271,304-4,271,550
xxxxx chr18:67,415,690-67,415,868
EPB41L3 chr18:5,477,803-5,478,046
EPB41L3 chr18:5,477,807-5,478,049
EPB41L3 chr18:5,464,774-5,465,031
xxxxx chr19:38,495,417-38,495,637
xxxxx chr19:38,546,354-38,546,674
ZC3H4 chr19:52,270,429-52,270,782
UNC13A chr19:17,592,713-17,593,010
xxxxx chr20:5,208,591-5,208,613
HCK-1 chr20:30,124,075-30,124,306
HCK-2 chr20:30,124,083-30,124,306
xxxxx chr20:20981453-20981697
xxxxx chr20:38,819,120-38,819,254
xxxxx chr20:6,409,295-6,409,467
DLGAP4 chr20:34,509,731-34,509,862
SLC24A chr20:19,470,315-19,470,636
xxxxx chr20:56,954,592-56,954,633
xxxxx chr20:22,425,650-22,425,844
TAF4 chr20:60,035,671-60,035,808
xxxxx chr21:46,839,434-46,839,770
DSCAM chr21:40,500,445-40,500,705
xxxxx chr21:29,070,614-29,070,718
TEF chr22:40,106,822-40,107,059
SPECC1L chr22:23,136,287-23,136,502
SPECC1L chr22:23,131,454-23,131,641
xxxxx chr22:48,533,162-48,533,485
Dach2 chrX:85,692,067-85,692,170
xxxxx chrX:42,003,959-42,004,274
xxxxx chrX:47,499,512-47,499,753
IL1RAPL2 chrX:104,156,125-104,156,405
BRCC3 chrX:153,962,819-153,962,892
MAP7D3 chrX:135,155,247-135,155,406
xxxxx chrX:23,430,034-23,430,351
MTND5 chrM:13,203-13,348
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LOC388630 chr1:48,083,241-48,083,398
xxxxx chr1:188,584,756-188,584,913
xxxxx chr1:225,821,071-225,821,358
GOLPH3L chr1:148,907,336-148,907,424
xxxxx chr2:19,126,992-19,127,222
xxxxx chr2:56,566,107-56,566,628
xxxxx chr2:164,619,339-164,619,453
UBE2D2 chr5:138,933,187-138,933,417
xxxxx chr5:36,727,352-36,727,431
BXDC1 chr6:111,443,336-111,443,433
xxxxx chr7:128,052,033-128,052,507
MAD1L1 chr7:2,066,599-2,066,676
xxxxx chr7:28,897,200-28,897,271
RELN chr7:103,294,128-103,294,225
xxxxx chr7:140,312,334-140,312,510
RPL8 chr8:145,987,229-145,987,271
xxxxx chr8:72,095,204-72,095,338
xxxxx chr9:86,325,049-86,325,258
xxxxx chr9:112,325,280-112,325,579
xxxxx chr9:7,390,649-7,390,727
GLIS3 chr9:3,997,177-3,997,447
RPL12 chr9:129,252,059-129,252,156
xxxxx chr10:19,414,208-19,414,332
xxxxx chr10:120,657,634-120,657,919
xxxxx chr10:113,790,106-113,790,223
xxxxx chr11:9,306,630-9,306,689
xxxxx chr11:14,387,044-14,387,122
xxxxx chr11:21,690,638-21,690,684
xxxxx chr12:88,753,565-88,753,669
SPATS2 chr12:48,079,443-48,079,562
xxxxx chr13:18,681,821-18,681,957
xxxxx chr14:70,384,616-70,384,701
VRK1 chr14:96,381,405-96,381,808
xxxxx chr16:59,534,555-59,534,644
ALOX12B chr17:7,928,474-7,928,637
xxxxx chr17:12,259,283-12,259,601
xxxxx chr17:27,438,809-27,438,960
xxxxx chr19:11,565,514-11,565,644
xxxxx chr21:20,791,023-20,791,269
xxxxx chr21:43,564,596-43,564,683
GNB1L chr22:18,199,983-18,200,115
TSPAN7 chrX:38,361,789-38,362,093
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Associated gene Forward Primer Reversed Primer Probe
CNTNAP2 5’ AGCAGAAGGAGTTGAAATGC 3’ 5’ GCTGTCATTTGGCAGTAGC 3’ 5’ CAGATAGGGGGATCGCAGCC 3’
ITGA9 5’ GAGGGTGATGACAAGTTTGG 3’ 5’ ATATGGATGCAAAAGGAACC 3’ 5’ CTGGCCAGAGGAGAGCTTTCAGC 3’
ACCNA1 5’ CTAGCTTCCTTGGGCTTCTG 3’ 5’ CCAAGAGAGGGTCCTTGC 3’ 5’ TCAAGTGGTGTCCCATCGGGG 3’
SPECCL1 5’ ATTGCAGAGGTTTTTGATGG 3’ 5’ GGCTGTAGCCTCAACTCTGC 3’ 5’ CAGCCCTGCCCCACTCCTGT 3’
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Background
In this study, we performed a genome-wide search for effector genes bound by 
STOX1A, a winged helix transcription factor recently demonstrated to be involved in 
late onset Alzheimer’s disease and affecting the amyloid processing pathway.
Methodology/Principal Findings
Our results show that out of 218 genes bound by STOX1A as identified by chromatin-
immunoprecipitation followed by sequencing (ChIP-Seq), the serine/arginine-
rich splicing factor 7 (SFRS7) was found to be induced, both at the mRNA and 
protein levels, by STOX1A after stable transfection in glial cells. The increase in 
SFRS7 was followed by an increase in the 4R/3R ratios of the microtubule-associated 
protein tau (MAPT) by differential exon 10 splicing. Secondly, STOX1A also induced 
expression of total tau both at the mRNA and protein levels. Upregulation of total tau 
expression (SFRS7-independent) and tau exon 10 splicing (SFRS7-dependent), as 
shown in this study to be both affected by STOX1A, is known to have implications in
neurodegeneration.
Conclusions
Our data further supports the functional importance and central role of STOX1A in 
neurodegeneration.
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Introduction
Storkhead box 1 (STOX1A), a transcription factor structurally and functionally 
related to the forkhead family of transcription factors, characterized by a 100 amino 
acid DNA-binding motif termed the winged helix domain, was recently found to be 
a susceptibility gene for pre-eclampsia [1, 2], a hypertensive disorder of pregnancy 
which remains a major cause of maternal and perinatal mortality and morbidity [3]. 
Paradoxically, STOX1A was also found to be functionally involved in Late-Onset 
Alzheimer's Disease (LOAD) [4], a progressive neurodegenerative disease of 
the brain which is characterized by memory loss and impaired visiospatial skills 
involving elderly patients (>65 years) of both sexes [6]. In the latter study, van Dijk and 
co-workers showed that STOX1A is expressed abundantly in the brain, correlates with 
the severity of late onset Alzheimer's disease (LOAD) and transactivates the leucine-
rich repeat transmembrane 3 (LRRTM3) gene [4]. Upregulation of the LRRTM3 
gene by STOX1A leads to increased amyloid-β precursor protein (APP) processing 
resulting in higher levels of amyloid β peptide [4]. Amyloid β deposition is a key event 
in the etiology of Alzheimer's disease (AD) [5, 6]. However, STOX1A transactivation 
of LRRTM3 could not explain the complete STOX1A expression profile identified in 
the Alzheimer brain. Given the importance of this finding in neurodegeneration, but 
the lack of insight in the number and nature of genes controlled by STOX1A in the 
brain, we started a systematic search for downstream effector genes in the brain. For this, 
we performed a genome-wide search for STOX1A binding sites in the neuroblastoma 
cell-line SK-N-SH by chromatin-immunoprecipitation followed by sequencing 
(ChIP-Seq) [7]. Subsequently, genes selected for their involvement in pathways 
leading to LOAD and other neurodegenerative diseases were explored in detail.
Table 1. STOX1A regulated genes identified using ChIP sequencing. CEAS annotation software was used to filter for 
regions of known functional importance for which 13 genes were positioned directly in known promoter regions.
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Results
High throughput sequencing identifies a STOX1A DNA binding region in the promoter 
of SFRS7, a gene involved in the splicing of tau exon 10. 
Using a genome-wide, antibody-independent approach, 218 genomic regions 
were found to be bound by STOX1A in SK-N-SH cells (Dataset S1). With the 
algorithm Cis-regulatory Element Annotation System (CEAS) we filtered for known 
functionally important genomic regions [8]. This resulted in a top list of 115 hits 
associated with their corresponding regulated genes (Dataset S2). Out of 13 genes 
directly positioned in known promoter elements (Table 1), we selected the serine/
arginine splicing factor 7 (SFRS7) for in-depth functional analysis given its proven 
effect on tau exon 10 splicing [9, 17]. Misregulation of tau exon 10 splicing has a 
pathogenic role in neurodegenerative diseases [10, 11].
SFRS7 mRNA and protein expression levels are increased in SK-N-SH cells stably 
transfected with STOX1A. 
Following independent confirmation by Q-PCR of the STOX1A binding site in 
the SFRS7 promoter region (Fig. 1), the effect of STOX1A on SFRS7 transcription 
and translation was tested in SK-N-SH cells stably transfected with STOX1A or 
MOCK (negative control) constructs (Fig. 2A). Both SFRS7 mRNA (Fig. 2B) and 
protein levels (Fig. 2C) were found to be increased significantly and specifically upon 
STOX1A overexpression.
STOX1A effectuates changes in 4R/3R tau ratio in SK-N-SH cells. 
Isoforms of the tau protein exhibit either three (3R) or four microtubule-binding 
repeats (4R) depending on alternative splicing of tau exon 10 [11]. As it has been 
shown that SFRS7 effects tau 4R splicing [9, 17], we argued that the increased SFRS7 
transcript levels cause a change in tau 4R/3R ratios. Indeed, STOX1A leads to a 
significant increase in the tau 4R/3R ratio (Fig. 2D). Secondly, endogenous total tau 
levels were also elevated, both at the mRNA (Fig. 3A) and protein levels (Fig. 3B).
Figure 1. Validation by quantitative PCR of SFRS7 binding by STOX1A. Results show a mean 125 fold (mean ΔΔCt 
is 6,96) enrichment for SFRS7 in STOX1A stimulated ChIP DNA compared with their negative controls (ChIP sample 
vs ChIP blocked sample). Bars are mean ± SEM. Asterisks indicate P<0.05 (one sample t-test with theoretical mean 0). 
Data were obtained from at least five independent ChIP samples from which each DNA sample was measured in triplicate.
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SFRS7-dependent tau exon 10 splicing by STOX1A is specific for glial cells. 
The cell line, SK-N-SH, we used for the above in-vitro experiments comprises 
a heterogeneous subpopulation of neuroblastic (N-type) and substrate-adherent 
(S-type) cells [12–15]. As we observed a change in morphology due to clonal 
selection following stable transfection (Fig. 4A vs 4B) we tested the possibility that 
the phenomenon we observed was cell-specific, i.e. either restricted to the neuroblastic 
(N-type) or glial (S-type) cell. Immunostaining for disialoganglioside (GD2) (Figs. 
4C, –D) and calcyclin (Figs. 4E–F) showed the stably-transfected cells to consist 
of glial cells (S-type) only (calcyclin- positive, GD2-negative) [15]. Furthermore, 
no significant changes in SFRS7 expression and tau 4R/3R ratios were found upon 
stable transfection of STOX1A in the SK-N-SH N-type subclone cell-lineage SH-
Figure 2. STOX1A-induced SFRS7 expression is followed by increased tau splicing in SK-N-SH cells. (A) Expression 
of STOX1A protein was determined with an anti-Halotag specific antibody by western blot using total cell protein 
extracts obtained from stable STOX1A (left lane) and MOCK (right lane) transfected SK-N-SH cells. A specific band 
representing STOX1A-halotag protein was observed at its expected size of 150 kd. Halotag protein (MOCK) was detected 
at its expected size of 34 kd. Westernblot image is a representative of at least 3 independent experiments. (B) Quantitative 
RT-PCR data shows a mean 1.32 fold (mean ΔΔCt is 0,4) increased mRNA expression for SFRS7. Bars are mean ± SEM. 
* indicate P<0.05 (one sample t-test with theoretical mean 0). N= 4, each sample was measured in triplicate. (C, left image) 
Expression of endogenous SFRS7 protein was determined with an SFRS7 specific antibody by western blot using total cell 
protein extracts obtained from stable STOX1A and MOCK transfected SK-N-SH cells. An antibody specific for actin 
was used as a loading control. (C, right graph) Quantification of SFRS7 protein was performed using densitometry. The 
ratio number of obtained band intensities for STOX1A divided by actin was compared to the ratio number of obtained 
band intensities for MOCK divided by actin for 3 independent experiments. A significant increase for the STOX1A ratio 
number was found compared to the MOCK ratio number. P-values were calculated using two-tailed unpaired t-test, 
error bars represent ± SEM, ** indicate P<0.01. (D) Ratio numbers were obtained by dividing endogenous 4R and 3R tau 
mRNA concentrations for SK-N-SH cells stably transfected with STOX1A or MOCK constructs. Endogenous 4R and 
3R mRNA concentrations were obtained as described in the material and methods section. A highly significant increase 
of the 4R/3R tau ratio was seen for STOX1A compared to MOCK transfected cells. P-values were calculated using two-
tailed unpaired t-test, error bars represent ± SEM, *** indicate P<0.001. N = 4, each sample was measured in triplicate.
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SY5Y (data not shown). Given this, and to independently confirm that the effect of 
STOX1A on exon 10 tau splicing via SFRS7 is glial cell-specific, we tested U-373 
MG cells as a cellular model for glial cells. To confirm that in the STOX1A-SFRS7-
tau splicing pathway,  the effect of SFRS7 on tau splicing is direct in U-373 MG cells 
we performed siRNA knockdown experiments against SFRS7 in the untransfected 
U-373 MG cell-line and measured 3R and 4R tau concentrations for SFRS7 
siRNA treated and control samples to calculate 4R/3R tau ratios. Significant SFRS7 
knockdown was confirmed by measuring endogenous SFRS7 mRNA levels (Fig. 5A) 
and protein levels on western blot (Fig. 5B). Furthermore, a significant decrease in 
the 4R/3R ratio for SFRS7 siRNA treated cells was seen compared to the scrambled 
control (Fig. 5C) which was confirmed on western blot (Fig. 5D). Next, we stably 
transfected U-373 MG cells with STOX1A to determine the effect of STOX1A 
on tau exon 10 splicing via SFRS7. First, we characterized the STOX1A expression 
pattern in U-373 MG cells using immunofluorescence which showed strong nuclear 
(Fig. 6A, –C) staining for STOX1A protein. Furthermore, expression of STOX1A 
was confirmed on westernblot (Fig. 6G). Secondly, we determined the effect of stable 
STOX1A expression on SFRS7 expression and tau exon 10 splicing. Identical effects 
on SFRS7 mRNA (Fig. 7A) and protein (Fig. 7B) levels were seen as for the SK-N-
SH (S-type) cells (Fig. 2). Furthermore, 4R/3R tau ratio’s (Fig. 7C) were significantly 
increased which was confirmed on western blot (Fig. 7D) thereby showing the effect 
of STOX1A on tau processing via SFRS7 in glial cells. Finally, as for the SK-N-SH 
Figure 3. STOX1A upregulates total tau RNA and protein levels in stable transfected SK-N-SH cells. (A) Quantitative 
RT-PCR show a mean 3,59 fold (mean ΔΔCt 1,84) increased mRNA expression for total tau. Bars are mean ± SEM. 
P<0.05 (one sample t-test with theoretical mean 0). N = 4, each sample was measured in triplicate.(B, upper image) 
Expression of endogenous total tau protein was determined with a total tau specific antibody by western blot using total 
cell protein extracts obtained from stable STOX1A and MOCK transfected SK-N-SH cells. An antibody specific for actin 
was used as a loading control. Westernblot image is a representative of at least 3 independent experiments. (B, lower graph) 
Quantification of total tau protein was performed using densitometry. The ratio number of obtained band intensities for 
STOX1A divided by actin was compared to the ratio number of obtained band intensities for MOCK divided by actin 
for 3 independent experiments. A significant increase for the STOX1A ratio number was found compared to the MOCK 
ratio number. P-values were calculated using two-tailed unpaired t-test, error bars represent SEM, *** indicate P<0.001.
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Figure 4. Stably transfected SK-N-SH cells consist of glial cells only. (A) Morphology of untransfected SK-N-SH 
cells or (B) stably transfected SK-N-SH cells. The G418 (Roche) antibiotic selection procedure for selection of positive 
STOX1A and MOCK stable transfected cells resulted by clonal selection in a homogeneous cell population that is 
composed of the glial (S-type) type. (C) Immunophenotype of untransfected SK-N-SH cells showing intense membrane 
staining for GD2 but lack nuclear calcylin staining (E). No GD2 membrane staining was observed in stably transfected 
SK-N-SH cells (D) while cells show high calcyclin nuclear staining (F). Green: GD2, Red: Calcyclin, Blue: DAPI.
(S-type) cells (Fig. 3), significantly increased endogenous total tau expression, both 
at the mRNA (Fig. 8A) and protein levels (Fig. 8B), was seen upon stable STOX1A 
overexpression in the U-373 MG cell-line.
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Figure 5. SFRS7 acts as a tau exon 10 splicing enhancer in the glial cell-line U- 373 MG. (A) Knockdown of 
endogenous SFRS7 protein was determined with quantitative RT-PCR showing a mean 9,13 fold (mean ΔΔCt 3.19) 
decreased endogenous mRNA expression for SFRS7. Bars are mean ± SEM.* indicate P<0.05 (one sample t-test with 
theoretical mean 0). N= 4, each sample was measured in triplicate. (B) Knockdown of endogenous SFRS7 protein was 
determined with a SFRS7 specific antibody by western blot using total cell protein extracts obtained from SFRS7 siRNA 
and scrambled transfected U-373 MG cells. An antibody specific for actin was used as a loading control. Westernblot image 
is a representative of at least 3 independent experiments. (C) Ratio numbers were obtained by dividing endogenous 4R and 
3R tau mRNA concentrations from U373-MG cells transfected with siRNA SFRS7 or scrambled siRNA. Endogenous 
4R and 3R mRNA concentrations were obtained as described in the material and methods section. A significant decrease 
of the 4R/3R tau ratio was seen for siRNA SFRS7 compare to scrambled siRNA transfected cells. P-values were
calculated using two-tailed unpaired t-test, error bars represent ± SEM, * indicate P<0.05. N= 4, each sample was measured 
in triplicate. With the use of densitometry on obtained westernblot images (D) a similar significant decrease of the 4R/3R 
tau ratio was seen on a protein level (D, right graph). Significance was calculated by combining the densitometry data from 3 
independent experiments. P-values were calculated using two-tailed unpaired t-test, error bars represent ± SEM, * indicate P<0.05
Discussion
Here we describe the genome-wide exploration of genomic regions bound by STOX1A 
in the neuroblastoma cell-line SK-N-SH. For this, an antibody-free chromatin 
immunoprecipitation procedure was used followed by massively parallel sequencing. 
Of the genes bound, the SFRS7 gene was selected for in-depth functional analysis. We 
found that SFRS7-mediated splicing of tau exon 10 is directly regulated by STOX1A 
in glial cells. Previously we showed the effect of STOX1A on the amyloid pathway 
in neuronal SK-N-SH cells [4]. Here we show the effect of STOX1A on both total 
tau expression as well as tau processing (exon 10 splicing) in glial cells. The effect 
of STOX1A on tau expression and processing additionally confirms the role of this 
transcription factor in central pathways underlying neurodegeneration including AD.
The data on tau splicing appear initially in conflict with the observation made by Gao 
and co-workers who found that SFRS7 acts as a tau exon 10 splicing silencer in SK-
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Figure 6. Expression analysis of STOX1A in stable transfected U-373 MG cells. (A, –C) Immunofluorescence shows 
primarily nuclear staining for STOX1A-Halotag protein in stable transfected U-373 MG cells while stable MOCK-
Halotag transfected U-373 MG cells shows diffuse cytoplasmatic staining (D, –F). (G) Expression of STOX1A protein 
was determined with an anti-Halotag specific antibody by western blot using total cell protein extracts obtained from 
stable STOX1A (left lane) and MOCK (right lane) transfected U373 cells. A specific band representing STOX1Ahalotag 
protein was observed at its expected size of 150 kd. Halotag (MOCK) protein was detected at its expected size of 34 kd. 
Westernblot image is a representative of at least 3 independent experiments.
N-SH cells thereby decreasing the ratio of 4R/3R tau [9]. Our results show the reverse. 
However, we cannot exclude that Gao and co-workers used a mixed SK-N-SH cell 
population consisting of primarily N-type and little S-type cells, while ours consisted 
of the S-type subpopulation only. Possibly, in our situation, the S-type cells transfected 
more easily. Therefore, transfected S-type cells were able to overgrow the N-type cells 
which died from the neomycin selection. This resulted in a cell population consisting 
of the S-type subpopulation only. Furthermore, while our results indicate that SFRS7 
acts as a splicing enhancer in the S-type of cells, the effect of STOX1A on SFRS7 is 
also restricted to the S-type cells whereas we could not find any significant changes in 
SFRS7 expression upon stable STOX1A expression in the N-type subclone cell line 
SH-SY5Y (data not shown). This does not exclude the role of SFRS7 acting as a tau 
364
STOX1A Mediated Tau Splicing in Glial Cells · 3
Figure 7. Tau exon 10 splicing is increased upon stable STOX1A overexpression via SFRS7 in U-373 MG cells. (A) 
Quantitative RT-PCR shows a mean 1,24 fold (mean ΔΔCt is 0,306) increased mRNA expression for SFRS7. Bars are 
mean ± SEM. * indicate P<0.05 (one sample t-test with theoretical mean 0). N= 4, each sample was measured in triplicate. 
(B) Expression of endogenous SFRS7 protein was determined with a SFRS7 specific antibody by western blot using total 
cell protein extracts obtained from stable STOX1A and MOCK transfected U-373 MG cells. Westernblot image is a 
representative of at least 3 independent experiments. (C) Ratio numbers were obtained by dividing endogenous 4R and 
3R tau mRNA concentrations for U373-MG cells stably transfected with STOX1A or MOCK constructs. Endogenous 
4R and 3R mRNA concentrations were obtained as described in the material and methods section. A highly significant 
increase of the 4R/3R tau ratio was seen for STOX1A compare to MOCK transfected cells. P-values were calculated using 
two-tailed unpaired t-test, error bars represent ± SEM, *** indicate P<0.001. N = 4, each sample was measured in triplicate. 
With the use of densitometry on obtained westernblot images (D) a similar significant decrease of the 4R/3R tau ratio was 
seen on a protein level. Significance was calculated by combining the densitometry data from 3 independent experiments. 
P-values were calculated using two-tailed unpaired t-test, error bars represent ± SEM, * indicate P<0.05
exon 10 splicing silencer in the neuronal S-type cells, in fact, SFRS7 has been shown 
to suppress tau exon 10 inclusions in the neuroblastoma cell-line SH-SY5Y by Ding 
et al. [17]. Given this, we hypothesize that both the function of SFRS7 acting as a 
splicing enhancer or silencer, and the effect of STOX1A on SFRS7 expression is cell-
type dependent (neuronal versus glial). Therefore our aim was to further investigate 
the function of STOX1A on SFRS7 in glial cells where SFRS7 acts as an exon 10 
splicing enhancer. This theory is supported by our finding that knockdown of SFRS7 
*
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Figure 8. STOX1A effectuates endogenous total tau expression in U-373 MG cells. (A) Quantitative RT-PCR show a 
mean 2,33 fold (mean ΔΔCt is 1,22) increased mRNA expression for total tau. Bars are mean ± SEM. * indicate P<0.05 
(one sample t-test with theoretical mean 0). N= 4, each sample was measured in triplicate. (B) Expression of endogenous 
total tau protein was determined with a total tau specific antibody by westernblot using total cell protein extracts obtained 
from STOX1A and MOCK transfected U-373 MG cells. An antibody specific for actin was used as a loading control. 
Westernblot image is a representative of at least 3 independent experiments. (B, lower graph) Quantification of total tau 
protein was performed using densitometry. The ratio number of obtained band intensities for STOX1A divided by actin 
was compared to the ratio number of obtained band intensities for MOCK divided by actin for 3 independent experiments. 
A significant increase for the STOX1A ratio number was found compared to the MOCK ratio number. P-values were 
calculated using two-tailed unpaired t-test, error bars represent ± SEM, *** indicate P<0.001.
in the U-373 MG cell-line shows an decrease in the 4R/3R tau ratio while stable 
over-expression of STOX1A, which induces SFRS7 expression, increases the 4R/3R 
tau ratio.
The opposite effect on tau exon 10 splicing seen after SFRS7 downregulation, as 
shown for glial cells in this paper, supports the cell type dependent regulation of this 
splicing factor which was also observed by Ding and co-workers [17]. Possibly, SFRS7 
acts as a tau exon 10 splicing enhancer in glial cells by binding to yet to be discovered 
exonic and intronic enhancers, which would not be surprising because it has been 
shown that SFRS7 mainly acts as a splicing enhancer, instead of silencer as shown by 
Gao and co-workers [17–20].
In LOAD, neurofibrillary tangles are one of the main hallmarks [21]. While we pre- 
viously found that in advanced stages of LOAD (Braak 3–6), STOX1A primarily 
stains positive in hippocampal neurons with neurofibrillary tangles (but also microglia) 
[4], the implication in LOAD with our presented findings for STOX1A in glial cells 
would therefore be possibly limited. However, while STOX1A expression is found 
primarily in the brain and dysregulation of the balance between glial 4R/3R tau 
ratio by a selective increase in either 3R-tau or 4R-tau is commonly seen in a range 
of diverse neurodegenerative diseases other than LOAD, including frontotemporal 
dementia with Parkinsonism linked to chromosome 17 (FTDP-17), Pick's disease 
(PD), progressive supra nuclearpalsy (PSP), and corticobasal degeneration [22], 
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further exploration of where STOX1A and/or SFRS7 expression are found in these 
neurodegenerative diseases would yield great insight into their involvement.
Interestingly, independently of SFRS7 transactivation by STOX1A we also observed a 
significant increase in total tau mRNA and protein levels in both SK-N-SH (S-type) 
and U-373 MG cells. While this effect is not seen after knockdown of SFRS7, this 
effect is also STOX1A-dependent. As no binding site was identified for STOX1A in 
the tau promoter (Dataset S1), it would therefore be interesting to further investigate 
which gene, other than tau or SFRS7 but bound by STOX1A, controls total tau 
expression in glial cells.
Although we selected a single gene for functional analysis, combined or follow-up 
analysis of the other genes identified will likely generate novel results providing and 
permitting mechanistic insight in pathways important for e.g. neurodegeneration. 
The antibody-free ChIP procedure can be applied to other transcription factors and 
cellular systems as well and is highly informative when combined with massively 
parallel sequencing as done in the present paper.
In conclusion, while previous findings by van Dijk and co-workers have shown a 
functional link between STOX1A and LOAD, we here provide further evidence that 
STOX1A has important functions in the pathways leading to neurodegeneration.
Materials and Methods 
Cell culture and transfection
SK-N-SH human neuroblastoma cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). All reagents for cell culture were purchased from 
Invitrogen Life Technologies, Inc. (Burlington, Canada). SK-N-SH and U-373 
MG cells were cultured at 37°C in a humidified atmosphere of 5% CO2 in Iscove's 
Modified Dulbecco's Medium (IMDM) supplemented with 10% fetal calf serum and 
100 U/ml penicillin, and 100 g/ml streptomycin. Cells were subcultured in medium 
every 2–3 days following harvesting by trypsinization (HBSS containing 5% trypsin). 
The ORF (Open Reading Frame) of the STOX1A gene was subcloned into the 
Halotag pF5K neomycin CMV Flexi vector according to the manufacturers protocol 
(Promega). For transfection the calcium phosphate method was used [16]. Briefly, 
at the time of transfection, cells were at 70% confluence. By vortexing 2X HEBS 
(HEPES-buffered saline) with a solution of 2.5 M CaCl2 and 20 µg of plasmid DNA 
a co-precipitate of DNA and CaPO4 was allowed to form. After incubation for 30 
min at room temperature, the precipitate was added to the cells and the medium was 
changed after 24 h. Cells were used 48 h post-transfection for further analysis.
For stable transfections SK-N-SH or U-373 MG cells were transfected either with 
the pF5K-STOX1A or empty pF5K constructs. Selection of positive clones was 
possible due to the presence of the neomycin resistant gene present in the constructs. 
Positive clones were maintained in complete IMDB medium supplemented with 800 
µg/ml G418 (Roche) until reaching confluence and subcultured every 2–3 days for 
about 4 weeks. A population of positive clones was harvested for further analysis. As 
confirmed with qRT-PCR (See below) using TaqMan probes (Applied Biosystems) 
for STOX1A, two stable SK-N-SH cell-lines which over-expressed STOX1A 25 and 
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30 fold, and 6 stable U-373 MG cell-lines with a mean 64 fold over-expression of 
STOX1A were selected. Protein expression of the STOX1A-Halotag proteins was 
confirmed by western blot. 
Additionally, plasmid DNA quantification using qPCR (see below) with primers and 
probe specific for the constructs backbone showed similar copy numbers in each cell-
line.
Knockdown of endogenous SFRS7 was performed by transfecting siRNA's against 
SFRS7 and control siRNA (Santa Cruz) in untransfected U-373 MG cells with 
Lipofectamine™ RNAiMAX (Invitrogen) according to the manufactures protocol. 
Cells were harvested 48 hours post-transfection and RNA was isolated as described in 
the Quantitative PCR and RT-PCR section.
Chromatin immunoprecipitation
Transfected cells were treated with formaldehyde to create protein-DNA crosslinks. 
Cytoplasmatic lysis was performed to reduce competition of cytoplasmatic STOX1A-
Halotag proteins against nuclear STOX1A-Halotag proteins with the Halotag resin. 
Nuclear lysate was subsequently fragmented by sonication. The nuclear lysates were 
split into two equal parts of which one was treated with Halotag blocking ligand 
to function as a negative control. Both the samples and controls were treated using 
Halotag resin according to the Halo-ChIP system protocol in the presence of 
proteinase inhibitors. After reversal of crosslinks the DNA was purified using the 
Qiaquick PCR purification kit (Qiagen). The ChIP-Seq method can be found in the 
additional material section (Text S1).
Quantitative PCR and RT-PCR
Standard quantitative PCR was performed on an ABI7300 (Applied Biosystems) 
using probes (5’-FAM 3’-TAMRA labeled SFRS7 probe 5’-CGCCCAGGGCTCGA 
GTGAC-3’) and primers (SFRS7 forward: 5’-ACGCGACATGATGACAGAC- 3’, 
SFRS7 reversed: 5’-CGCATATATAAACGCGAACC-3’) specific for the SFRS7 
region obtained in the ChIP-Seq experiments in the presence of 1M betaine and ROX 
reference dye, and corrected for input using the non-intron-spanning Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) gene expression assay (Applied Biosystems). 
Input ChIP DNA was obtained from at least five independent ChIP experiments.
RNA isolation from transfected cells was performed using the RNeasy kit (Qiagen) 
including on-column DNase treatment. Quantitative RT-PCR using gene 
expression assays (Applied Biosystems) for SFRS7 and total tau was performed on 
an ABI7300. In addition, transfection effiencies were corrected by plasmid DNA 
quantification using the pF5 CMV-neo Flexi® Vector backbone present in all 
plasmids (pF5 forward: 5’-GCTTCGAGCAGACATGATAAG-3’, pF5 reversed: 
5’-AGCAATAGCATCACAAA TTTCA-3’, 5’-FAM 3’-TAMRA labeled pF5 
probe: 5’-TGGACAAACCACAACT AGAATGCAGT-3’). Data were obtained 
from at least four transfections from which each RNA sample was measured in 
triplicate.
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Western blot
Protein lysates from stable transfected cells were obtained by directly scraping cells 
into loading Buffer including β-mercaptoethanol. Lysates were separated by SDS-
polyacrylamide gel electrophoresis, and electroblotted onto a PVDF-membrane. An 
antibody recognizing the Halotag protein (Promega) was used in combination with 
goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (DAKO). 
To detect endogenous levels of SFRS7 and tau, SFRS7 antibody (9G8, Santa Cruz) 
or total tau antibody (Abcam) was used in combination with donkey anti-goat IgG 
horseradish peroxidase-conjugated secondary antibody (Santa Cruz) and goat anti-
rabbit horseradish peroxidase-conjugated secondary antibody (DAKO), respectively. 
Mouse monoclonal antibodies specific for the tau 3R (RD3, clone 8E6/C11) or 
4R (RD4, clone 1E1/A6) splice variants were obtained from Millipore and used in 
combination with goat anti-mouse horseradish peroxidase-conjugated secondary 
antibody (DAKO). Endogenous actin used for loading controls was detected with 
mouse monoclonal anti-actin antibody (Sigma Aldrich) used in combination with goat 
anti-mouse horseradish peroxidase-conjugated secondary antibody (DAKO). Protein 
bands were detected by an enhanced-chemiluminescence assay (GE Healthcare) on 
a LAS3000.
Immunofluorescence
For immunofluorescence, untransfected and stable transfected SK-N-SH cells were 
grown on glass coverslips. Coverslips were fixed in 4% (PFA) paraformaldehyde for 15 
min at room temperature. After fixation, coverslips were rinsed in PBS, 0.1% Triton 
X-100 and incubated with 1% Triton X-100 in PBS for 15 min at room temperature 
for permeabilization. Coverslips were washed in wash buffer (PBS, 0.1% Triton 
X-100, 2% BSA (Bovine serum albumin)) blocked with PBS, 0.1% Triton X-100, 5% 
BSA for 1 h and incubated with Calcyclin (Santa Cruz biotechnology) or GD2 (BD 
Pharmingen) antibody at 4°C overnight.
After washing with wash buffer, cells were incubated for 1 hour with the appropriate 
secondary antibodies conjugated with Alexa Fluor 488 or Alexa Fluor 568 (Invitrogen), 
washed with washing buffer and mounted with vectashield mounting solution 
containing DAPI for DNA counterstaining (Vector Laboratories).
For STOX1A-Halotag immunofluorescence, stable transfected cells grown on 
coverslips were incubated with TMR-Halotag ligand according the manufactures 
instructions (Promega). Coverslips were fixed in 4% (PFA) paraformaldehyde for 
15 min at room temperature. After fixation, coverslips were washed with washing 
buffer and mounted with vectashield mounting solution containing DAPI for DNA 
counterstaining (Vector Laboratories).
Tau splicing Assay and ratio calculation
qRT-PCR was performed with RNA isolated from the stable STOX1A transfected 
SK-N-SH and U-373 MG cell-lines and transiently transfected SFRS7 and scrambled 
siRNA U-373 MG cells on a Lightcycler 480 (Roche) using the SYBR Green master 
kit and primers specific for the 3R (3R-forward: 5’-GGAAGGTGCAAATAGTC-3’, 
3R-reversed: 5’-CGACTGGACTCTGTCCTTGA-3’) or 4R tau 
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(4R-forward: 5’-CGGGAAGGTGCAGATAATTAA-3’, 4R-reversed: 
5’-GCCTAATGAGCCACACTTGGAG-3’) isoforms. Due to the high degree of 
homology between 3R and 4R isoforms, the 3R 5’-3’ primer has 4 Locked Nucleic 
Acid (LNA) modifications to ensure specificity. cDNA was synthesized with the 
SuperScript III Reverse Transcriptase kit (Invitrogen).Constructs containing the 3R 
or 4R tau isoforms with known DNA concentrations were used for the generation of a 
standard curve (concentrations for the constructs containing the 3R isoform were 10-2, 
10-3, 10-⁴, 10-⁵ and 10-⁶ ng/µl and for the constructs containing the 4R isoform 10-3, 10-
⁴, 10-⁵, 10-⁶ and 10-⁷ ng/µl). Experimental samples were measured and concentrations 
calculated by comparison to the standard curve. Tau ratios were calculated by dividing 
the mean 4R tau concentrations by the mean 3R tau concentrations of the treated 
samples. The same was done for the control treated samples. An unpaired t-test was 
used to calculate significance between the treated 4R/3R tau ratio and control treated 
4R/3R tau ratio. Error bars represent ± SEM.
Data analysis
For Real-time PCR data, a threshold cycle number, Ct, was measured as the PCR cycle 
at which the amount of amplified target reaches the threshold value. Quantification 
was determined by the 2-ΔΔCt method as described in Applied Biosystems “Guide to 
Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative 
PCR”, Section VII, Relative Quantitation of Gene Expression Experimental Design 
and Analysis http://www3.appliedbiosystems.com/cms/groups/mcb_support/
documents/generaldocuments/cms_042380.pdf ). Statistical analysis of the obtained 
data was carried out with the GraphPad Prism program.
For quantification of westernblots densitometry was used. Westernblot pictures 
were analysed with the software ImageJ according to the tutorial described on the 
website: http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-
with-image-j/. Statistical analysis on the obtained density values was carried out with 
Microsoft Excell and the GraphPad Prism program.
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Supporting Information 
Dataset S1.
BED file as outputted by QuEST. The BED file provided can be directly uploaded 
into the UCSC browser (http://genome.ucsc.edu/) as a custom track. The human 
assembly (NCBI36/hg 18) was selected as reference genome. Custom tracks show 
genomic regions in blue and potential binding peaks in red as calculated by QuEST. 
(http://www.plosone.org/article/fetchSingleRepresentation.action?uri=info:doi/10.1371/journal.pone.0021994.s001)
Dataset S2.
Regions (BED file, Dataset S1) of functional importance generated by CEAS as 
RefSeq genes. Can be opened in Microsoft Excell.
(http://www.plosone.org/article/fetchSingleRepresentation.action?uri=info:doi/10.1371/journal.pone.0021994.s002)
Text S1. Supplementary ChIP sequencing methods. 
Massively Parallel Genomic Sequencing 
Multiple samples of precipitated HaloChIP DNA were validated with QPCR on 
enrichment with a confirmed STOX1 bound region found in a previously performed 
ChIP-shotgun cloning procedure (Data not shown). Enriched samples were pooled 
and used for high-throughput sequencing (ChIP-Seq) on a Genome Analyzer 
IIx (Illumina). 10–80 ng of pooled HaloChIP DNA was used for DNA library 
construction by the Genomic DNA Sample Preparation Kit (Illumina) following 
the manufacturer’s protocol of sample preparation for ChIP-Sequencing of DNA. 
Enriched adapter-ligated DNA fragments in the range of 200–350 bp were size 
selected using 2% agarose electrophoresis. The selected DNA libraries were then 
additionally amplified using a 15-cycle PCR. The adapter ligated DNA was purified 
directly using spin columns provided in a QIAquick PCR purification kit (Qiagen).
Sequence Alignment
Single-read sequencing for 36 cycles was performed. All 36-bp sequence reads were 
aligned to the repeat-masked human genomic reference sequence (NCBI Build 36, 
version 48) downloaded from the Ensembl Genome Browser (http://www.ensembl.
org), using the ELAND program in the GAPipeline-1.4.0 software package provided 
by Illumina. A result output file was generated after running ELAND.
ChIPseq peak calling
For peak calling we used the ELAND output files in the program QuEST 2.4. Firstly, 
ChIP default parameters were selected for a transcription factor with defined motif 
and narrow binding site (bandwidth = 30 bp and region size = 300 bp). Stringent peak 
calling parameters were then selected as recommended by QuEST (ChIP threshold = 
0.164, Enrichment fold = 3 and Rescue fold = 3).  
Each peak was ranked according to a Q-value produced from the p-values calculated 
by Benjamini correction in QuEST. This ranking indicated the certainty of enrichment 
between the experimental versus control data on a genome-wide level.
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Transcription factor STOX1A promotes mitotic entry by 
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Background: In this study we investigated the involvement of the transcription factor 
STOX1A in the regulation of the cell cycle. 
Methodology/Principal Findings:
We found that several major cell cycle regulatory genes were differentially expressed 
upon STOX1A stimulation and knockdown in the neuroblastoma cell line SH-SY5Y. 
This includes STOX1A dependent differential regulation of cyclin B1 expression, a 
cyclin which is known to regulate mitotic entry during the cell cycle. The differential 
regulation of cyclin B1 expression by STOX1A is direct as shown with chromatin 
immunoprecipitation. Results furthermore suggest that mitotic entry is enhanced 
through the direct upregulation of cyclin B1 expression effectuated by STOX1A. 
Conclusions: In conclusion, we hereby show that STOX1A is directly involved in the 
regulation of the cell cycle.
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Introduction
Mammalian cell division is controlled by the expression of cyclins and activation of 
their associated cyclin dependent kinases (CDKs). While the CDK components are 
generally expressed ubiquitously during the cell cycle, expression of cyclins accumulate 
periodically during distinct phases (G1, S , G2, and M phase) of the cell cycle [1]. In 
each phase, binding of cyclins with their corresponding CDK forms an active cyclin/
CDK complex. In general, G1 to S phase progression is controlled by CDK2 bound 
to S-phase cyclins [2] (E- and A-type) whereas G2 to M phase is triggered by CDK1 
associated with mitotic cyclins [3] (A- and B-type). Active cyclin/cdk complexes can 
phosphorylate several substrates, which subsequently trigger cell cycle progression 
[4-6]. Many of these cyclin/cdk complex substrates and regulators of the cell cycle 
machinery itself have been characterized in detail, and recently it was shown to include 
a group of proteins belonging to the forkhead transcription factors. These transcription 
factors are characterized by a 100 amino acid DNA-binding motif termed the winged 
helix domain [7-10]. Several studies have confirmed the role of forkhead transcription 
factors in regulating the transcription of cell cycle regulatory genes during the cell 
cycle [8-10]. Additionally, it has been shown that multiple members of the forkhead 
transcription factors are regulated by components of the cell cycle itself. These include 
FOXM1 [8], FOXO1 [9], and FOXK2 [10].
Recently, Storkhead box 1A (STOX1A), a transcription factor structurally and 
functionally related to the forkhead family of transcription factors [11, 12], has been 
shown to be expressed abundantly in the brain and found to be upregulated in advanced 
stages of Late Onset Alzheimer’s Disease (LOAD, Braak 3–6). Secondly, STOX1A 
was found to be expressed at the centrosomes of dividing  cells [13]. Centrosomes 
serve as reaction centres for several key regulators of the cell cycle machinery [14, 15], 
where in particular G2 to M-phase transition is triggered by cyclin B1-CDK1 [16, 
17]. Together with the increasing evidence that neurons, generally in a non-dividing 
state called G0,  re-express a multitude of cell-cycle regulators in Alzheimer’s disease 
(AD) [18-20], led us to explore the involvement of STOX1A in cell cycle related 
events. Here we show that in the neuroblastoma SH-SY5Y cell line STOX1A directly 
regulates the expression of the mitotic cyclin B1. Hereby we show that STOX1A, in 
addition to other members of the forkhead transcription factors, is directly involved 
in regulating the cell cycle. Upregulated expression of STOX1A in LOAD therefore 
potentially influences neuronal cell cycle re-entry.
Results 
Expression analysis of SH-SY5Y cells stably transfected with STOX1A during distinct 
phases of the cell cycle. 
To identify the expression pattern of STOX1A in stably transfected SH-SY5Y cells 
we performed immunofluorescence using an antibody against the Halotag attached to 
the STOX1A recombinant protein. During interphase we observed primarily nuclear 
and to a lesser extent cytoplasmic STOX1A staining (Fig 1A) which confirms the 
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model of STOX1A nucleo-cytoplasmic shuttling as previously described by our lab 
[12]. Nuclear localization represents the active form of STOX1A. 
To investigate the expression pattern of STOX1A during mitosis, cells were arrested 
at the G2/M-phase boundary. As also observed for the forkhead transcription factor 
FOXK2 [10], STOX1A shows a non-overlapping immunofluorescence pattern with 
DNA (STOX1A-halotag / DAPI merge) shortly after nuclear envelope breakdown in 
prometaphase. The non-overlapping immunofluorescence pattern is best seen during 
metaphase and anaphase until cytokinesis occurs when STOX1A immunofluorescence 
overlaps with DNA (DAPI) (Fig 1B). As shown previously by us [15], STOX1A is 
concentrated at the centrosomes during metaphase (Fig 1B, white arrows). 
STOX1A regulates cell proliferation in SH-SY5Y cells. 
As the results above indicate that STOX1A is involved in mitosis, the effect of 
STOX1A on cell proliferation was tested by using STOX1A siRNA knockdown 
in comparison to scrambled siRNAs in the neuroblastoma SH-SY5Y cell line. 
Figure 1. Expression analysis of STOX1A in stably transfected SH-SY5Y cells. (A) Immunofluorescence shows 
exclusively nuclear or cytoplasmic (white arrows) staining for STOX1A-Halotag protein in STOX1A stably transfected 
SH-SY5Y cells. (B) Cells undergoing mitosis showing a non-overlapping STOX1A / DAPI immunofluorescence pattern 
during metaphase and anaphase until cytokinesis when STOX1A immunofluoresence overlaps with DAPI (DNA) 
immunofluorescence.
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Knockdown of STOX1A resulted in a significant reduction of cell proliferation 
compared to the scrambled siRNA control (Fig 2A, left graph). In parallel, at each time 
point, the amount of death cells were counted. However we did not found significant 
differences in cell dead between STOX1A siRNA or scrambled siRNA transfected 
cells (Fig 2A, right graph). In concordance with the reduction in cell proliferation 
upon STOX1A siRNA transfection, cells that were stably transfected with STOX1A 
showed a significant increase in cell proliferation compared to empty vector (MOCK) 
Figure 2. The effect of STOX1A on cell proliferation in the neuroblastoma cell-line SH-SY5Y. (A, left graph) The 
proliferation curve shows significantly decreased cell proliferation for STOX1A siRNA transfected SH-SY5Y cells 
compared to scrambled controls after 1, 2, and 3 days in culture. (A, right graph) In parallel we did not found significant 
differences in cell death between STOX1A siRNA and scrambled siRNA transfected cells at each of the indicated time 
points. (B, left graph) The proliferation curve shows significantly increased cell proliferation for STOX1A compared to 
MOCK stably transfected SH-SY5Y cells after 1, 2, and 3 days in culture. (B, right graph) In parallel we did not found 
significant differences in cell death between STOX1A and MOCK transfected cells at each of the indicated time points. 
Bars are mean ± SEM. P-values for each timepoint were calculated using two-tailed unpaired t-test. (C) Overexpression 
and knockdown of STOX1A was determined with quantitative RT-PCR showing a mean 21 fold (mean ΔΔCt 4.4) 
increase in mRNA expression for STOX1A in stably transfected SH-SH5Y cells compared to the controls (Left bar) and a 
mean 71 fold (mean ΔΔCt 6.15) decreased mRNA expression for STOX1A siRNA transfected SH-SY5Y cells compared 
to the scrambled controls (right bar). Bars are mean ± SEM. *** indicate P<0.001 (one sample t-test with theoretical mean 
0). N = 4, each sample was measured in triplicate. (D, Bottom left graph) Quantification of STOX1A-Halotag protein 
was performed using densitometry. The ratio number of obtained band intensities for STOX1A (at the expected band size 
of 150 Kd)  divided by actin was compared to the ratio number of obtained band intensities for MOCK divided by actin 
for 3 independent experiments. A significant increase for the STOX1A ratio number was found compared to the MOCK 
ratio number. (D, Bottom right graph) Quantification of endogenous STOX1A protein was performed using densitometry. 
The ratio number of obtained band intensities for STOX1A siRNA (at the expected band size of 110 Kd) divided by actin 
was compared to the ratio number of obtained band intensities for scrambled siRNA divided by actin for 3 independent 
experiments. A significant increase for the STOX1A siRNA ratio number was found compared to the scrambled siRNA 
ratio number. P-values were calculated using two-tailed unpaired t-test, error bars represent ± SEM, * indicate P<0.05, *** 
indicate P<0.001. Westernblot images are a representative of at least 3 independent experiments.
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transfected SH-SY5Y cells (Fig 2B, left graph).  In parallel, at each time point, the 
amount of dead cells were counted. No significant differences in cell death between 
STOX1A and MOCK transfected cells were found (Fig 2B, right graph). Knockdown 
and stable overexpression of STOX1A in the SH-SY5Y cell-line was confirmed at the 
mRNA (Fig 2C) and protein level (Fig 2D). 
Reduced cell proliferation by STOX1A siRNA knockdown and increased cell 
proliferation by STOX1A overexpression suggest STOX1A dependent cell cycle 
regulation. To test this we measured mRNA levels of four major mammalian cell cycle 
regulatory genes; cyclin A2 (CCNA2, involved in the S to G2 phase and G2 to M 
phase progression [21]), cyclin B1 (CCNB1, involved in G2 to M phase progression 
Figure 3. STOX1A induces changes in several major cell cycle regulatory genes. (A) The effect of stable STOX1A 
overexpression in the SH-SY5Y neuroblastoma cell line on four major mammalian cell cycle regulatory genes was 
determined with quantitative RT-PCR showing a mean 1,4 fold  (mean ΔΔCt is −0,49) and mean 1,72 fold (mean ΔΔCt 
is −0,78) increased mRNA expression for CCNA2 and CCNB1, respectively, and a mean 1,22 fold (mean ΔΔCt is 0,29) 
decreased mRNA expression for CCNC in STOX1A stably transfected cell compared to their negative controls. (B) The 
effect of STOX1A knockdown in the SH-SY5Y neuroblastoma cell line on four major mammalian cell cycle regulatory 
genes was determined with quantitative RT-PCR showing a mean 11,8 fold (mean ΔΔCt is 3,56 ), mean 10.3 fold (mean 
ΔΔCt is 3,37) and mean 3,8 fold (mean ΔΔCt is 1,92) decreased mRNA expression for CCNA2, CCNB1 and CCNE1 
respectively, and a mean 1,7 fold (mean ΔΔCt is -0,77) increased mRNA expression for CCNC in STOX1A siRNA 
treated cells compared to their negative controls. (A,B) Bars are mean ± SEM. * indicate P<0.05, ** indicate P<0.01, *** 
indicate P<0.001 (one sample t-test with theoretical mean 0). N = 4, each sample was measured in triplicate. (C) Expression 
of endogenous CCNB1 protein and the active form of the CDK1 protein was determined by western blot using total cell 
protein extracts obtained from STOX1A siRNA and control treated SH-SY5Y cells. CCNB1 proteins were detected by 
a specific antibody recognizing total CCNB1 protein. CDK1 proteins were detected using an antibody detecting total 
CDK1 protein levels and a specific antibody recognizing the active form of CDK1 phosphorylated at threonine 161. An 
antibody specific for actin was used as a loading control. Westernblot image is a representative of at least 3 independent 
experiments.
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[4]), cyclin C (CCNC, involved in G0 to G1 phase progression [22]), and cyclin E1 
(CCNE1, involved in G1 to S phase progression [23]). In stably STOX1A transfected 
cells we found that CCNA2 and CCNB1 mRNA levels were significantly increased. 
CCNC mRNA levels were significantly downregulated but no significant differences 
in mRNA levels were seen for CCNE1 compared to stably MOCK transfected cells 
(Fig 3A). STOX1A siRNA knockdown resulted in significantly decreased mRNA 
levels of CCNA2, CCNB1 and CCNE1, and significantly upregulated CCNC 
mRNA levels compared to scrambled controls (Fig 3B). Since CCNB1 is the cyclin 
involved in mitosis, CCNB1 reduction upon STOX1A knockdown was also confirmed 
on westernblot. The CCNB1 associated kinase CDK1 showed reduced activity 
upon reduced CCNB1 protein levels as measured on westernblot using an antibody 
specifically recognizing the active form of CDK1 (Fig 3C). In contrastparallel, 
comparable protein levels of total CDK1 were found (Fig 3C).
STOX1A directly regulates expression of CCNB1 thereby enhancing progression into 
mitosis. 
Given the importance of CCNB1 at the G2/M-phase boundary [6], and our results 
showing CCNB1 expression to be affected by both knockdown and overexpression of 
STOX1A we tested if STOX1A could also be directly involved in the regulation of 
CCNB1 through binding to its promotor region. Therefore we performed chromatin 
immunoprecipitation (ChIP). The 5’ upstream regulatory region of the CCNB1 gene 
[24, 25] (Fig 4A) was tested for enrichment in STOX1A ChIP DNA compared 
Figure 4. STOX1A binds to the 5’ upstream regulatory region of the CCNB1 gene. (A) The DNA sequence previously 
characterized as the 5’ upstream regulatory region of the CCNB1 gene [24, 25] indicating the fragment used for quantitative 
PCR. (B) Chromatin immunoprecipitation was performed with asynchronized STOX1A stably transfected cells in parallel 
with STOX1A stably transfected cells synchronized at the G2/M phase boundary. Significantly higher enrichment for the 
5’ upstream regulatory region of the CCNB1 gene was found in asynchronized cells compared to cells synchronized at the 
G2/M-phase boundary (left vs right bar). Bars are mean ± SEM, P-values were calculated using two-tailed unpaired t-test. 
# indicates P<0.001. (B, left bar). Quantitative PCR results show a mean 75 fold (mean ΔΔCt is -6.23) enrichment for 
the 5’ upstream regulatory region of the CCNB1 gene in STOX1A stimulated ChIP DNA, compared to their negative 
controls (ChIP sample vs ChIP negative sample) obtained from asynchronized STOX1A stably transfected SH-SY5Y 
cells. (B, right bar) Results show a mean fold 18 (mean ΔΔCt is -4,18), enrichment for the 5’ upstream regulatory region 
of the CCNB1 gene in STOX1A stimulated ChIP DNA, compared to their negative controls (ChIP sample vs ChIP 
negative sample) obtained from  STOX1A stably transfected SH-SY5Y cells synchronized at the G2/M-phase boundary. 
Bars are mean ± SEM. Asterisks indicate P< 0.05 (one sample t-test with theoretical mean 0). 
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to the negative control in unsynchronized stably STOX1A transfected SH-SY5Y 
cells. Because STOX1A expression analysis shows a non-overlapping STOX1A 
immunofluorescence-DNA (DAPI) pattern at specific phases during mitosis we 
speculated that a direct interaction of STOX1A with the 5’ upstream regulatory region 
of the CCNB1 gene is like most transcription factors transiently lost during mitosis. 
Therefore, in parallel, we also tested enrichment of the 5’ upstream regulatory region 
of the CCNB1 gene [24, 25] in stably STOX1A transfected SH-SY5Y cells arrested 
at the G2/M-phase boundary. We found significant enrichment for the 5’ upstream 
regulatory region of the CCNB1 gene [24, 25] in STOX1A ChIP DNA compared 
to their negative controls in unsynchronized stably STOX1A transfected SH-SY5Y 
cells and cells synchronized at the G2/M-phase boundary (Fig 4B). Furthermore, 
Figure 5. Direct upregulation of CCNB1 effectuates enhanced mitotic entry. (A) Stably transfected STOX1A and 
MOCK SH-SY5Y cells were synchronized in the S-phase and total cell extracts were prepared from 0, 4 and 8 h after 
release from the 2x thymidine block. Western blotting was performed using antibodies to Phospho-Histone H3 (Ser 10) 
and CCNB1.  An antibody specific for actin was used as a loading control. Westernblot image is a representative of at 
least 3 independent experiments. (B) Westernblot (see 5A) quantification of Phospho-H3 (ser 10) was performed using 
densitometry. The ratio number of obtained band intensities for STOX1A divided by actin was compared to the ratio 
number of obtained band intensities for MOCK divided by actin for 3 independent experiments. A significant increase 
for the STOX1A ratio number was found at all time points compared to the MOCK ratio number. (C) Westernblot 
(see 5A) quantification of CCNB1 was performed using densitometry. The ratio number of obtained band intensities for 
STOX1A divided by actin was compared to the ratio number of obtained band intensities for MOCK divided by actin for 
3 independent experiments. A significant increase for the STOX1A ratio number was found at all time points compared to 
the MOCK ratio number. P-values were calculated using two-tailed unpaired t-test, error bars represent ± SEM, * indicate 
P<0.05, ** indicate P<0.01, *** indicate P<0.001.
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enrichment for the 5’ upstream regulatory region of CCNB1 in the unsynchronized 
cells (Fig 4B, left bar) was compared with cells synchronized at the G2/M-phase 
boundary (Fig 4B, right bar). As expected, cells that were harvested directly after a G2/
M-phase block showed a significantly lower enrichment for the 5’ upstream regulatory 
region of the CCNB1 gene compared to cells that were growing asynchronously (Fig 
4B).
To see if the direct regulation of STOX1A on CCNB1 expression would influence 
transition into the G2/M-phase boundary we synchronized STOX1A and MOCK 
stably transfected cells in the early S phase with thymidine. 0, 4, and 8 hours after 
thymidine release CCNB1 protein expression levels were significantly higher in 
STOX1A compared to MOCK transfected cells (Fig 5). Furthermore, western blot 
analysis also showed significantly higher protein expression of the mitosis marker 
phospho-histone H3 (ser 10) in STOX1A compared to the MOCK transfected cells 
at these timepoints (Fig 5). 
Discussion
Here we show, in addition to other members of the forkhead transcription factors, 
that STOX1A is directly involved in controlling the cell cycle via CCNB1. CCNB1 
expression is directly regulated via STOX1A by binding to a region previously 
characterized  as the 5’ upstream regulatory region of the CCNB1 gene [24, 25]. 
While CCNB1 is known to be a key regulator for mitotic entry [26], the direct up-
regulation of CCNB1 by STOX1A led us to speculate if this would have an effect on 
this phase of the cell cycle. Indeed, in stably STOX1A transfected SH-SY5Y cells 
that were released from an S-phase block an earlier appearance of the specific mitosis 
marker PhosH3 (ser10) in parallel with higher CCNB1 protein levels was found. 
These results show that STOX1A transfected cells progress more rapidly into mitosis 
compared to control transfected cells. The finding that knockdown of STOX1A causes 
a decrease in CCNB1 protein levels and that the activity of CDK1 is also dramatically 
reduced elucidates a role for STOX1A in mitotic entry. 
Enrichment of the 5’ upstream regulatory region of the CCNB1 gene in STOX1A 
transfected SH-SY5Y cells growing asynchronously was significantly higher than in 
cells synchronized at the G2/M-phase boundary. This implies that during the G2/ 
M phase of the cell cycle the transcriptional potential of STOX1A is temporarily 
lost. We therefore speculate that STOX1A is necessary for the entry of mitosis but 
transcriptional activity is transiently lost during mitosis. This is likely happening in 
metaphase and anaphase. During these phases STOX1A is not bound to DNA. This 
has also been shown for the forkhead transcription factor FOXK2 [10] and is in 
general also found for most other transcription factors which temporarily lose their 
transcriptional potential during mitosis. This is in contrast to FoxI1 which continually 
remains associated with DNA during mitosis [27]. The translocation of STOX1A 
away from DNA in these specific phases during mitosis, thereby losing the potential 
to activate or repress target gene transcription, is possibly necessary for proper mitotic 
progression or exit. 
CCNB1 concentrates at the centrosomes in metaphase during mitosis [17]. While 
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centrosomes serve as reaction centres for several key regulators of the cell cycle 
machinery [14, 15], and several forkhead transcription factors have been shown 
to physically interact with the cyclin B1 protein [8-10], we hypothesize that 
STOX1A also interacts with the cyclin B1 protein. Indeed, preliminary data using 
co-immunoprecipitation suggest this interaction (data not shown). This interaction 
further suggests that CDK1, the active binding partner of CCNB1, is potentially 
capable of regulating the transcriptional activity of STOX1A by phosphorylation. 
Previously, CDK1 has been shown to phosphorylate FOXM1 [8], FOXO1 [9], and 
FOXK2 [10] thereby influencing their activity.
While we studied the effect of STOX1A on CCNB1 in detail, it is likely that other 
cell cycle associated proteins are also directly or indirectly differentially affected 
by STOX1A. Significant changes of CCNA2 and CCNC1 mRNA levels upon 
STOX1A overexpression and knockdown, and significant downregulation of CCNE1 
upon STOX1A knockdown suggest that STOX1A is also involved in regulating other 
checkpoints of the cell cycle. 
As STOX1A is highly expressed in the brain and upregulated in LOAD makes 
exploration of STOX1A expression in neuronal cells in combination with cell cycle 
events very interesting; STOX1A might have a role in cell cycle re-entry as observed 
in AD. 
In conclusion, we show for the first time that STOX1A is involved in regulating cell 
cycle events by binding to CCNB1 thereby regulating mitotic entry.
Materials and Methods
Cell culture and transfection
SH-SY5Y human neuroblastoma cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). All reagents for cell culture were purchased from 
Invitrogen Life Technologies, Inc. (Burlington, Canada). SH-SY5Y cells were cultured 
at 37 ºC in a humidified atmosphere of 5% CO₂ in Iscove's Modified Dulbecco's 
Medium (IMDM) supplemented with 10% fetal calf serum and 100 U/ml penicillin, 
and 100 g/ml streptomycin. Cells were subcultured in medium every 2–3 days following 
harvesting by trypsinization (HBSS containing 5% trypsin). The ORF (Open Reading 
Frame) of the STOX1A gene was subcloned into the pF5K-neomycin CMV Flexi 
vectors according to the manufacturers protocol (Promega) and transfected into SH-
SY5Y cells. For transfection the calcium phosphate method was used [28]. Briefly, 
at the time of transfection, cells were at 70% confluence. By vortexing 2X HEBS 
(HEPES-buffered saline) with a solution of 2.5 M CaCl₂ and 20 µg of plasmid DNA 
a co-precipitate of DNA and CaPO₄ was allowed to form. After incubation for 30 
min at room temperature, the precipitate was added to the cells and the medium was 
changed after 24 h. For stable transfections SH-SY5Y cells were transfected either 
with the pF5K-STOX1A or empty pF5K constructs. Selection of positive clones was 
possible due to the presence of the neomycin resistant gene present in the constructs. 
Positive clones were maintained in complete IMDB medium supplemented with 800 
µg/ml G418 (Roche) until reaching confluence and subcultured every 2-3 days for 
about 4 weeks. A population of positive clones was harvested for further analysis. As 
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confirmed with qRT-PCR (See below) using TaqMan probes (Applied Biosystems) 
for STOX1A, 3 stable SH-SY5Y cell-lines with an at least 10 fold STOX1A over-
expression compared to mock transfected cells were selected. Additionally, plasmid 
DNA quantification using qPCR (see below) with primers and probe specific for the 
constructs backbone showed similar copy numbers between STOX1A and MOCK 
transfected cells.
Knockdown of STOX1A was performed by transfecting 4 siRNA’s against STOX1A 
and control siRNA (Qiagen) in SH-SY5Y cells with Lipofectamine™ RNAiMAX 
(Invitrogen) according to the manufactures protocol. Cells were harvested 48 hours 
post-transfection and RNA was isolated as described in the Quantitative PCR and 
RT-PCR section.
Cell proliferation assay in vitro
In each well of a 6-well culture plate 1.5×10-5 untransfected, STOX1A or MOCK 
stably transfected SH-SY5Y cells were seeded. The untransfected cells were transfected 
with STOX1A siRNAs (see above). The cell numbers from three wells were counted 
every day with a time interval of 24 hours for a total of 72 hours. Viable cells were 
counted on a Countess® Automated Cell Counter (Invitrogen) according to the 
manufactures instructions. Three independent experiments were performed, and the 
means were used to depict the growth curve. 
Cell synchronization
Cells were synchronized in an early S-phase by double thymidine treatment. Briefly, 
±20% confluent cells were treated with 2 mM thymidine for 16 h. After being released 
to normal growing medium for 8 h, the cells were treated with 2 mM thymidine for 
an additional 16 h. Again, after being released to normal growing medium, cells were 
harvested or analysed in time intervals of 2 hours for a total of 8 hours.
For cells to be synchronized at the G2/M-phase boundary, cells were treated with a 
thymidine/nocadazole block. Briefly, ±40% confluent cells were treated with 2 mM 
thymidine for 24 h. After being released to normal growing medium for 3 h, the cells 
were treated with 100 ng/ml nocodazole for 12 h and the cells were arrested at the 
G2/M-phase boundary.
Chromatin immunoprecipitation
Stably transfected STOX1A cells (asynchronous or G2/M-phase boundary arrested) 
were treated with formaldehyde to create protein-DNA crosslinks. Cytoplasmic lysis 
was performed to reduce competition of cytoplasmic STOX1A-Halotag proteins 
against nuclear STOX1A-Halotag proteins with the Halotag resin. Nuclear lysate was 
subsequently fragmented by sonication. The nuclear lysates were split into two equal 
parts of which one was treated with Halotag blocking ligand to function as a negative 
control. Both the samples and controls were treated using Halotag resin according to 
the Halo-ChIP system protocol in the presence of proteinase inhibitors. After reversal 
of crosslinks the DNA was purified using the Qiaquick PCR purification kit (Qiagen).
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Quantitative PCR and RT-PCR
Standard quantitative PCR was performed on an ABI7300 (Applied Biosystems) 
using a probe and primers specific for a fragment in the 949-bp region previously 
characterized  as the 5’ upstream regulatory region of the CCNB1 gene 24. Probe and 
primer characteristics were: CCNB1_foward 5’ GTGCGGGGTTTAAATCTGAG 
3’, CCNB1_reversed 5’ CATGGCTTCCTCTTCACCAG 3’ and 5’-FAM 
3’-TAMRA labeled probe: 5’ TGTTCTGCTTCTCCCCGCTG 3’. Reactions were 
performed in the presence of 1M betaine and ROX reference dye, and corrected for 
input using the non-intron-spanning Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) gene expression assay (Applied Biosystems). Input ChIP DNA was 
obtained from at least four independent ChIP experiments.
RNA isolation from transfected cells was performed using the RNeasy kit (Qiagen) 
including on-column DNase treatment. Quantitative RT-PCR using gene expression 
assays (Applied Biosystems) for CCNA2, CCNB1, CCNC, CCNE1 and STOX1A 
were performed on an ABI7300. In addition, transfection effiencies were corrected 
by plasmid DNA quantification using the pF5 CMV-neo Flexi® Vector backbone 
present in all plasmids (pF5 forward: 5’-GCTTCGAGCAGACATGATAAG-3’, 
pF5 reversed: 5’-AGCAATAGCATCACAAATTTCA-3’, 5’-FAM 3’-TAMRA 
labeled pF5 probe: 5’-TGGACAAACCACAACT AGAATGCAGT-3’). Data were 
obtained from at least four transfections from which each RNA sample was measured 
in triplicate.
Western blot
Protein lysates from transfected cells were obtained by directly scraping cells into 
Loading Buffer including β-mercaptoethanol. Lysates were separated by SDS-
polyacrylamide gel electrophoresis, and electroblotted onto a PVDF-membrane. 
An antibody recognizing endogenous STOX1 (Sigma), Phospho-cdc2 Thr161 (cell 
signalling) or Phospho-Histone H3 (cell signalling) was used in combination with 
goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (DAKO). 
An antibody recognizing CCNB1 (Millipore) and total cdc2 (clone POH1, cell 
signalling) were used in combination with goat anti-mouse IgG horseradish 
peroxidase-conjugated secondary antibody (DAKO). Protein bands were detected by 
an enhanced-chemiluminescence assay (GE Healthcare) on a LAS3000.
Immunofluorescence
For immunofluorescence, stably transfected SH-SY5Y cells were grown on glass 
coverslips. Coverslips were fixed in 4% (PFA) paraformaldehyde for 15 min at 
room temperature. After fixation, coverslips were rinsed in PBS, 0.1% Triton X-100 
and incubated with 1% Triton X-100 in PBS for 15 min at room temperature for 
permeabilization. Coverslips were washed in wash buffer (PBS, 0.1% Triton X-100, 
2% BSA (Bovine serum albumin)) blocked with PBS, 0.1% Triton X-100, 5% BSA 
for 1 h and incubated with anti-Halotag (Promega) antibody at 4ºC overnight. After 
washing with wash buffer, cells were incubated for 1 hour with anti-rabbit secondary 
antibodies conjugated with Alexa Fluor 568 (Invitrogen), washed with washing 
buffer and mounted with vectashield mounting solution containing DAPI for DNA 
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counterstaining (Vector Laboratories).
Data analysis
For Real-time PCR data, a threshold cycle number, Ct, was measured as the PCR cycle 
at which the amount of amplified target reaches the threshold value. Quantification 
was determined by the 2-ΔΔCt method as described in Applied Biosystems “Guide to 
Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative 
PCR”, Section VII,  Relative Quantitation of Gene Expression Experimental Design 
and Analysis http://www3.appliedbiosystems.com/cms/groups/ mcb_support/
documents/generaldocuments/cms_042380.pdf ). Statistical analysis of the obtained 
data was carried out with the GraphPad Prism program.
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Abstract
Intraneuronal fibrillary tangles are a major hallmark of several neurodegenerative dis-
eases including Alzheimer’s disease. The major constituents of these hallmarks are 
hyper-phosphorylated tau. In this study we used a neuronal cellular model which 
over-expresses transcription factor STOX1A in combination with the longest human 
tau isoform to test the effect of STOX1A overexpression on tau phosphorylation. 
Our results show that STOX1A induces phosphorylation of the longest human tau 
isoform at phospho-epitopes typically found in neurofibrillary tangles in Alzheimer’s 
disease. In conclusion, our results show a STOX1A-dependent effect on tau phospho-
rylation found in neurodegenerative diseases such as Alzheimer’s disease.
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Introduction
Alzheimer’s disease (AD) is a chronic neurodegenerative disease with severe 
neurodegeneration and cognitive impairment. Classically, AD pathology is 
characterized by amyloid beta (Aβ) containing senile plaques and intra-neuronal 
neurofibrillary tangles (NFT). While Aβ is formed by the sequential cleavage of 
the amyloid precursor protein (APP), intra-neuronal aggregates of NFT are densely 
packed networks of the hyper-phosphorylated insoluble microtubule associated 
protein tau (MAPT) [7], [12], and [20]. Normal tau function, which has been shown 
to be important in stabilizing microtubules, neurite outgrowth and axonal transport, 
is tightly regulated by a balance between phosphorylation and dephosphorylation 
[26]. However, hyper-phosphorylation of tau as found in AD and other related 
neurodegenerative diseases causes failure of tau to bind and stabilize microtubules 
resulting in neuronal dysfunction [2], [5], [9], [27], and [35]. Therefore, much effort 
has been made to identify phosphorylated tau residues to understand the mechanisms 
that lead to NFT formation as found in AD and other similar neurodegenerative 
diseases. As a result, currently more that 30 serine/threonine residues have been 
identified in NFT-tau with the use of immunologic studies and mass spectroscopy 
[3], [22], [23], and [30]. Furthermore, several tau protein kinases and the major tau 
protein phosphatase have been characterized which are capable of regulating the 
phosphorylation status at many of these tau residues [17] and [38]. 
Recently, Storkhead box 1A (STOX1A), a transcription factor structurally and 
functionally related to the forkhead family of transcription factors has been shown 
to be expressed abundantly in the brain and the expression level to correlate with the 
severity of Late Onset Alzheimer Disease (LOAD, Braak 3–6) [14]. Transcription 
factors like STOX1A regulate the expression of hundreds of downstream target genes 
and we therefore speculated that STOX1A potentially influences transcriptional 
networks which are associated with phosphorylation and/or de-phosphorylation of 
tau residues. Furthermore, phosphorylation of tau is known to be driven by kinases 
which are activated in a cell cycle dependent manner [8] and [13]. STOX1A has 
recently been shown to be directly involved in the cell cycle [1] which further indicates/
suggests a role for STOX1A in tau phosphorylation. Together, in this study we tested 
if there is a potential relationship between the phosphorylation status of tau proteins 
and STOX1A overexpression. To test this we used a neuronal cellular model in which 
stably transfected STOX1A cells were stably co-transfected with the longest human 
tau isoform (hTau40) in the neuroblastoma cell-line SH-SY5Y. With the use of 
western blot and antibodies recognizing phospho-specifc tau epitopes we found that 
STOX1A hyperphosphorylates epitopes which are abundantly found in NFT in AD. 
In conclusion, these results suggest that elevated STOX1A expression in advanced 
stages of LOAD patients is linked to hyper-phosphorylation of tau as found in NFT. 
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Results
STOX1A induces tau phosphorylation 
Several monoclonal antibodies have been created which specifically recognize 
phosphorylated tau residues as found in NFT of AD patients. In this study we used 
immunoblotting analysis with the previously characterized monoclonal phospho-
specific tau antibodies AT8 [19] and [32], and E178 [25] and [33] to determine if 
STOX1A overexpression can effectuate the phospho-specific tau epitopes recognized 
by these antibodies (S202/T205 for AT8 [19] and [32] and S396 for E178 [25] and 
[33]). Therefore we stably co-transfected the previously characterized STOX1A 
stably transfected SH-SY5Y cells [1] with the htau40 or htau40control constructs 
(For clarity termed: STOX1A-htau40 and STOX1A-htau40control, respectively). 
Furthermore, to monitor the effect without STOX1A overexpression we also stably 
transfected wild type SH-SY5Y cells either with the htau40 or htau40control construct 
(For clarity termed: WT-htau40 and WT-htau40control, respectively). Protein 
expression of STOX1A in the stably transfected cell-lines STOX1A-htau40 and 
STOX1A-htau40control was validated with western blotting (Fig 1A). As expected 
no immunoreactivity of STOX1A overexpression was observed in the WT-htau40 or 
WT-htau40control cells (Fig 1A). 
Overexpression of htau40 in the WT-htau40 and STOX1A-htau40 cells was confirmed 
with an antibody which detects both the phosphorylated and unphosphoryalated tau 
protein. Results show that the WT-htau40 and STOX1A-htau40 cell-lines equally 
overexpressed the recombinant htau40 protein (Fig 1B, lower figure). When using 
the tau phospho-epitope specific antibodies AT8 and E178, we could primarily detect 
high immunoreactivity in the lanes corresponding to the STOX1A-htau40 cells 
(Fig 1B, middle and upper figure). Immunofluorescent expression analyses showed 
similar results (Fig 2). Furthermore, high immunofluoresence for AT8 was observed 
in mitotically active cells (Fig 2G and H, white arrows). The immunofluorescent 
detection pattern for the E178 antibody was identical as for AT8 antibody (data not 
shown). 
Stably transfected STOX1A SH-SY5Y cells have enhanced CDK1 activity levels.
Above results show a STOX1A dependent effect on htau40 phosphorylation. It has 
been shown that in vitro tau phosphorylation is catalysed by several well described 
protein kinases. These include P44/42 (MAPK) [15], [17], [18], and [34]) and cyclin 
dependent kinases 1 and 5 (CDK1 and CDK5) [6], [24], [28] and [31]. While 
STOX1A has been found to be involved in cell cycle regulation [1], and secondly the 
above kinases are known for their implications in the cell cycle [10], [11] and [16] and 
the phosphorylation of tau protein [6], [28], and [29], we speculated there might be 
a correlation between STOX1A overexpression, tau phosphorylation, and activation 
of these kinases. Therefore, we tested if STOX1A overexpression could effectuate 
changes in expression and/or activation of these kinases. 
As a model we used the previously characterized stably transfected STOX1A SH-
SY5Y cells and compared those with their corresponding MOCK cells (for clarity: 
WT-STOX1A and WT-MOCK, [1]). Quantification of Westernblot results (Fig 
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3A) show that immunoreactivity levels of active CDK1 (Thr161) were significantly 
increased in WT-STOX1A compared to WT-MOCK cells (Fig 3B). However, 
no significant differences in immunoreactivity (Fig 3A) levels were found for total 
CDK1, CDK5, the CDK5 neuronal-specific activator p35 [37], MAPK or phospho-
MAPK (Data not shown).
Discussion
In this study we used a neuronal cell model where htau40 was stably co-expressed in 
STOX1A overexpressing cell-lines previously created by us [1]. Our results show that 
the stably overexpressing STOX1A cells effectuate a robust increased phosphorylation 
of the co-expressed htau40 protein at specific epitopes recognized by the antibodies 
AT8 and E178. This effect was not seen in cells stably overexpressing htau40 without 
STOX1A overexpression. Therefore, this effect was STOX1A dependent. The 
phospho-epitopes recognized by AT8 and E178 antibodies are S202/T205 [19] and 
[32] and S396 [25] and  [33], respectively. These residues have also been shown to be 
hyper-phosphorylated in  NFT in Alzheimer’s disease [4]. 
While we found abundant immunoreactivity for the AT8 and E178 antibodies in 
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Figure 1 The effect of STOX1A on htau40 phosphorylation. Total cell extracts were prepared from WT-htau40, WT-
htau40control, STOX1A-htau40 and STOX1A-htau40control. Western blotting was performed using an antibody against 
STOX1A (A). Westernblot image is a representative of at least 3 independent experiments. (B) Western blotting was 
performed using the phospho-epitope specific antibody’s E178 (upper figure) and AT8 (middle figure) or a phospho-
epitope independent antibody against total tau (Lower figure). In parallel, as a positive control for specificity of tau 
phosphorylation, we used total brain homogenates from an Alzheimer’s disease patient and compared it to a non-demented 
control. Westernblot image is a representative of at least 3 independent experiments. An antibody specific for actin was 
used as a loading control. 
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STOX1A-htau40 cells compared to the STOX1A-htau40control cells, there was also 
a minor degree of immunoreactivity found in the WT-htau40 compared to the WT-
htau40control cells (Fig 1B). The finding of this small amount of immunoreactivity 
can be explained by the specific staining of mitotically active cells by the AT8 and 
E178 antibodies, including in the WT-htau40 cells (Fig. 2G and H). This is consistent 
with previous findings where it has been shown that abnormal tau phosphorylation 
occurs specifically during mitosis [13]. 
The correlation between hyper-phosphorylated tau in NFT and AD pathology has 
led to a focus towards research on protein kinases and phosphatases that have been 
shown to phosphorylate and/or de-phosphorylate residues on tau proteins. In general, 
two types of tau kinases have been described which are the proline directed serine-
threonine protein kinases and non-proline directed serine-threonine protein kinases 
[30]. The major focus lies on the proline directed serine-threonine protein kinases as 
Ser/Thr–Pro sites are the major abnormally phosphorylated tau sites found in AD 
[21] and [30]. In an attempt to provide a possible mechanism for STOX1A induced 
tau phosphorylation, we tested the expression and activity of the well described 
proline directed serine-threonine tau protein kinases CDK1, CDK5, and P44/42 
(MAPK) which are  associated with tau phosphorylation [6], [28] and [29] and cell 
cycle events [10], [11], and [16].  STOX1A has previously been shown to be involved 
in the regulation of the cell cycle as well [1] and therefore we speculated that there 
might be a correlation between STOX1A, the cell cycle and tau phosphorylation. Our 
results show that the active form of CDK1 (CDK1 phosphorylated at thr161) was 
induced in stably transfected STOX1A SH-SY5Y cells. Our data therefore indicate 
that STOX1A dependent tau phosphorylation is, at least in part, mediated through 
Figure 2. Immunofluorescent detection of tau in stably transfected SH-SY5Y cells. Immunostaining of overexpressed 
htau40 was detected with total tau (A, B, E and F) or AT8 (C, D, G and H) antibody in the STOX1A-htau40 (A, B, C 
and D) or WT-htau40 (E, F, G and H) cell lines. Arrows (G and H) indicate mitotically active cells. Green (A, B, E and 
F: Total tau), Green (A, B, E and F: AT8), Blue: DAPI.
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induced activity levels of CDK1. This is consistent with previous findings in our lab 
where cyclin B1 (CCNB1) expression, the activating binding partner of CDK1, was 
found to be directly upregulated by STOX1A [1]. This could explain the higher CDK1 
kinase activity levels in these cells. Further insight in the exact mechanisms that result 
in the enhanced activity of CDK1 by STOX1A is therefore needed to clarify this. 
Furthermore, we do not exclude the effect of STOX1A overexpression on other known 
or currently undiscovered tau kinases or phosphatases. As STOX1A target genes are 
largely unknown, it is very likely that STOX1A transactivates expression of genes 
which could indirectly modulate the activity or expression of one or more tau kinases 
or phosphates as well. Whole genome expression analysis using STOX1A induced 
experimental models could reveal these STOX1A target genes and their associated 
transcriptional networks. This would greatly expand our knowledge of how STOX1A 
operates and therefore functions in these networks.
In conclusion, our results suggest a correlation between STOX1A expression and 
tau phosphorylation. Overexpression of STOX1A in the disease progression of 
Alzheimer’s disease could therefore be associated with the formation NFT. 
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Figure 3. Stably STOX1A transfected SH-SY5Y cells have enhanced activity levels of CDK1. (A) Total cell extracts 
were prepared from WT-STOX1A and WT-MOCK SH-SY5Y cells and western blotting was performed using antibodies 
to P44/42 (ERK1/2), Phospho-P44/42 (Phospho-ERK1/2), CDK1, CDK1 (Thr161), CDK5 and P35. An antibody 
specific for actin was used as a loading control. Westernblot image is a representative of at least 3 independent experiments. 
(B) Westernblot quantification was performed using densitometry. The ratio number of obtained band intensities for 
WT-STOX1A divided by actin was compared to the ratio number of obtained band intensities for WT-MOCK divided 
by actin for 3 independent experiments. A significant increase for the WT-STOX1A ratio numbers was found for CDK1 
(Thr161) compared to their WT-MOCK ratio numbers. P-values were calculated using two-tailed unpaired t-test, error 
bars represent ± SEM, * indicate P<0.05.
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Material and methods
Human tissues
Human brain specimens of an Alzheimer’s disease case (Braak stage 6) and a non-
demented control case (Braak stage 1)  were obtained as previously described [14] 
and used as a positive and a negative control for tau phosphorylation in western blot.
Cell culture and transfection
SH-SY5Y human neuroblastoma cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). All reagents for cell culture were purchased 
from Invitrogen Life Technologies, Inc. (Burlington, Canada). SH-SY5Y cells 
were cultured at 37 ºC in a humidified atmosphere of 5% CO2 in Iscove's Modified 
Dulbecco's Medium (IMDM) supplemented with 10% fetal calf serum and 100 U/
ml penicillin, and 100 g/ml streptomycin. Cells were subcultured in medium every 
2–3 days following harvesting by trypsinization (HBSS containing 5% trypsin). The 
ORF (Open Reading Frame) of the STOX1A gene was sub-cloned into the pF5K-
neomycin CMV Flexi vector according to the manufacturers protocol (Promega). The 
ORF of the longest human tau (hTau40) isoform was obtained from the pNG2 donor 
vector (Dr. E.M. Mandelkow) by digestion with the restriction enzymes NdeI and 
BamHI. Both sites were rendered blunt ended using Klenow. The htau40 insert was 
ligated into the HindIII and BamHI sites of the pcDNA4 vector (Invitrogen) that 
were blunted with Klenow, to obtain the pcDNA4-htau40 construct.
For transfection the calcium phosphate method was used [36]. Briefly, at the time 
of transfection, cells were at 70% confluence. By vortexing 2X HEBS (HEPES-
buffered saline) with a solution of 2.5 M CaCl2 and 20 µg of plasmid DNA a co-
precipitate of DNA and CaPO4 was allowed to form. After incubation for 30 min at 
room temperature, the precipitate was added to the cells and the medium was changed 
after 24 h. Three previously created stably transfected STOX1A SH-SY5Y cell-lines 
(WT-STOX1A) with STOX1A over-expression of at least 10 fold compared to 
mock transfected cells (WT-MOCK) [1] were stably co-transfected either with the 
htau40-pcDNA4 or empty pcDNA4 constructs (STOX1A-htau40 and STOX1A-
htau40control). Furthermore, wild type SH-SY5Y cells were stably transfected either 
with the htau40-pcDNA4 or empty pcDNA4 constructs (WT-htau40 and WT-
htau40control). Selection of WT-STOX1A and WT-MOCK cells was possible due 
to the presence of a Neomycin resistant gene as previously described [1]. Selection 
of positive clones with either the htau40-pcDNA4 or empty pcDNA4 constructs 
was possible due to the presence of a Zeocintm (Invitrogen) resistant gene present 
in these constructs. Positive clones were maintained in complete IMDM medium 
supplemented with 300 µg/ml Zeocintm (Invitrogen) until reaching confluence and 
sub-cultured every 2-3 days for about 4 weeks. Three stably transfected STOX1A-
htau40, STOX1A-htau40control, WT-htau40 and WT-htau40control cell-lines were 
selected for further analysis. As confirmed with qRT-PCR using TaqMan probes 
(Applied Biosystems) for Total tau, the STOX1A-htau40 and WT-htau40 had an at 
least 60 fold htau40 mRNA over-expression compared to STOX1A-htau40control 
and WT-htau40control respectively (data not shown). 
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Western blot
Protein lysates from stably transfected cells were obtained by directly scraping cells 
into loading Buffer including β-mercaptoethanol. Lysates were separated by SDS-
polyacrylamide gel electrophoresis, and electroblotted onto a PVDF-membrane. 
Rabbit polyclonal antibodies recognizing the STOX1A protein (Sigma), Total tau 
protein (clone Tau-5, Abcam), Phospho-P44/42, (MAPK, Cell signaling), Phospho-
CDK1 (Thr161, Cell signaling) and P35 (Cell signalling) were used in combination 
with goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (DAKO). 
Mouse monoclonal antibodies specific for Phospho-Tau S202/T205 (Clone AT8, 
Pierce Biotechnology), Phospho-Tau S396 (Clone E178, Abcam), P44/42, (Phospho-
MAPK, Cell signaling), CDK1 (Clone POH1, Cell signaling) and CDK5 (Clone 
DC17, Millipore) were used in combination with goat anti-mouse horseradish 
peroxidase-conjugated secondary antibody (DAKO). Endogenous actin used for 
loading controls was detected with mouse monoclonal anti-actin antibody (Sigma 
Aldrich) and used in combination with goat anti-mouse horseradish peroxidase-
conjugated secondary antibody (DAKO). Protein bands were detected by an enhanced-
chemiluminescence assay (GE Healthcare) on a LAS3000.
Immunofluoresence
For immunofluorescence, WT-htau40, WT-htau40control, STOX1A-htau40 or 
STOX1A-htau40control cells were grown on glass coverslips. Coverslips were fixed 
in 4% (PFA) paraformaldehyde for 15 min at room temperature. After fixation, 
coverslips were rinsed in PBS, 0.1% Triton X-100 and incubated with 1% Triton 
X-100 in PBS for 15 min at room temperature for permeabilization. Coverslips were 
washed in wash buffer (PBS, 0.1% Triton X-100, 2% BSA [Bovine serum albumin]) 
blocked with PBS, 0.1% Triton X-100, 5% BSA for 1 h and incubated with AT8, 
E178 or Tau-5 antibody (See above) or without a first antibody (serving as a negative 
control) at 4ºC overnight. After washing with wash buffer coverslips were incubated 
for 1 hour with anti-mouse secondary antibodies conjugated with Alexa Fluor 488 
(Invitrogen), washed with washing buffer and mounted with vectashield mounting 
solution containing DAPI for DNA counterstaining (Vector Laboratories).
Data analysis
For quantification of westernblots densitometry was used. Westernblot pictures 
were analysed with the software ImageJ according to the tutorial described on the 
website: http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-
with-image-j/. Statistical analysis on the obtained density values was carried out with 
Microsoft Excell and the GraphPad Prism program.
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Abstract
Previous studies in our lab have shown that transcription factor STOX1A has a potential 
role in the etiology of Alzheimer’s disease and possibly other neurodegenerative 
diseases. Unfortunately, neuronal STOX1A transcriptional regulation is not yet fully 
understood but is of great importance to shed light on the underlying pathogenetic 
mechanisms operating in these diseases. In this study we used RNA-sequencing 
(RNA-seq) to determine changes in the transcriptomes between STOX1A compared 
to MOCK transfected neuronal SH-SY5Y cells. Data were analysed using TopHat 
and Cufflinks software and resulted in a significant amount of differential expression. 
Our data indicate that STOX1A has an important function in axonal guidance 
signalling, an important process during nervous system development. 
Overall, the data presented in this study can be used as a valuable source of information 
for in-depth follow-up analysis and could reveal additional information on how 
STOX1A operates in neuronal transcriptional regulation.
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Introduction
Storkhead box 1A (STOX1A), a transcription factor which contains a winged helix 
DNA-binding motif, is structurally and functionally similar to the family of forkhead 
box transcription factors [1-3]. Forkhead box transcription factors have been shown 
to be important regulators of the cell-cycle, cell proliferation, signal transduction, 
cell differentiation, - patterning and -metabolism, and therefore have been linked to 
several developmental mechanisms including embryonic development and neuro-
developmental processes [4, 5]. Not surprisingly, many of them have been found to be 
associated with the pathology of a wide variety of diseases [6].
STOX1 is a susceptibility gene for pre-eclampsia in the Dutch population [2], a 
pregnancy associated disease [7]. Interestingly, STOX1A has also been found to be 
expressed abundantly in the brain, where increased expression of STOX1A in the 
hippocampus has been shown to correlate with the severity of Late-onset Alzheimer’s 
disease (LOAD). Additionally, it was found that STOX1A dependent upregulation 
of one of its target genes, LRRTM3, leads to increased amyloid-β precursor protein 
(APP) processing resulting in higher levels of Aβ peptides [8]. Deposition of Aβ 
peptides is one of the key pathological hallmarks in LOAD [9]. 
Besides the role for LRRTM3 in APP processing, the LRRTM family members 
are proposed to function as synaptic organizers during synapse development [10]. 
Two other genes, Integrin alpha-9 (ITGA9) and Contactin-associated protein-like 
2 (CNTNAP2), recently found by ChIP-cloning as direct targets for STOX1A 
(unpublished results), have similar roles in synapse development. ITGA9 in neurite 
outgrowth [11] and CNTNAP2 as a cell type-specific promotor or inhibitor of neurite 
outgrowth [12]. Furthermore, expression of the microtubule associated protein tau 
(MAPT), also found to be differentially expressed by STOX1A [13], has a function 
in neurite outgrowth [14]. Defects in regulation of neurite outgrowth and similar 
processes like axon guidance signaling, have been linked to autism spectrum disorders 
(ASD) [15-17]. While speculatively, besides the association of STOX1A with LOAD, 
discovery of its target genes and their biological roles could also reveal novel potential 
roles for STOX1A in diseases like ASD. 
Together, the results from previous studies have gained some interesting insights 
in the increasingly expanding functions in which STOX1A is potentially involved. 
These mechanisms are far from fully understood and therefore additional functional 
exploration and detailed studies are necessary to completely understand these 
emerging roles for STOX1A functioning in neuronal signalling. The expanding range 
of STOX1A target genes, their functions, and associated pathways can furthermore 
give novel insight on how STOX1A operates in disease like LOAD and neuronal 
developmental diseases like ASD. Therefore, in the present study we explored the 
downstream effects of STOX1A on neuronal transcriptional networks to expand and 
try to understand the biological processes that are controlled by STOX1A in neuronal 
cells on a genome-wide scale. For this, the transcriptome of neuronal SH-SY5Y cells 
stimulated with STOX1A was assessed using RNA sequencing (RNA-Seq) coupled 
to the TopHat and the Cufflinks software package [18].
Our results successfully demonstrate the use of RNA-seq transcriptome analysis to 
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explore STOX1A induced differential expression. Furthermore, our data can be of 
great importance in yielding new insights into neuronal STOX1A signalling. 
Results
RNA-seq data collection and Tophat alignment
As a model to study neuronal differential expression induced by STOX1A we used 
the neuroblastoma cell-line SH-SY5Y stably transfected with STOX1A or MOCK 
constructs. Total RNA was isolated from 3 stably transfected STOX1A and 3 stably 
transfected MOCK cell-lines and subsequently pooled (3x STOX1A and 3x MOCK). 
Each pool (STOX1A and MOCK) was further processed as described in the material 
and method section and sequencing on an Illumina machine was performed. 
Fastq output files generated by the RNA-seq procedure were used as input for TopHat 
[19]. A paired-end RNA-seq run outputs fastq files consisting of a forward (R1) and a 
reverse (R2) sequence file per sample. The total number of TopHat input reads for the 
STOX1A DNA library were 208,266,806 R1 reads and 208,466,165 R2 reads. Input 
for the MOCK DNA library reads were 227.389.087 R1 reads and 227,564,492 R2 
reads. The TopHat post-run key metrics are summarized in Table 1 which includes 
the quality of the mapped reads to the reference genome. As results show, a small 
percentage of reads (0.02% for STOX1A and 0.05% for MOCK) were removed from 
the analysis prior to mapping to the reference, due to low quality. The mean percentage 
of reads from all samples that were uniquely mapped by TopHat to the reference 
genome lies around 45 %. This percentage of mapped read coverage greatly exceeds the 
30 Million reads that are recommended to achieve reliable measurement of mRNA 
expression across all genes in the genome [20].
To ensure uniformity of the read coverage of both STOX1A and MOCK reads, the 
TopHat BAM output files were imported into the SeqMonk program as described 
in the material and methods section and visually inspected. As an example, the 
read coverage of  chromosome 1 is shown in Figure 1 for both the STOX1A and 
MOCK DNA library. As expected, no reads mapped to the centromere or areas of the 
chromosome without genes.
The final output of TopHat resulted in the detection of 386,360 splice junctions in 
the STOX1A DNA library and 349,161 splice junctions in the MOCK DNA library. 
Splice junction data was outputted as UCSC BED tracks for STOX1A (Supplementary 
Figure 1. The transcriptional profile for SH-SY5Y cells for chromosome 1. The RNAseq read density was plotted for 
STOX1A and MOCK samples along chromosome 1. Each bar represents the Log2 frequency of reads plotted against 
chromosome coordinates along with a refseq track (top figure) representing all coding genes.
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data 1) and MOCK (Supplementary data 2). TopHat read alignments were outputted 
in SAM format and further processed by Cuffdiff.
Differentially expressed genes
TopHat output was used as input for Cuffdiff to calculate the differential expression 
on both a gene level and a transcript level [18]. Furthermore, Cuffdiff also calculated 
alternative promoter usage (Table S1) and alternative splicing (Table S2) between 
STOX1A and MOCK samples. Here, we focus primarily on the gene and transcript 
level differential expression results. 
Gene and transcript level differential expression results calculated by Cuffdiff were 
called at a q-value threshold of ≤ 0.05 and are presented as supplementary tables; 
differential gene expression (N = 1032, Table S3), differential isoform expression (N 
= 2618, Table S4), differential transcription start site groups (TSS groups, N = 1575, 
Table S5) and differential coding DNA sequences (CDS, N = 1635, Table S6). The 
expression level distribution of all genes between STOX1A and MOCK samples 
obtained by these four tests were plotted with the program CummeRbund [18]. Results 
show that normalized Fragments Per Kilobase of exon per Million fragments mapped 
(FPKM) densities for all genes are similar between both conditions (STOX1A vs 
MOCK) in all four Cuffdiff tests (Figure S1). 
Visualisation of differential expression between STOX1A and MOCK for genes, 
isoforms, TSS groups and CDS at a q-value threshold of ≤ 0.05 was plotted with 
CummeRbund as volcano plots (Figure S2). 
The top 10 most significantly up- and down- regulated genes, isoforms, TSS, and 
CDS between STOX1A and MOCK expression are given in Tables 2, 3, 4, and 6, 
respectively. As expected, STOX1A differential expression was found in all tests.
Among the top 10 upregulated genes we found the LOAD associated gene, nitric 
oxide synthase 1 (NOS1). NOS1 was found to be significantly upregulated (Fold 
change 18.65, (Log2 Fold change 4.22), p-value ≤ 0, q-value ≤ 0), Table 3). NOS1 is 
an important inter- and intracellular messenger molecule in several types of cells [21] 
and has been suggested to play a role in the etiology of LOAD [22, 23] but has also 
been associated with ASD [24]. The ASD associated gene, synapsin III (SYN3) [17], 
was significantly upregulated (Fold change 15.83, (Log2 Fold change 3.98), p-value ≤ 
0, q-value ≤ 0), Table 3). SYN3 and other synapsins are involved in neurite outgrowth 
Table 1. Several metrics from the TopHat run were extracted from the log files. 
Shown are the total amounts of reads, the percentages of those reads removed due to low quality and the percentage of total 
reads that were uniquely mapped to the UCSC Human genome build 18 (Hg18) reference genome by TopHat.
STO X1A-R1 STO X1A-R2 MO CK-R1 MO CK-R2
Reads processed 208,266,806 208,466,165 227,389,087 227,564,492
Reads with at least one reported alignment 98,374,552 (47.23%) 115,988,379 (55.64%) 715,449,93 (31.46%) 109,129,540 (47.96%)
Reads that failed to align 109,774,869 (52.71%) 92,312,338 (44.28%) 155,782,016 (68.51%) 118,319,269 (51.99%)
Reads suppressed due to low quality 117,385 (0.06%) 165,448 (0.08%) 62,078 (0.03%) 115,683 (0.05%)
Total Reported reads 126,225,239 154,378,283 93,360,477 148,890,531
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and synapse formation as well as in synaptic transmission [25].
Among the top 10 down regulated genes we found additional ASD associated genes. 
Results show that the ASD associated leucine rich repeat neuronal 3 (LRRN3) and 
roundabout homolog 2 (ROBO2) genes [26, 27] were significantly downregulated; 
LRRN3 (Fold change -2.03, (Log2 Fold change -1.02), p-value ≤ 0, q-value ≤ 0) Table 
3) and ROBO2 (Fold change -2.80, (Log2 Fold change -1.48), p-value = 1.14 x 10-13 , 
q-value 1.66 x 10-11), Table 3). While little is known about the biological activities of 
LRRN3, the ROBO2 gene functions in axonal guidance [28].
Among the top 10 upregulated isoforms we found Dynamin 2 (DNM2) which 
has been shown to be associated with LOAD [29, 30] and was found to be 
primarily differentially expressed on a transcript level (Refseq isoform specific ID: 
NM_001005361, Fold change 84.58 (Log2 Fold change 6.402), p-value ≤ 0, q-value ≤ 
0, Table 4). Dynamins play essential roles in endocytosis, but other functions associated 
with the actin cytoskeleton, mitogen-activated protein kinase (MAPK) signaling and 
apoptosis are also suggested [31]. 
Engulfment and cell motility protein 1 (ELMO1), has recently been found as an 
ASD candidate gene [17], was significantly upregulated on a transcript level (Refseq 
isoform specific ID:NR_038121, Fold change 20.99 (Log2 Fold change 4.40), 
p-value ≤ 0, q-value ≤ 0, Table 3). ELMO1 is suggested to play roles in the promotion 
of phagocytosis [32], dendritic spines morphogenesis [33], and cell migration 
(interneuron migration) [34]. 
Two specific downregulated isoforms were found to be associated with LOAD. 
Reticulon 4 (RTN4, or Nogo) [35], an inhibitor of neurite outgrowth [36] and insulin-
like growth factor 2 (IGF2), a growth promoting hormone abundantly expressed in 
Table 2. Top 10 up- and down-regulated genes in STOX1A compared to MOCK treated cells as calculated by Cuffdiff 
at the 5% false-discovery rate (FDR, q-value = 0.05). 
Gene Symbol Description Chromosome FPKM MO CK FPKM STO X1A Fold change (Log2) Fold change p -value q -value
IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1 chr17 0,044 1,921 43,229 5,434 0 0
STOX1 storkhead box 1 chr10 0,272 4,714 17,313 4,114 0 0
SYN3  synapsin III chr22 0,068 1,070 15,827 3,984 0 0
FAM5B family with sequence similarity 5, member B chr1 0,328 4,754 14,480 3,856 0 0
SOX14 SRY (sex determining region Y)-box 14 chr3 0,173 2,474 14,299 3,838 0 0
FGFR2 fibroblast growth factor receptor 2 chr10 0,260 3,194 12,261 3,616 0 0
NOS1 nitric oxide synthase 1 (neuronal) chr12 0,040 0,448 11,218 3,488 0 0
TBC1D30 TBC1 domain family, member 30 chr12 0,203 2,245 11,062 3,468 0 0
TRIM67 tripartite motif-containing 67 chr1 0,535 5,723 10,696 3,419 0 0
SYT13 synaptotagmin XIII chr11 0,196 1,987 10,112 3,338 0 0
C6orf192 chromosome 6 open reading frame 192 chr6 1,538 0,014 -107,011 -6,742 0 0
TRIM29  tripartite motif-containing 29 chr11 2,186 0,531 -4,115 -2,041 0 0
NELL1 NEL-like 1 chr11 7,601 2,208 -3,443 -1,783 0 0
COL3A1 collagen, type III, alpha 1 chr2 3,554 1,093 -3,252 -1,701 0 0
GPR64  G protein-coupled receptor 64 chrX 5,012 1,825 -2,746 -1,457 0 0
HGF hepatocyte growth factor (hepapoietin A; scatter factor) chr7 2,857 1,311 -2,180 -1,124 0 0
LRRN3  leucine rich repeat neuronal 3 chr7 3,161 1,557 -2,030 -1,021 0 0
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 chr12 2,949 0,803 -3,673 -1,877 2,22E-16 4,45E-14
ROBO2 roundabout, axon guidance receptor, homolog 2 chr3 1,426 0,510 -2,797 -1,484 1,14E-13 1,66E-11
GYG2 glycogenin 2 chrX 3,440 1,066 -3,228 -1,691 2,08E-12 2,57E-11
The fold change is the ratio of FPKM between STOX1A and MOCK and converted to Log2. The differentially expressed 
genes were first ranked on their q-value and then fold change. The 10 with the highest or lowest fold change are shown here. 
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the placenta and important in placental growth [37]; RTN4 (Refseq isoform specific 
ID: NM_007008, Fold change -29.017 (Log2 Fold change -4.95), p-value ≤ 0, q-value 
≤ 0, Table 3) and IFG2 (Refseq isoform specific ID: NM_001127598, Fold change 
-27.09 (Log2 Fold change 4.76), p-value ≤ 0, q-value ≤ 0, Table 3)
While not within the top 10 of most significant STOX1A differentially expressed 
genes, we found additional genes with relevance in ASD with high significance and 
within the q-value threshold of ≤ 0.05 (Table S1). These include Contactin-associated 
protein-like 4 (CNTNAP4, Fold change -3.59, Log2 Fold change -1.84, P-value = 4.59 
x 10-07,  q-value = 2.27 x 10-05) [38], Contactin-associated protein-like 5 (CNTNAP5, 
Fold change 6.14 Log2 Fold change 2.62, P-value = 8.22 x 10-14, q-value = 1.22 x 
10-11  ) [39], neurexin 2 (NRXN2, Fold change 4.45, Log2 Fold change 2.15, P-value = 
0,  q-value = 0 ) [40], Contactin-2 (CNTN2, Fold change 6.45, Log2 Fold change 2.70, 
P-value =2.13 x 10-11,  q-value = 2.22 x 10-09) and SH3 and multiple ankyrin repeat 
domains 2 (SHANK2, Fold change 3.93, Log2 Fold change 1,97 , P-value =1.66  x 10-
08,  q-value = 1.08 x 10-06) [41, 42].
Validation of STOX1A target genes
Previous studies in our lab resulted in the identification of several differentially 
expressed genes in STOX1A manipulated neuronal cell-lines. These consist of the 
STOX1A downstream target genes LRRTM3 [8], microtubule-associated protein tau 
(MAPT) [13], Contactin-associated protein-like 2 (CNTNAP2, unpublished results) 
and Integrin alpha-9 (ITGA9, unpublished results). Additionally, STOX1A has also 
been shown to have a role in cell cycle regulation, specifically at the G2/M phase 
[43]. In the latter study we found several cyclin genes to be differentially expressed by 
Gene Symbol Refseq Isoform ID Description Chromosome FPKM MO CK FPKM STO X1A Fold change (Log2) Fold change p -value q -value
DNM2 NM_001005361 dynamin 2 chr19 0,084 7,122 84,584 6,402 0 0
STOX1 NM_001130159 storkhead box 1 chr10 0,235 13,846 58,891 5,880 0 0
STOX1 NM_001130161 storkhead box 1 chr10 0,193 10,548 54,711 5,774 0 0
IGF2BP1 NM_006546 insulin-like growth factor 2 mRNA binding protein 1 chr17 0,044 1,921 43,229 5,434 0 0
FGFR2 NM_000141  fibroblast growth factor receptor 2 chr10 0,089 2,189 24,730 4,628 0 0
FERMT2 NM_001135000 fermitin family homolog 2 (Drosophila) chr14 0,294 6,730 22,921 4,519 0 0
ELMO1 NR_038121  engulfment and cell motility 1 chr7 0,533 11,172 20,978 4,391 0 0
FAM131B NM_001031690  family with sequence similarity 131, member B chr7 0,079 1,497 18,973 4,246 0 0
NOS1 NM_000620 nitric oxide synthase 1 (neuronal) chr12 0,024 0,448 18,654 4,221 0 0
HOOK2 NM_013312 hook homolog 2 (Drosophila) chr19 0,258 4,639 18,010 4,171 0 0
C6orf192 NM_052831 chromosome 6 open reading frame 192 (SLC18B1) chr6 1,538 0,014 -107,011 -6,742 0 0
WASF2 NM_001201404 WAS protein family, member 2 chr1 8,623 0,279 -30,888 -4,949 0 0
RTN4 NM_007008  reticulon 4 chr2 18,671 0,643 -29,017 -4,859 0 0
IGF2 NM_001127598 insulin-like growth factor 2 (somatomedin A) chr11 235,237 8,681 -27,099 -4,760 0 0
STX16 NM_001204868 syntaxin 16 chr20 1,702 0,087 -19,606 -4,293 0 0
PTPN12 NM_001131008 protein tyrosine phosphatase, non-receptor type 12 chr7 9,800 0,558 -17,578 -4,136 0 0
TARBP2 NM_004178 TAR (HIV-1) RNA binding protein 2 chr12 8,834 0,611 -14,452 -3,853 0 0
GPR64 NM_005756 G protein-coupled receptor 64 chrX 1,966 0,148 -13,292 -3,733 0 0
8-sep NM_001098813 septin 8 chr5 7,407 0,682 -10,862 -3,441 0 0
ARL6IP6 NR_024526 ADP-ribosylation-like factor 6 interacting protein 6 chr2 8,259 0,878 -9,402 -3,233 0 0
Table 3. Top 10 up- and down-regulated isoforms in STOX1A compared to MOCK treated cells as calculated by 
Cuffdiff at the 5% false-discovery rate (FDR, q-value = 0.05). 
The fold change is the ratio of FPKM between STOX1A and MOCK and converted to Log2. The differentially expressed 
isoforms were first ranked on their q-value and then fold change. The 10 with the highest or lowest fold change are shown 
here.
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Gene Symbol TSS ID Description Chromosome FPKM MO CK FPKM STO X1A Fold change (Log2) Fold change p -value q -value
STOX1 TSS19336 storkhead box 1 chr10 0,428 24,395 57,007 5,833 0 0
IGF2BP1 TSS23967 insulin-like growth factor 2 mRNA binding protein 1 chr17 0,044 1,921 43,229 5,434 0 0
FAM131B TSS26131 family with sequence similarity 131, member B chr7 0,079 1,497 18,973 4,246 0 0
NOS1 TSS25258 nitric oxide synthase 1 (neuronal) chr12 0,024 0,448 18,654 4,221 0 0
ELMO1 TSS3965  engulfment and cell motility 1 chr7 0,722 11,802 16,336 4,030 0 0
FGFR2 TSS10118  fibroblast growth factor receptor 2 chr10 0,211 3,183 15,073 3,914 0 0
FAM5B TSS21127 family with sequence similarity 5, member B chr1 0,328 4,754 14,480 3,856 0 0
SOX14 TSS2041 SRY (sex determining region Y)-box 14 chr3 0,173 2,474 14,299 3,838 0 0
RAP1GAP TSS15125  RAP1 GTPase activating protein chr1 0,217 2,535 11,707 3,549 0 0
TBC1D30 TSS1456 TBC1 domain family, member 30 chr12 0,203 2,245 11,062 3,468 0 0
C6orf192 TSS19968 chromosome 6 open reading frame 192 (SLC18B1) chr6 1,538 0,014 -107,011 -6,742 0 0
RTN4 TSS2786 reticulon 4 chr2 18,671 0,643 -29,017 -4,859 0 0
IGF2 TSS23255 insulin-like growth factor 2 (somatomedin A) chr11 235,237 8,681 -27,099 -4,760 0 0
8-sep TSS1410 septin 8 chr5 7,407 0,682 -10,862 -3,441 0 0
PTPN12 TSS25345 protein tyrosine phosphatase, non-receptor type 12 chr7 10,841 1,321 -8,205 -3,036 0 0
GUK1 TSS9380 guanylate kinase 1 chr1 62,525 12,049 -5,189 -2,376 0 0
UBE2H TSS3222 ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) chr7 9,585 1,868 -5,132 -2,359 0 0
C1orf93 TSS27960 chromosome 1 open reading frame 93 chr1 16,892 3,445 -4,904 -2,294 0 0
KLHL13 TSS9776  kelch-like 13 (Drosophila) chrX 21,545 4,654 -4,629 -2,211 0 0
TRIM29 TSS2204  tripartite motif-containing 29 chr11 21,861 5,313 -4,115 -2,041 0 0
The fold change is the ratio of FPKM between STOX1A and MOCK and converted to Log2. The differentially expressed 
TSS groups were first ranked on their q-value and then fold change. The 10 with the highest or lowest fold change are 
shown here. 
Table 4. Top 10 up- and down-regulated TSS groups in STOX1A compared to MOCK treated cells as calculated by 
Cuffdiff at the 5% false-discovery rate (FDR, q-value = 0.05). 
STOX1A; Cyclin A2 (CCNA2), Cyclin B1 (CCNB1), Cyclin C (CCNC) [43]. 
Of the above validated STOX1A target genes we found MAPT, ITGA9, and CCNC 
to be significantly differentially expressed within the q-value threshold of ≤ 0.05. 
Expression details for the latter genes are given in Table 5. CCNC was found to be 
specifically differentially expressed on a transcript level as no significant gene expression 
was detected (Table 5). A group of isoforms of another interesting cyclin, CCNA1, 
was found to be significantly upregulated at TSS id: TSS20256 (Fold change 2.25, 
Log2 Fold change 1.17, P-value = 6.85 x 10-07, q-value =  3.02 x 10-05).  The lowest fold 
change of a STOX1A validated gene was found for the MAPT isoform NM_016841 
(log2 fold change 1.09, table 5). This value (log2 fold change 1.09) was therefore chosen 
as a reliable log2 fold change threshold in further data exploration.
Isoform FPKM MO CK FPKM STO X1A Fold change Log2 (Fold change) p -value q -value
ITGA9 NM_002207 8,271 22,250 2,69 1,428 2,12E-11 2,65E-09
MAPT NM_016841 8,913 19,004 2,13 1,092 4,87E-08 2,91E-06
NM_016834 0,744 1,928 2,59 1,374 1,33E-04 2,34E-03
CCNC NM_001013399 9,011 2,437 -3,70 -1,886 2,29E-08 1,49E-06
Table 5. Previously validated STOX1A target genes significantly differential expressed in this study as calculated by 
Cuffdiff at the 5% false-discovery rate (FDR, q-value = 0.05).
The fold change is the ratio of FPKM between STOX1A and MOCK and converted to Log2.
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Gene Symbol CDS ID Description Chromosome FPKM MO CK FPKM STO X1A Fold change (Log2) Fold change p -value q -value
STOX1 P11035 storkhead box 1 chr10 0,235 13,846 58,891 5,880 0 0
STOX1 P5413 storkhead box 1 chr10 0,193 10,548 54,711 5,774 0 0
IGF2BP1 P3995 insulin-like growth factor 2 mRNA binding protein 1 chr17 0,044 1,921 43,229 5,434 0 0
FGFR2 P4526  fibroblast growth factor receptor 2 chr10 0,089 2,189 24,730 4,628 0 0
FERMT2 P23224 fermitin family homolog 2 (Drosophila) chr14 0,294 6,730 22,921 4,519 0 0
FAM131B P27220 family with sequence similarity 131, member B chr7 0,079 1,497 18,973 4,246 0 0
NOS1 P23638 nitric oxide synthase 1 (neuronal) chr12 0,024 0,448 18,654 4,221 0 0
HOOK2 P28828  hook homolog 2 (Drosophila) chr19 0,258 4,639 18,010 4,171 0 0
FAM5B P14757 family with sequence similarity 5, member B chr1 0,328 4,754 14,480 3,856 0 0
SOX14 P5732 SRY (sex determining region Y)-box 14 chr3 0,173 2,474 14,299 3,838 0 0
AHCYL1 P1478 adenosylhomocysteinase-like 1 chr1 8,799 0,060 -145,611 -7,186 0 0
C6orf192 P20413 chromosome 6 open reading frame 192 (SLC18B1) chr6 1,538 0,014 -107,011 -6,742 0 0
WASF2 P15809 WAS protein family, member 2 chr1 8,623 0,279 -30,888 -4,949 0 0
RTN4 P22238 reticulon 4 chr2 18,671 0,643 -29,017 -4,859 0 0
PTPN12 P28628 protein tyrosine phosphatase, non-receptor type 12 chr7 9,800 0,558 -17,578 -4,136 0 0
GPR64 P6183  G protein-coupled receptor 64 chrX 1,966 0,148 -13,292 -3,733 0 0
8-sep P19502 septin 8 chr5 7,407 0,682 -10,862 -3,441 0 0
ARL5A P20649  ADP-ribosylation factor-like 5A chr2 4,132 0,404 -10,237 -3,356 0 0
PTPRU P23809  protein tyrosine phosphatase, receptor type, U chr1 11,926 1,514 -7,875 -2,977 0 0
UBE2H P18673 ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) chr7 9,585 1,868 -5,132 -2,359 0 0
Table 6. Top 10 up- and down-regulated CDS in STOX1A compared to MOCK treated cells as calculated by Cuffdiff 
at the 5% false-discovery rate (FDR, q-value = 0.05). 
The fold change is the ratio of FPKM between STOX1A and MOCK and converted to Log2. The differentially expressed 
CDS were first ranked on their q-value and then fold change. The 10 with the highest or lowest fold change are shown here.
Canonical pathway analysis of differentially expressed genes and isoforms
Differentially expressed genes, isoforms, TSS groups, and CDS lists (Table S3, S4, S5 
and S6) were submitted to Ingenuity Pathway Analysis (IPA), build 140500 (Ingenuity 
Systems, Inc., Redwood City, CA). Parameters were set at the q-value threshold of ≤ 
0.05 and a log2 fold change threshold of 1.09. 
Canonical pathways analysis identified the pathways from the IPA library of canonical 
pathways that were most significantly enriched in the data sets. Consistently, our 
results show that the top Canonical pathway which was most significantly enriched in 
all Cuffdiff expression tests was Axonal guidance Signalling (Table 7). 
Discussion
In our approach using RNA-seq to determine changes in the transcriptome between 
STOX1A compared to MOCK transfected neuronal SH-SY5Y cells we used a 
pipeline which includes the alignment of reads to a reference genome by TopHat 
[19] coupled to the Cufflinks software package for transcriptome assembly [18, 44, 
45]. This resulted in a significant number of specific STOX1A induced differentially 
expressed genes. Additional LOAD associated genes and/or isoform specific 
transcripts were found to be differentially expressed by STOX1A in our Top 10 lists 
(NOS1, DNM2, and RTN4). Therefore, validation and functional exploration of these 
STOX1A differentially expressed genes and/or isoform specific transcripts could 
reveal new functional relationships between STOX1A and LOAD. It would also be 
very interesting to investigate if other STOX1A differentially expressed genes and/
or isoform specific transcripts found in this study (but not previously associated with 
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LOAD) are in vivo differentially expressed in LOAD compared to control brains. 
These may represent novel candidates for involvement in LOAD, and speculatively, in 
the future could potentially serve as novel biomarkers. 
As cell cycle events are recently suggested to be associated with LOAD and STOX1A 
has been shown to be involved in cell cycle regulation we expected differential 
expression of cell cycle proteins previous found to be validated. In concordance, we 
found the STOX1A validated cell cycle associated gene CCNC to be significantly 
downregulated. Interestingly, with the use of Cuffdiff we discovered that this gene 
was specifically regulated on a transcript level.  Furthermore, we found significant 
upregulated differential expression of CCNA1 isoforms expressed from the same TSS. 
CCNA1 is a cyclin that has been suggested to function during the S- and the G2/M 
phase of the cell cycle [46] . The transactivation potential of STOX1A on CCNA1 
could therefore be potentially interesting as previous results have show that STOX1A 
has an important role during the G2/M phase of the cell cycle [43]. Therefore 
validation and exploration of the (in)direct functional relationship between STOX1A 
and CCNA1 could further reveal the mechanisms in which STOX1A is involved 
during mitosis. Strangely, we could not detect the previously validated genes Cyclin 
Table 7. Top 5 significant canonical pathways affected by differential expression induced by STOX1A as determined 
by IPA.
Pathways with a P-value less than 0.05 were defined as significant. 
Diffrential expression test Top 5 Canonical Pathways p -value
Gene 1 .Axonal Guidance Signaling 1,29E-04
2. Neuropathic Pain Signaling In Dorsal Horn Neurons 1,14E-03
3. Synaptic Long Term Depression 1,30E-03
4. Glutamate Receptor Signaling 6,83E-03
5. nNOS Signaling in Neurons 1,24E-02
Isoforms 1. Axonal Guidance Signaling 7,88E-07
2. Huntington's Disease Signaling 2,22E-04
3. Neuropathic Pain Signaling In Dorsal Horn Neurons 2,24E-04
4. Cardiac β-adrenergic Signaling 2,53E-04
5. Synaptic Long Term Potentiation 1,50E-03
TSS group 1. Axonal Guidance Signaling 1,57E-05
2. Neuropathic Pain Signaling In Dorsal Horn Neurons 4,03E-04
3. Synaptic Long Term Potentiation 5,02E-03
4. Synaptic Long Term Depression 1,02E-03
5. Glutamate Receptor Signaling 1,51E-03
CDS 1. Axonal Guidance Signaling 4,75E-05
2. Neuropathic Pain Signaling In Dorsal Horn Neurons 7,54E-04
3. Dopamine-DARPP32 Feedback in cAMP Signaling 2,19E-03
4. PTEN Signaling 3,14E-03
5. Calcium Signaling 3,31E-03
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A2 (CCNA2) and Cyclin B1 (CCNB1) to be significantly differentially expressed by 
STOX1A. As expression of these cyclins is greatly dependent on cell cycle phase, we 
suggest that this may be the reason that these previous validated genes have skipped 
detection in this study. To correctly investigate the functional relationship between 
STOX1A and the cell cycle on a genome wide level it would therefore be necessary to 
synchronize the cells at specific phases of the cell cycle and then determine differential 
expression effectuated by STOX1A. 
Furthermore, we found several potential STOX1A differentially expressed genes and/
or isoform specific transcripts (SYN3, NOS1, LRRN3, ROBO2, and ELMO1) in our 
top 10 lists which have previously been shown to be associated with autism spectrum 
disorders (ASD), a neurodevelopmental disorder. In addition, within our cuttoff value 
(q-value ≤ 0.05, log2 fold change 1.09), we also indentified other potential STOX1A 
differentially expressed genes and/or isoform specific transcripts which have previously 
been linked to ASD; CNTNAP4, CNTNAP5, NRXN2, CNTN2, and SHANK2. Most 
of these ASD associated genes have a known or suggested function in pathways 
regulating neurite outgrowth and/or axon guidance signaling [17]. Axon guidance 
signalling is an important process in the development of the central nervous system 
CNS [47] and interestingly, defective axonal guidance signalling has been suggested 
as one of the underlying mechanisms in the pathophysiology of autism spectrum 
disorders (ASD) [17, 27]. Our results show significant enrichment of axonal guidance 
signaling in IPA pathway analyses of differential expression induced by STOX1A 
which further suggests a potential link with ASD. Additionally, recent studies in 
our lab identified  LRRTM3 [8], CNTNAP2 (unpublished results), and ITGA9 
(unpublished results) as target genes for STOX1A in the neuroblastoma cell-line SK-
N-SH. These genes have also been found to be linked to ASD [15-17]. We could 
however not confirm significant differential expression for CNTNAP2 or LRRTM3 
in this study. The reason for this is possibly due to the difference in cell-lines used 
between the studies, SK-N-SH compared to SH-SY5Y in this study. Also different 
STOX1A transfection methods, transient in SK-N-SH versus stable in SH-SY5Y 
were used. We however did find ITGA9 to be significantly upregulated. Together, the 
great overlap of STOX1A induced differential expression with genes associated with 
ASD, and significant overrepresentation of a pathway associated with this disease, 
makes it very interesting to explore the functional relationship between STOX1A and 
ASD. However, this potential relationship would first have to be clarified by validation 
and functional experimentation of relevant genes and transcripts that are differentially 
expressed by STOX1A. 
In conclusion, we have shown that the amount of data generated in this study can be 
used as a valuable source of information for further experimentation and could give 
great insight in the biological role of STOX1A in neuronal transcriptional networks. 
This information is crucial in the understanding of the underlying functional 
mechanisms of STOX1A in diseases like LOAD, where STOX1A has been shown to 
be deregulated. Furthermore, our data can also serve to reveal novel roles for STOX1A 
in other diseases like ASD, as suggested by this study. 
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Materials and methods
Cell culture and transfection
SH-SY5Y human neuroblastoma cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). All reagents for cell culture were purchased 
from Invitrogen Life Technologies, Inc. (Burlington, Canada). SH-SY5Y cells were 
cultured at 37 ºC in a humidified atmosphere of 5% CO2 in Iscove’s Modified 
Dulbecco’s Medium (IMDM) supplemented with 10% fetal calf serum and 100 U/
ml penicillin, and 100 g/ml streptomycin. Cells were subcultured in medium every 
2–3 days following harvesting by trypsinization (HBSS containing 5% trypsin). The 
ORF (Open Reading Frame) of the STOX1A gene was sub-cloned into the pF5K-
neomycin CMV Flexi vector according to the manufacturers protocol (Promega). 
For transfection the calcium phosphate method was used [48]. Briefly, at the time 
of transfection, cells were at 70% confluence. By vortexing 2X HEBS (HEPES-
buffered saline) with a solution of 2.5 M CaCl2 and 20 µg of plasmid DNA a co-
precipitate of DNA and CaPO4 was allowed to form. After incubation for 30 min at 
room temperature, the precipitate was added to the cells and the medium was changed 
after 24 h. For stable transfections, SH-SY5Y cells were transfected either with the 
pF5K-STOX1A or empty pF5K constructs. Selection of positive clones was possible 
due to the presence of the neomycin resistant gene present in the constructs. Positive 
clones were maintained in complete IMDB medium supplemented with 800 µg/ml 
G418 (Roche) until reaching confluence and subcultured every 2–3 days for about 4 
weeks. 3 stable SH-SY5Y cell-lines with an at least 10 fold STOX1A over-expression 
compared to mock transfected cells were selected as described previously [43].
Transcript assembly and quantification by RNA-sequencing
Total RNA (1 µg / sample, DNase-treated, RIN ≥9.8) was subjected to a double round 
of  poly-A mRNA purification, fragmented and primed for cDNA library synthesis 
using the TruSeq RNA sample preparation kit (FC-122-1001). All procedures were 
done according to the manufacturers instructions (Illumina). Following validation 
(Agilent 2100 Bioanalyzer, DNA High Sensitivity) and normalization (area under 
curve 200-1000 bp fragments), samples were clustered (TruSeq paired-end cluster 
kit v3-cBot-HS) (PE-401-3001) followed by paired-end sequencing (100 bp) 
(TruSeq SBS kit v3-HS (200 cycles) (FC-401-3001) on a HiSeq2000. To maximize 
coverage with inclusion of low abundancy transcripts  [44, 49], each lane contained 
a single DNA library. Cluster densities were between 623-970 K/mm2, Q-scores 
(>=Q30) between 43.2-80.5 %, and FastQ output between 44.44-69.17 GB for both 
forward (R1) and reverse reads (R2). RNA-seq reads (unzipped, concatenated R1 
and R2 fastQ files) were aligned to the pre-assembled reference genome (Illumina 
iGenome, data source UCSC, version hg18, June 20, 2011) using TopHat (1.4.0) 
in combination with Bowtie (0.12.5) and SAMtools (0.1.18) with default settings 
(adjusted for maximal threading) [19]. Transcript assembly, abundancy estimation 
(defined as Fragments Per Kilobase of exon per Million fragments mapped, FPKM) 
and differential expression was performed by sequential analysis of TopHat output 
files (accepted_hits.bam). For this, transcripts were assembled using cufflinks (1.3.0) 
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which has implemented correction for fragment bias to account for biases in library 
preparation [50]. Differential analysis of significant changes on a gene and transcript 
level between experimental (STOX1A) and control (MOCK) conditions, was tested 
with Cuffdiff. 
Results of differential gene, isoform, transcription start site group (TSS group) and 
coding sequence expression (CDS), as outputted by cuffdiff, were sorted in Excell 
(Microsoft) by q-value (False discovery rate (FDR) adjusted p-value of the test 
statistic). 
TopHat and Cufflinks were installed and run on a 64-bit Linux desktop computer, 
Intel core I5 3.3 GHz quad-core and 16GB of internal memory. Running time for 
TopHat was approximately 1 week per DNA library (corresponding to one lane). 
Running time for cufflinks/cuffdiff was approximately 1 day per analysed TopHat 
output.
Visualization of mapped reads
Aligned TopHat reads were visualized with the program SeqMonk (http://www.
bioinformatics.babraham.ac.uk/projects/seqmonk/). The BAM files generated by 
TopHat were directly uploaded into SeqMonk and  then converted into probes to 
create average alignment tracks viewable as a bar chart as described in the online 
tutorial. The log2 of the frequency of the probes was plotted to better visualize the 
extensive range of the read coverage.
Ingenuity canonical pathway analysis
Canonical pathways analysis identified the pathways from the IPA library of canonical 
pathways that were most significant to the data set. Molecules from the data set that 
met the q-value cutoff of 0.05 (and Log2 fold change 1.09) and were associated with a 
canonical pathway in the Ingenuity Knowledge Base were considered for the analysis. 
The significance of the association between the data set and the canonical pathway was 
measured in 2 ways: 1) A ratio of the number of molecules from the data set that map 
to the pathway divided by the total number of molecules that map to the canonical 
pathway is displayed. 2) Fisher’s exact test was used to calculate a P-value determining 
the probability that the association between the genes in the dataset and the canonical 
pathway is explained by chance alone.
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Figure S1. Density plots of expression level distribution of log10 (FPKM) values across all STOX1A and MOCK ex-
pressed (A) genes (B) isoforms, (C) TSS groups and (D) CDS.
Supplementary Figure 1
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Figure S2. Volcano plots of –log10 (P-value) versus log2-fold changes. Blue dots were detected as significant differential 
expression between STOX1A and MOCK at the 5% false-discovery rate (FDR, q-value = 0.05). Differential expressed (A) 
genes (B) isoforms (C) TSS groups and (D) CDS.
Supplementary Figure 2
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Table S1. Genes showing alternative promoter usage. 
Appendix Table_S1.pdf
Table S2. Genes showing alternative splicing. 
Appendix Table_S2.pdf
Table S3. Significant differential expressed genes in STOX1A compared to MOCK 
treated cells as calculated by Cuffdiff at the 5% false-discovery rate (FDR, q-value 
= 0.05). The fold change is the ratio of FPKM between STOX1A and MOCK and 
converted to Log2. The differentially expressed genes were first ranked their q-value 
and then fold change. The 10 with the highest or lowest fold change are shown here. 
Appendix Table_S3.pdf
Table S4. Significant differential expressed isoforms in STOX1A compared to MOCK 
treated cells as calculated by Cuffdiff at the 5% false-discovery rate (FDR, q-value = 
0.05). The fold change is the ratio of FPKM between STOX1A and MOCK and 
converted to Log2. The differentially expressed isoforms were first ranked their q-value 
and then fold change. The 10 with the highest or lowest fold change are shown here. 
Appendix Table_S4.pdf
Table S5. Significant differential expressed TSS groups in STOX1A compared to 
MOCK treated cells as calculated by Cuffdiff at the 5% false-discovery rate (FDR, 
q-value = 0.05). The fold change is the ratio of FPKM between STOX1A and MOCK 
and converted to Log2. The differentially expressed TSS groups were first ranked their 
q-value and then fold change. The 10 with the highest or lowest fold change are shown 
here. 
Appendix Table_S5.pdf
Table S6. Significant differential expressed CDS in STOX1A compared to MOCK 
treated cells as calculated by Cuffdiff at the 5% false-discovery rate (FDR, q-value 
= 0.05). The fold change is the ratio of FPKM between STOX1A and MOCK and 
converted to Log2. The differentially expressed CDS were first ranked their q-value 
and then fold change. The 10 with the highest or lowest fold change are shown here. 
Appendix Table_S6.pdf
6  6 · STOX1A induced transcriptome analysis
             121
Brennan RG: The winged-helix DNA-binding motif: another helix-turn-helix 
takeoff. Cell 1993, 74(5):773-776.
van Dijk M, Mulders J, Poutsma A, Konst AA, Lachmeijer AM, Dekker GA, 
Blankenstein MA, Oudejans CB: Maternal segregation of the Dutch preeclampsia 
locus at 10q22 with a new member of the winged helix gene family. Nature genetics 
2005, 37(5):514-519.
van Dijk M, van Bezu J, van Abel D, Dunk C, Blankenstein MA, Oudejans CB, 
Lye SJ: The STOX1 genotype associated with pre-eclampsia leads to a reduction 
of trophoblast invasion by alpha-T-catenin upregulation. Human molecular genetics 
2010, 19(13):2658-2667.
Tuteja G, Kaestner KH: Forkhead transcription factors II. Cell 2007, 131(1):192.
Tuteja G, Kaestner KH: SnapShot: forkhead transcription factors I. Cell 2007, 
130(6):1160.
Hannenhalli S, Kaestner KH: The evolution of Fox genes and their role in development 
and disease. Nature reviews 2009, 10(4):233-240.
Duley L: The global impact of pre-eclampsia and eclampsia. Seminars in perinatology 
2009, 33(3):130-137.
van Dijk M, van Bezu J, Poutsma A, Veerhuis R, Rozemuller AJ, Scheper W, 
Blankenstein MA, Oudejans CB: The pre-eclampsia gene STOX1 controls a 
conserved pathway in placenta and brain upregulated in late-onset Alzheimer's 
disease. J Alzheimers Dis 2010, 19(2):673-679.
Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of 
Alzheimer's disease. Trends in pharmacological sciences 1991, 12(10):383-388.
Linhoff MW, Lauren J, Cassidy RM, Dobie FA, Takahashi H, Nygaard HB, 
Airaksinen MS, Strittmatter SM, Craig AM: An unbiased expression screen for 
synaptogenic proteins identifies the LRRTM protein family as synaptic organizers. 
Neuron 2009, 61(5):734-749.
Andrews MR, Czvitkovich S, Dassie E, Vogelaar CF, Faissner A, Blits B, Gage FH, 
ffrench-Constant C, Fawcett JW: Alpha9 integrin promotes neurite outgrowth on 
tenascin-C and enhances sensory axon regeneration. J Neurosci 2009, 29(17):5546-
5557.
Lieberoth A, Splittstoesser F, Katagihallimath N, Jakovcevski I, Loers G, Ranscht 
B, Karagogeos D, Schachner M, Kleene R: Lewis(x) and alpha2,3-sialyl glycans 
and their receptors TAG-1, Contactin, and L1 mediate CD24-dependent neurite 
outgrowth. J Neurosci 2009, 29(20):6677-6690.
van Abel D, Holzel DR, Jain S, Lun FM, Zheng YW, Chen EZ, Sun H, Chiu 
RW, Lo YM, van Dijk M et al: SFRS7-mediated splicing of tau exon 10 is directly 
regulated by STOX1A in glial cells. PloS one 2011, 6(7):e21994.
Liu CW, Lee G, Jay DG: Tau is required for neurite outgrowth and growth cone 
motility of chick sensory neurons. Cell motility and the cytoskeleton 1999, 43(3):232-
242.
Sousa I, Clark TG, Holt R, Pagnamenta AT, Mulder EJ, Minderaa RB, Bailey AJ, 
Battaglia A, Klauck SM, Poustka F et al: Polymorphisms in leucine-rich repeat 
genes are associated with autism spectrum disorder susceptibility in populations of 
European ancestry. Molecular autism 2010, 1(1):7.
Wang K, Zhang H, Ma D, Bucan M, Glessner JT, Abrahams BS, Salyakina D, 
Imielinski M, Bradfield JP, Sleiman PM et al: Common genetic variants on 5p14.1 
associate with autism spectrum disorders. Nature 2009, 459(7246):528-533.
References
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
6STOX1A induced transcriptome analysis · 6
122
Hussman JP, Chung RH, Griswold AJ, Jaworski JM, Salyakina D, Ma D, Konidari 
I, Whitehead PL, Vance JM, Martin ER et al: A noise-reduction GWAS analysis 
implicates altered regulation of neurite outgrowth and guidance in autism. Molecular 
autism 2011, 2(1):1.
Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg 
SL, Rinn JL, Pachter L: Differential gene and transcript expression analysis of RNA-
seq experiments with TopHat and Cufflinks. Nature protocols 2012, 7(3):562-578.
Trapnell C, Pachter L, Salzberg SL: TopHat: discovering splice junctions with RNA-
Seq. Bioinformatics (Oxford, England) 2009, 25(9):1105-1111.
Wang Y, Ghaffari N, Johnson CD, Braga-Neto UM, Wang H, Chen R, Zhou H: 
Evaluation of the coverage and depth of transcriptome by RNA-Seq in chickens. 
BMC bioinformatics 2011, 12 Suppl 10:S5.
Alderton WK, Cooper CE, Knowles RG: Nitric oxide synthases: structure, function 
and inhibition. The Biochemical journal 2001, 357(Pt 3):593-615.
Reif A, Grunblatt E, Herterich S, Wichart I, Rainer MK, Jungwirth S, Danielczyk 
W, Deckert J, Tragl KH, Riederer P et al: Association of a functional NOS1 promoter 
repeat with Alzheimer's disease in the VITA cohort. J Alzheimers Dis 2011, 
23(2):327-333.
Galimberti D, Scarpini E, Venturelli E, Strobel A, Herterich S, Fenoglio C, Guidi 
I, Scalabrini D, Cortini F, Bresolin N et al: Association of a NOS1 promoter repeat 
with Alzheimer's disease. Neurobiology of aging 2008, 29(9):1359-1365.
Kim HW, Cho SC, Kim JW, Cho IH, Kim SA, Park M, Cho EJ, Yoo HJ: Family-
based association study between NOS-I and -IIA polymorphisms and autism 
spectrum disorders in Korean trios. Am J Med Genet B Neuropsychiatr Genet 2009, 
150B(2):300-306.
Fornasiero EF, Bonanomi D, Benfenati F, Valtorta F: The role of synapsins in neuronal 
development. Cell Mol Life Sci 2010, 67(9):1383-1396.
Anitha A, Nakamura K, Yamada K, Suda S, Thanseem I, Tsujii M, Iwayama Y, Hattori 
E, Toyota T, Miyachi T et al: Genetic analyses of roundabout (ROBO) axon guidance 
receptors in autism. Am J Med Genet B Neuropsychiatr Genet 2008, 147B(7):1019-
1027.
Suda S, Iwata K, Shimmura C, Kameno Y, Anitha A, Thanseem I, Nakamura K, 
Matsuzaki H, Tsuchiya KJ, Sugihara G et al: Decreased expression of axon-guidance 
receptors in the anterior cingulate cortex in autism. Molecular autism 2011, 2(1):14.
Kim M, Roesener AP, Mendonca PR, Mastick GS: Robo1 and Robo2 have 
distinct roles in pioneer longitudinal axon guidance. Developmental biology 2011, 
358(1):181-188.
Aidaralieva NJ, Kamino K, Kimura R, Yamamoto M, Morihara T, Kazui H, Hashimoto 
R, Tanaka T, Kudo T, Kida T et al: Dynamin 2 gene is a novel susceptibility gene 
for late-onset Alzheimer disease in non-APOE-epsilon4 carriers. Journal of human 
genetics 2008, 53(4):296-302.
Kamagata E, Kudo T, Kimura R, Tanimukai H, Morihara T, Sadik MG, Kamino 
K, Takeda M: Decrease of dynamin 2 levels in late-onset Alzheimer's disease alters 
Abeta metabolism. Biochemical and biophysical research communications 2009, 
379(3):691-695.
Sever S: Dynamin and endocytosis. Current opinion in cell biology 2002, 14(4):463-
467.
Lu Z, Elliott MR, Chen Y, Walsh JT, Klibanov AL, Ravichandran KS, Kipnis J: 
Phagocytic activity of neuronal progenitors regulates adult neurogenesis. Nature cell 
biology 2011, 13(9):1076-1083.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
6  6 · STOX1A induced transcriptome analysis
             123
Kim JY, Oh MH, Bernard LP, Macara IG, Zhang H: The RhoG/ELMO1/Dock180 
signaling module is required for spine morphogenesis in hippocampal neurons. The 
Journal of biological chemistry 2011, 286(43):37615-37624.
De Marco Garcia NV, Karayannis T, Fishell G: Neuronal activity is required for the 
development of specific cortical interneuron subtypes. Nature 2011, 472(7343):351-
355.
Prior M, Shi Q, Hu X, He W, Levey A, Yan R: RTN/Nogo in forming Alzheimer's 
neuritic plaques. Neuroscience and biobehavioral reviews 2010, 34(8):1201-1206.
Bandtlow CE, Schwab ME: NI-35/250/nogo-a: a neurite growth inhibitor restricting 
structural plasticity and regeneration of nerve fibers in the adult vertebrate CNS. Glia 
2000, 29(2):175-181.
Constancia M, Hemberger M, Hughes J, Dean W, Ferguson-Smith A, Fundele R, 
Stewart F, Kelsey G, Fowden A, Sibley C et al: Placental-specific IGF-II is a major 
modulator of placental and fetal growth. Nature 2002, 417(6892):945-948.
Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, Zhang H, Estes A, 
Brune CW, Bradfield JP et al: Autism genome-wide copy number variation reveals 
ubiquitin and neuronal genes. Nature 2009, 459(7246):569-573.
Pagnamenta AT, Bacchelli E, de Jonge MV, Mirza G, Scerri TS, Minopoli F, 
Chiocchetti A, Ludwig KU, Hoffmann P, Paracchini S et al: Characterization of a 
family with rare deletions in CNTNAP5 and DOCK4 suggests novel risk loci for 
autism and dyslexia. Biological psychiatry 2010, 68(4):320-328.
Gauthier J, Siddiqui TJ, Huashan P, Yokomaku D, Hamdan FF, Champagne N, 
Lapointe M, Spiegelman D, Noreau A, Lafreniere RG et al: Truncating mutations 
in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Human 
genetics 2011, 130(4):563-573.
Leblond CS, Heinrich J, Delorme R, Proepper C, Betancur C, Huguet G, Konyukh 
M, Chaste P, Ey E, Rastam M et al: Genetic and functional analyses of SHANK2 
mutations suggest a multiple hit model of autism spectrum disorders. PLoS genetics 
2012, 8(2):e1002521.
Sato D, Lionel AC, Leblond CS, Prasad A, Pinto D, Walker S, O'Connor I, Russell C, 
Drmic IE, Hamdan FF et al: SHANK1 Deletions in Males with Autism Spectrum 
Disorder. American journal of human genetics 2012.
van Abel D, Abdul-Hamid O, Dijk M, Oudejans CB: Transcription factor STOX1A 
promotes mitotic entry by binding to the CCNB1 promotor. PloS one 2012, 
7(1):e29769.
Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg 
SL, Wold BJ, Pachter L: Transcript assembly and quantification by RNA-Seq reveals 
unannotated transcripts and isoform switching during cell differentiation. Nature 
biotechnology 2010, 28(5):511-515.
Roberts A, Pimentel H, Trapnell C, Pachter L: Identification of novel transcripts 
in annotated genomes using RNA-Seq. Bioinformatics (Oxford, England) 2011, 
27(17):2325-2329.
Yang R, Muller C, Huynh V, Fung YK, Yee AS, Koeffler HP: Functions of cyclin 
A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb 
family of proteins. Molecular and cellular biology 1999, 19(3):2400-2407.
Chedotal A, Richards LJ: Wiring the brain: the biology of neuronal guidance. Cold 
Spring Harbor perspectives in biology 2010, 2(6):a001917.
Song W, Lahiri DK: Efficient transfection of DNA by mixing cells in suspension 
with calcium phosphate. Nucleic acids research 1995, 23(17):3609-3611.
Garber M, Grabherr MG, Guttman M, Trapnell C: Computational methods for 
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
6STOX1A induced transcriptome analysis · 6
124
transcriptome annotation and quantification using RNA-seq. Nature methods 2011, 
8(6):469-477.
Roberts A, Trapnell C, Donaghey J, Rinn JL, Pachter L: Improving RNA-Seq 
expression estimates by correcting for fragment bias. Genome biology 2011, 
12(3):R22.
50

7
Chapter 7
Summarizing Discussion
Directions for future research
7Summarizing Discussion · 7
128
Summarizing discussion
This thesis describes the exploration of STOX1A in neuronal transcriptional networks, 
a transcription factor previously shown to be associated with late onset Alzheimer’s 
disease (LOAD). Previous studies have shown that over-expression of STOX1A 
is already detected in early Braak stages i.e. prior to the full blown development of 
LOAD. This raises the possibility that STOX1A itself or its target genes can be 
used as potential targets for therapeutic intervention in LOAD. However, although 
preclinical studies in cell systems and animal models have already supported the 
concept of directly targeting transcription factors in diseases like cancer [1], these 
approaches currently remain not yet suitable for therapeutic use. Furthermore, 
such drugs would block widely-present signalling mechanisms where STOX1A is 
potentially involved in. Therefore, targeting STOX1A directly without knowing 
its normal neuronal function could have severe side effects. Alternatively, neuronal 
STOX1A up- or downstream signalling cascades could be modulated by drugs, and in 
the future can serve as potential targets for therapeutic drug design to treat diseases like 
LOAD. It is therefore essential to identify and clarify up- and downstream regulatory 
mechanisms for STOX1A in neuronal transcriptional signalling.  These mechanisms 
for STOX1A are still largely unknown. Therefore, in this thesis our primary goal was 
to identify such mechanisms and to find out how STOX1A is operating in neuronal 
transcriptional networks. This knowledge would be of great importance to give insight 
in how STOX1A operates in the normal brain but could also explain why STOX1A 
expression or function is deregulated or disrupted, respectively, in neurodegenerative 
diseases like LOAD. Furthermore, STOX1A itself or its target genes could also serve 
as potential biomarkers in LOAD provided they are detectable in spinal fluid and/or 
reflected in blood.
In this chapter our main findings are summarized and discussed. Furthermore, 
directions for future research are given.
In addition to the previously discovered STOX1A target genes leucine rich repeat 
transmembrane neuronal 3 (LRRTM3) and Alpha-T-Catenin (CTNNA3), our 
first study (Chapter 2) describes the discovery of several potential STOX1A target 
genes with the use of ChIP-cloning. In this study, potential STOX1A bound 
DNA fragments were immunoprecipitated, cloned, and subsequently sequenced. 
Corresponding genes linked to these sequenced fragments, e.g. Contactin-associated 
protein-like 2 (CNTNAP2), a cell-cell adhesion molecule that may play a role in the 
local differentiation of the axon into distinct functional subdomains [2, 3],  were 
determined. We found that expression of CNTNAP2 is directly and negatively 
regulated by STOX1A in neuronal SK-N-SH cells. Interestingly, we found that 
CNTNAP2 expression levels are decreased in the hippocampus of LOAD patients 
where STOX1A expression levels are increased. This suggests that expression of 
STOX1A and CNTNAP2 are inversely associated in the hippocampus of LOAD 
patients. 
CNTNAP2 has previously been shown to be linked to autism spectrum disorders 
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(ASD) but to our knowledge never with LOAD pathology. We therefore show for the 
first time that CNTNAP2 is also associated with another brain disorder, Alzheimer’s 
disease.  
In Chapter 3 we extended our search for STOX1A target genes by performing ChIP-
seq, a technique to discover fragments of DNA that bind to the experimental protein 
of interest on a genome wide scale. By applying this technique we discovered several 
potential STOX1A target genes. One target gene we validated, and found to be directly 
regulated by STOX1A, is serine/arginine-rich splicing factor 7 (SFRS7). While this 
study was performed in a neuronal cell model, we found that the transcriptional 
effect of STOX1A on SFRS7 was only occurring in glial cells. Therefore, the effect of 
STOX1A on SFRS7 was found to be cell type specific. 
SFRS7 itself also appears to operate in a cell type-dependent manner. While SFRS7 
has previously been shown to inhibit the splicing of tau at exon 10 in neuronal cells 
[4] we expected to find a similar effect in glial cells. However, STOX1A dependent 
transactivation of SFRS7 in glial cells resulted in an increase in tau exon 10 splicing. 
In concordance, we found that knockdown of SFRS7 in glial cells inhibits tau exon 
10 splicing. Therefore, our results suggest that SFRS7 acts as a tau exon 10 splicing 
enhancer in glial cells instead of a tau exon 10 splicing silencer in neuronal cells. 
Future perspectives of this finding are discussed below.
Besides the systematic search for STOX1A target genes with ChIP-cloning and 
Chip-seq, we also investigated a previously suggested role for STOX1A:  regulation 
of the cell-cycle. Chapter 4 describes the results of the direct interaction between 
STOX1A and the promoter region of the CCNB1 gene. CCNB1 is known as an 
important regulator of the G2/M phase transition of the cell cycle where CCNB1 
binds to CDK1 to form an active kinase necessary for proper G2/M phase progression 
[5]. The potential relationship between STOX1A, CCNB1, and G2/M phase cell 
cycle progression was therefore investigated. As the results show, the direct interaction 
between STOX1A and the CCNB1 promoter transactivated CCNB1 expression and, 
as hypothesised, resulted in enhanced progression of cells into mitosis. 
Although we primarily focussed on a functional relationship between CCNB1 and 
STOX1A, we also found additional cyclins to be differentially expressed. This indicates 
that STOX1A is important during other phases of the cell cycle as well. 
According to the “two hit hypothesis” a combination of both oxidative stress and cell 
cycle aberration may be necessary for a normal neuron to become a LOAD neuron. The 
aberrant neuronal cell cycle regulation is possibly one of the underlying mechanism 
that reflects hyper-phosphorylated tau proteins in neurofibrillary tangles (NFT) by 
over-activated cell cycle related kinases like CDK1 [6]. Because STOX1A is involved 
in regulation of the cell cycle (Chapter 4), we speculated there might be a correlation 
between STOX1A, the cell cycle, and tau phosphorylation. This was investigated in 
chapter 5. In this chapter we show that stable overexpression of STOX1A in neuronal 
SH-SY5Y cells is associated with hyper-phosphorylation of tau proteins at epitopes 
also found in NFT in LOAD. Furthermore, results show that hyper-phosphorylation 
of tau epitopes could in part be explained by the increase in CDK1 activity levels 
specifically induced by STOX1A in these cells. This is also consistent with the findings 
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of chapter 4, where we show that CCNB1, the activating binding partner of CDK1, 
is a direct target gene transactivated by STOX1A. 
In our final chapter (Chapter 6) we extended our search to unravel the functional 
role of STOX1A in neuronal transcriptional signalling using another genome-wide 
approach. Here, we sequenced (RNA-seq) and determined the entire transcriptome 
of neuronal SH-SY5Y cells that were stimulated with STOX1A recombinant protein. 
Although preliminary, these results show some new insights for a potential role for 
STOX1A in neuronal development e.g. an abundant amount in the top 10  of most 
significantly STOX1A differentially expressed genes and transcripts are involved in 
the neurodevelopmental processes neurite outgrowth and axon guidance signalling. 
Furthermore, canonical pathway analysis with STOX1A differentially expressed 
genes and transcripts resulted in significant enrichment in axon guidance signalling. 
These mechanisms have been found to be deregulated in the pathogenesis of autism 
spectrum disorder (ASD). Speculatively, these results, together with other related 
findings shown in this thesis (discusses below), imply a potential functional role for 
STOX1A in the etiology of ASD. 
We have also identified additional potential STOX1A target genes which may 
represent novel candidates for involvement in LOAD, and speculatively, in the future 
could serve as novel biomarkers. 
Directions for future research
CNTNAP2 and STOX1A 
The expression of STOX1A is already increased at early Braak stages during the 
development into LOAD. Secondly, we found that the direct STOX1A target gene 
CNTNAP2 is downregulated in LOAD, indicating that (besides STOX1A itself ) 
this gene might be used as a potential biomarker for the early diagnosis of LOAD. 
However, CNTNAP2 expression is significantly downregulated in the final stages 
(Braak 5/6) of the disease. Therefore, we first have to confirm that CNTNAP2 
expression is also changed at early Braak stages as was seen for STOX1A.
It would also be necessary to see if CNTNAP2 proteins can be detected in cerebrospinal 
fluid (CSF) or blood to serve as a biomarker. If this would be the case, a detection of 
decreased levels of CNTNAP2 in CSF or blood could be used to predict development 
into LOAD. 
As shown above, discovery of STOX1A target genes can be very helpful to understand 
underlying transcriptional changes in LOAD which can also potentially serve as novel 
biomarkers. Interestingly, STOX1A target genes themselves can also serve to predict 
potential roles for STOX1A in other pathologies. As discussed above, CNTNAP2 
has been found to be associated with ASD. This association is also found with other 
previously characterised STOX1A target genes i.e. polymorphisms in LRRTM3 
have recently been found to be associated with ASD susceptibility in populations of 
European ancestry [7]. Additionally, CTNNA3, has been suggested to be associated 
with ASD susceptibility [8]. Because CTNNA3, LRRTM3, and CNTNAP2 (Chapter 
2) are validated STOX1A target genes, this strongly suggests that STOX1A operates 
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upstream in pathways associated with ASD. This is furthermore supported by our 
genome-wide transcriptome analysis of STOX1A-induced differential expression. In 
this study (Chapter 6) we found several additional potential STOX1A target genes 
associated with ASD. A majority of these genes also operate in pathways associated 
with neuronal developmental processes, neurite outgrowth and/or axon guidance 
signalling. This suggests that STOX1A has a potential role in neuronal development.
In conclusion, besides the potential implication for the new STOX1A target gene 
CNTNAP2 as a novel biomarker for LOAD, it would be very interesting to further 
investigate the role of STOX1A in neuronal development and its implications in the 
etiology of ASD. 
STOX1A dependent transcription operates in a cell type specific manner 
Our findings show that STOX1A is unable to transactivate SFRS7 in neuronal cells. 
In contrast, we found that in glial cells STOX1A is capable of transactivating SFRS7 
Figure 1. A model for STOX1A which summarizes our findings described in this thesis. Together, as many STOX1A 
(un)validated target genes have functions in neuronal developmental processes we speculate a potential role for STOX1A 
in central nervous system (CNS) development. Hypothetically, in LOAD, active CCNB1/CDK1 phosphorylates inactive 
STOX1A at sites which prevent 14-3-3 molecules from binding to PI3K/AKT phosphorylation sites. STOX1A is then 
consequently transported into the nucleus where it can perform its transcriptional activity. The resulting transcription 
of CCNB1 by STOX1A results in an increase in active CCNB1/CDK1 which initiates a positive feedback loop. The 
resulting accumulating active CCNB1/CDK1 induces phosporylation of MAPT proteins resulting in NFT formation. 
Upstream mechanisms influence the expression of STOX1A. Chronic oxidative stress and for instance epigenetic changes 
in LOAD could possibly cause overexpression of STOX1A. PS1 mutations in familial alzheimer’s disease (FAD) results in 
inhibition of the PI3K/AKT pathway, speculatively this results in translocation of STOX1A to the nucleus. Stars indicate 
phosphorylation events.
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thereby changing 3R/4R tau ratios. Several tauopathies show deregulation of 3R-tau 
and 4R-tau isoform expression altering the 3R/4R tau ratio (increased splicing of 
tau exon 10 results in more 4R-tau). Corticobasal degeneration and progressive 
supranuclear palsy (PSP) show mainly 4R-tau pathology [9] which occurs not only in 
neurons but also in astrocytes, a type of glial cells [10]. The clinical significance of tau 
accumulation in astrocytes is not clear but a recent study indicated that in a transgenic 
mouse model of specific astrocytic tau pathology there was mild blood-brain barrier 
disruption, induction of low-molecular-weight heat shock proteins, and focal neuron 
degeneration [11]. It would therefore be very interesting to investigate if STOX1A 
and SFRS7 are associated with astrocytic 4R-tau pathology. 
We found cell type-specific effects of STOX1A on SFRS7 expression, suggesting that 
other factors can influence the transcriptional activation of STOX1A on SFRS7 in 
a cell type-specific manner. These factors could for instance be co-activators which, 
in complex with STOX1A, are capable of activating transcription at the SFRS7 
promoter in glial cells but are absent in neuronal cells. Another possibility would be 
that in neuronal cells co-repressors bind to STOX1A thereby inhibiting transcription 
at the SFRS7 promoter. Gaining knowledge regarding the potential co-factors which 
are bound to STOX1A in neurons and glial cells will help explain the cell type-specific 
transactivation of SFRS7. These co-factors could also suppress or activate STOX1A 
dependent transcription of other genes and are therefore crucial in understanding 
STOX1A gene regulation. In the future they might also be of great therapeutic 
relevance as they can modulate the transcriptional activity of STOX1A. For instance, 
inhibitors targeting STOX1A co-factors could block gene expression of genes like 
LRRTM3, thereby altering the production of Aβ. Further exploration of these co-
factor associated mechanisms would therefore be of great significance.
A potential role for STOX1A in neuronal development 
In vitro results described in this thesis show that STOX1A is involved in the regulation 
of the cell cycle and regulates genes shown to be important in neuronal differentiation 
and development, like MAPT and CNTNAP2. Similar functions have been found 
for several FOX transcription factors which are key players in CNS development; for 
example, FOXG1 regulates proliferation and differentiation of neuronal progenitor 
cells of the telencephalon [12]. 
Although care has to be taken interpreting our in vitro results into an actual in vivo 
situation, our results might suggest that STOX1A also has an important function 
in CNS development. To reveal such association, primary neuronal cell-lines could 
serve as models to further explore the functional relevance of STOX1A during CNS 
development. These can be primary cultures of mouse hippocampus and cerebral 
cortex, which are widely used model systems for molecular and cell biological studies 
of neuronal development and function. Ideally, STOX1A transgenic or knockout mice 
would be perfect models to study neuronal developmental roles for STOX1A. 
STOX1A and upstream mechanisms in LOAD 
Our results have given new insight in the functional roles of STOX1A in neuronal 
signalling. However, important questions that remain are; why and how is STOX1A 
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expression deregulated in LOAD? In view of the “two hit hypothesis” it is speculated 
that the two main causal factors for LOAD are a combination of oxidative stress and 
cell cycle aberration [6]. Both could also be potential inducers of STOX1A expression 
and/or activity. For example, oxidative stress has been shown to be capable of inducing 
the expression of transcription factor SP1 [13] and thereby results in the expression of 
several AD-related proteins [14]. STOX1A expression could be induced in a similar 
way. Therefore, investigating STOX1A expression or activity in response to oxidative 
stress could reveal such upstream mechanisms. 
The cell cycle itself, specifically active CDK1, might also induce STOX1A activity. 
STOX1A can potentially be phosphorylated by CDK1 in a cell cycle dependent 
manner, a mechanism that has been shown to operate upstream of several forkhead 
transcription factors including FOXM1  [15], FOXO1 [16],  and FOXK2 [17]. For 
these it has been shown that phosphorylation of residues by active CDK1,  takes place 
near residues phosphorylated by the PI3K/AKT pathway. The residues phosphorylated 
by active CDK1 may cause conformational changes, which inhibit 14-3-3 proteins 
from interacting with resdiues phosphorylated by PI3K/AKT pathway. When 14-3-3 
proteins are bound to residues phosphorylated by PI3K/AKT pathway they prevent 
forkhead transcription factors from entering the nucleus thereby inhibiting their 
transcriptional activity. In contrast, CDK1 phosphorylation therefore leads to more 
nuclear localization of the transcription factors thereby increasing their transcriptional 
activity.  
Software tools, which can predict post-translational modifications, might reveal 
CDK1 target sites on STOX1A, and together with mutagenesis applied on these 
potential specific CDK1 residues in the STOX1A sequence could mimic CDK1 
phosphorylation. The functional effect can be investigated which would reveal the 
potential upstream regulatory effect of CDK1 on STOX1A activity.
Together, oxidative stress and cell cycle aberrations (like abundantly active CDK1), 
which appear very early in the disease progression of LOAD and precede formation 
of Aβ and NFT’s [18], could be responsible for abnormally induced expression and 
activity of transcription factors like STOX1A. In this scenario, overexpression and 
overactivated STOX1A subsequently leads to induced expression of cell cycle genes 
like CCNB1. CCNB1 can then associate with CDK1 forming an active kinase capable 
of further phosphorylating STOX1A, thus activating STOX1A in a positive feedback 
loop. 
Accumulation of cell cycle kinases can furthermore hyperphosphorylate tau proteins 
to form NFT until the cell eventually succeeds in apoptosis by mechanisms explained 
by the “two hit hypothesis”.
Secondly, the resulting overexpression and/or overactivity of STOX1A could suppress 
or induce expression of CNTNAP2 and LRRTM3, respectively. Suppression of 
CNTNAP2 by STOX1A, as shown in chapter 2, could potentially disrupt local 
differentiation of axons into distinct functional subdomains and therefore aggravate 
neurodegeneration. Transactivation of LRRTM3 by STOX1A contributes to 
abnormal production of Aβ.
Other upstream regulatory mechanisms most likely exist as well. One of the 
mechanisms which certainly operates upstream of STOX1A is the PI3K/AKT 
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pathway [19]. Phosphorylation of STOX1A by the PI3K/AKT pathway inhibits its 
activity by translocation to the cytoplasm. In LOAD it has been found that AKT 
activity is decreased [20], which could explain higher activity (nuclear expression) of 
STOX1A in LOAD. 
With the latter notion, STOX1A could also be important in early-onset familial 
Alzheimer’s disease (FAD). It has been shown that wild-type PS1 acts upstream in 
the regulation of the PI3K/AKT pathway. Mutations in PS1 as found in FAD cause 
an impairment in its ability to phosphorylate AKT and thereby inhibiting the PI3K/
AKT pathway [21]. Speculatively, this suggests that reduced activity of the PI3K/AKT 
by PS1 mutations in FAD can consequently cause an over-activity of transcription 
factors which are regulated by the PI3K/AKT pathway, as shown for STOX1A. 
Therefore it would be very interesting to test if STOX1A is also deregulated in FAD 
and whether PS1 mutations in a cellular or mouse model can cause an effect on the 
activity levels of STOX1A through reduced activity of PI3K/AKT. 
A consensus binding site for STOX1A
When STOX1A is located in the nucleus it can perform its transcriptional activity 
through specific binding to DNA elements which in turn regulates transcription of 
nearby genes. Unfortunately, no such DNA binding consensus sequence has been 
discovered for STOX1A. One of the goals of our ChIP-seq study was to identify 
a DNA binding consensus sequence for STOX1A. With the use of our predicted 
STOX1A binding sequences from our ChIP-seq study we uploaded these sequences 
into the bioinformatics tool MEMECHIP [22] which predicted several potential 
binding motifs. However, changes in the number of input sequences seemed to 
strongly affect the outcome of these results. Possibly, the input sequences included 
false positive sequences which influenced the outcomes. Therefore, another approach 
is needed. One possibility would be to validate potential STOX1A binding sites 
by quantitative PCR and then use these validated binding site sequences for motif 
analysis. This would exclude false positive sequences which greatly increases reliability 
in the motif analysis. Furthermore, additional ChIP-seq experiments would reveal 
binding sites that overlap between individual ChIP-seq experiments and therefore 
have a greater reliability to identify true STOX1A binding sites.
Concluding remarks
This thesis describes the functional exploration of the transcription factor STOX1A 
in neuronal signalling. As we have shown, discovery of STOX1A target genes can be 
useful to reveal underlying mechanisms operating in LOAD which are not previously 
described in literature, such as CNTNAP2 (Chapter 2). Other STOX1A target 
genes identified by our genome-wide approaches might result in similar findings. 
STOX1A is therefore an interesting protein, which target genes might be used for 
future therapeutic drug design. Furthermore, its target genes can potentially serve as 
novel  biomarkers in LOAD.
Secondly, we have shown that the discovery of STOX1A target genes and their 
associated transcriptional networks suggest the possible implication of STOX1A in 
other diseases, e.g.  glial tau pathologies (Chapter 3) and  ASD (Chapter 2 and 6). 
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In conclusion, the results presented in this thesis elucidate the emerging biological 
roles of STOX1A in neuronal signalling and its importance in the development of 
neurological diseases. 
Finally, the findings and hypothesized mechanisms which are presented in this thesis 
are summarized in figure 1.
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Nederlandse Samenvatting
De rol van transcriptiefactor STOX1A in neurodegeneratieve transcriptionele 
netwerken.
Dit proefschrift beschrijft de exploratie van STOX1A, een transcriptiefactor die 
geassocieerd is met Late Onset Alzheimer Disease (LOAD). LOAD is de meest 
voorkomende vorm van de ziekte van Alzheimer en uit zich na de leeftijd van 65 jaar. 
De ziekte van Alzheimer is de meest voorkomende vorm van dementie en kenmerkt 
zich door een algemene achteruitgang in cognitieve functies zoals geheugen en spraak. 
Pathologisch wordt LOAD gekenmerkt door de zogenaamde plaques bestaande uit 
het amyloid-β (Aβ) eiwit, en de neurofibrillaire “tangles” (NFT). Excessieve ophoping 
van deze eiwitten in de hersenen resulteert onder andere in afsterving van neuronen 
(zenuwcellen). 
Transcriptiefactoren zoals STOX1A zijn in staat specifiek aan bepaalde stukken 
DNA te binden en kunnen daardoor over het algemeen vele doelwitgenen reguleren. 
Transcriptiefactoren zullen deze fragmenten op een specifieke manier binden en 
daardoor in staat zijn de expressie (uiteindelijke vorming van een eiwit) van hun 
doelwitgenen te reguleren. Het vinden van deze specifieke stukken DNA is dus 
belangrijk om inzicht te krijgen over de doelwitgenen die STOX1A reguleert. 
Transcriptiefactoren zijn door deze eigenschap per definitie betrokken bij belangrijke 
cellulaire processen. De doelwitgenen en bijbehorende cellulaire processen zijn 
voor STOX1A grotendeels onbekend. Echter, eerdere studies hebben aangetoond 
dat STOX1A het Leucine Rich Repeat Transmembrane Neuronal 3 (LRRTM3) 
doelwitgen aanstuurt in neuronale cellen (cellen representatief voor zenuwcellen) 
en via verhoging van het LRRTM3 eiwit indirect bijdraagt aan de productie en 
vorming van het Aβ eiwit. Verder toont deze studie ook aan dat verhoogde expressie 
van transcriptiefactor STOX1A zelf al te ontdekken is in de eerste stadia van de 
ziekte, dat wil zeggen vóór de volledige ontwikkelde vorm van LOAD. STOX1A 
is dus aangetoond betrokken te zijn in het ziekteproces van LOAD. Hierdoor is 
het in de toekomst potentieel mogelijk om STOX1A als therapeutisch doelwit te 
gebruiken voor therapeutische interventie in LOAD. Het gebruik van STOX1A 
als aangrijppunt voor therapeutische interventie zal vanwege zijn brede actieradius 
op zijn vele doelwitgenen lastig zijn. Dergelijke drugs zouden bijvoorbeeld op grote 
schaal belangrijke neuronale signaalroutes, waar STOX1A een normale functie in zou 
kunnen hebben, blokkeren. Andere mogelijkheden behoren tot mechanismen die op 
een hoger niveau (upstream) in de signaalroutes van STOX1A liggen. Deze kunnen 
potentieel door drugs gemoduleerd worden en daarmee op een regulerende manier de 
activiteit en/of expressie van STOX1A beïnvloeden. Dit zou dan een indirect gevolg 
hebben op expressie van zijn doelwitgenen. Een andere optie zou zijn om STOX1A 
doelwitgenen zelf (downstream) als drug target te gebruiken. Naast potentiële 
therapeutische interventie kunnen STOX1A doelwitgenen ook dienen als potentiële 
biomarkers voor diagnose in LOAD mits ze aantoonbaar zijn in het ruggenmerg 
vocht en / of in bloed. 
Het is daarom van essentieel belang om deze up- en downstream mechanismen 
te identificeren maar ook hun fundamentele werking in neuronale signaalroutes te 
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verkennen. Dit proefschrift had het primaire doel om dergelijke mechanismen te 
identificeren en uit te zoeken hoe STOX1A werkt in neuronale signaalroutes. Deze 
kennis is van groot belang om zo inzicht te geven in de manier waarop STOX1A 
werkt in de normale hersenen, maar geeft ook informatie over waarom de functie van 
STOX1A verstoord is in neurodegeneratieve ziekten zoals LOAD.
In aanvulling op de eerder ontdekte STOX1A doelwitgenen LRRTM3 en Alpha-T-
catenine (CTNNA3), beschrijft de eerste studie (hoofdstuk 2) de ontdekking van een 
reeks nieuwe STOX1A doelwitgenen. Hierbij is Contactin Associated Protein Like 
2 (CNTNAP2) bevestigd als een nieuw STOX1A doelwitgen. CNTNAP2 is een gen 
dat een eiwit tot expressie brengt dat mogelijk een rol speelt bij de lokalisatie van 
kaliumkanalen binnen differentiërende axonen. Axonen zijn uitlopers van zenuwcellen 
en belangrijk voor de overdracht van elektrische impulsen. Deze studie bewijst dat 
STOX1A in de neuronale cellijn SK-N-SH, direct bindt aan een DNA fragment dat 
de expressie van het CNTNAP2 eiwit negatief beïnvloedt.
Interessant is dat de CNTNAP2 expressie niveaus zijn verminderd in de hippocampus 
van LOAD patiënten waar STOX1A expressie verhoogd is. Dit suggereert dat de 
expressie van STOX1A en CNTNAP2 omgekeerd geassocieerd zijn in de hippocampus 
van LOAD patiënten. Studies hebben aangetoond dat CNTNAP2 geassocieerd 
is met stoornissen in het autisme spectrum (ASD), maar zover bekend nog nooit 
met LOAD. Deze studie laat daarom voor de eerste keer zien dat CNTNAP2 ook 
geassocieerd is met een andere stoornis in de hersenen, de ziekte van Alzheimer. 
In hoofdstuk 3 is de zoektocht naar STOX1A doelwitgenen uitgebreid door met 
behulp van de techniek ChIP-seq op grote schaal (verspreid over het gehele genoom) 
DNA-fragmenten te identificeren die potentieel aan STOX1A gebonden zijn. 
Door het toepassen van deze techniek zijn meerdere potentiële STOX1A doelwitgenen 
ontdekt. Een van deze doelwitgenen is in onze studie bevestigd en in detail onderzocht. 
Onze resultaten laten daarbij zien dat het desbetreffende doelwitgen, serine / arginine-
rich splicing factor 7 (SFRS7), positief word gereguleerd door STOX1A. Verder laten 
de resultaten zien dat dit effect alleen plaatsvindt in een bepaald type cel. Het effect 
van STOX1A op SFRS7 bleek daarbij dus celtype specifiek te zijn. 
Studies hebben aangetoond dat SFRS7 in staat is om de vorming van het zogenaamde 
tau eiwit te beïnvloeden door middel van een proces dat splicing heet. Eenvoudig 
gezegd kunnen door middel van splicing uit hetzelfde tau gen verschillende vormen 
van het tau eiwit geproduceerd worden die ook verschillen in eigenschappen. De eerder 
genoemde NFT vormen, kenmerkend voor de ziekte van Alzheimer (maar ook andere 
vormen van dementie) bestaan voornamelijk uit abnormaal gefosforyleerd tau eiwit 
(zie ook later in de tekst). Veranderingen in tau splicing spelen hierbij mogelijk een 
belangrijke rol. Bepaalde vormen van het tau eiwit kunnen door abnormale splicing 
in grotere hoeveelheid aanwezig zijn dan normaal en daardoor vatbaar worden voor 
fosforylatie. Dit zal als gevolg hebben dat er NFT gevormd kunnen worden. Onze 
bevindingen laten dus zien dat STOX1A door middel van het reguleren van SFRS7, 
met daarbij een indirect effect op tau splicing, een belangrijke functie heeft bij de 
vorming van NFT. 
Naast het systematisch zoeken naar STOX1A doelwitgenen hebben we ook 
onderzocht of STOX1A betrokken is bij een eerder gesuggereerde functionele rol. 
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Het ging hierbij om een mogelijke functie voor STOX1A in het regelen van celdeling. 
Deze suggestie is bevestigd in Hoofdstuk 4. De studie in hoofdstuk 4 beschrijft 
de directe en positieve regulatie van STOX1A op een gen betrokken bij celdeling. 
Dit gen, Cyclin B1 (CCNB1) is een regulator van de zogenaamde G2 / Mitose fase-
overgang belangrijk voor een normale celcyclus. De mogelijke relatie tussen STOX1A, 
CCNB1 en de G2 / Mitose fase-overgang zijn daarom in detail onderzocht. Zoals 
verondersteld zorgt STOX1A, door middel van positieve regulatie van het CCNB1 
gen, voor een versnelde overgang van de G2 naar de Mitose fase. Resultaten laten 
bovendien ook zien dat STOX1A betrokken is bij de regulatie van andere doelwitgenen 
die belangrijk zijn voor een juiste celdeling. Deze resultaten geven daarom voor het 
eerst aan dat STOX1A een belangrijke functie heeft in de regulatie van de celcyclus 
(celdeling). 
In de afgelopen jaren wordt het steeds duidelijker dat celcyclus gerelateerde processen 
een belangrijke rol spelen in de vroege ontwikkeling van LOAD. Zoals hierboven al 
beschreven is abnormaal gefosforyleerd tau eiwit het belangrijkste bestandsdeel van 
NFT. Dit wil zeggen dat er bepaalde chemische groepen in een buitengewoon grote 
hoeveelheid op het tau eiwit zijn “vastgemaakt”. Onder normale omstandigheden 
heeft tau een belangrijke rol in de stabilisatie en flexibiliteit van het “skelet” van 
zenuwcellen. De netwerken bestaande uit dit “skelet” hebben daarnaast onder andere 
de functie om voedingstoffen te vervoeren naar plaatsen waar dat in de zenuwcel 
nodig is. Abnormaal gefosforyleerd tau eitwit belemmert deze normale functies en 
kan bovendien de vorming van NFT bewerkstelligen. Uiteindelijk zal dit de dood van 
de zenuwcel tot gevolg hebben. Verschillende studies suggereren dat een afwijkende 
neuronale celcyclus in LOAD een onderliggend mechanisme is dat bijdraagt aan de 
abnormale fosforylatie van het tau eitwit en daarbij gezien wordt als een belangrijke 
oorzaak voor de vorming van NFT in LOAD. Omdat STOX1A betrokken is bij 
de regulatie van de celcyclus (hoofdstuk 4), speculeerden wij dat er misschien een 
relatie bestaat tussen STOX1A, de celcyclus en tau fosforylatie. Dit is onderzocht 
in hoofdstuk 5. In hoofdstuk 5 laten we zien dat STOX1A expressie geassocieerd is 
met de abnormale fosforylatie van tau-eiwitten op plekken zoals die ook gevonden 
worden in NFT in LOAD. Bovendien suggereren onze resultaten dat dit komt door 
een toename in de activiteit van het cyclin dependent kinase 1 (CDK1), een ander 
belangrijk eiwit dat betrokken is bij de G2 / Mitose fase-overgang tijdens de celcyclus 
(zie hierboven). Onze resultaten laten zien dat CDK1 activiteit hoger is in cellen 
die gestimuleerd worden door STOX1A eiwit. Recente studies hebben eerder al 
bevestigd dat CDK1 in staat is tau te fosforyleren. Bovendien is CDK1 in verhoogde 
hoeveelheid aangetoond in de hersenen van LOAD patiënten. Samen suggereren de 
resultaten uit hoofdstuk 4 en 5 daarom dat er een relatie bestaat tussen STOX1A, 
regulatie van de celcyclus en vorming van NFT in LOAD. STOX1A is dus, zoals 
we eerder hebben aangetoond, niet alleen betrokken bij de vorming van het Aβ eiwit, 
maar ook betrokken bij de vorming van NFT. 
In ons laatste hoofdstuk (hoofdstuk 6) zijn we een verdere zoektocht gestart om meer 
duidelijkheid te krijgen over een algemene functionele rol voor STOX1A expressie 
in zenuwcellen. Hierbij hebben we een relatief nieuwe techniek (RNA-seq) gebruikt 
die het mogelijk maakt om de totale verzameling van alle zogenoemde messenger 
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RNA-moleculen (en hun hoeveelheid), die op dat moment onder een bepaalde 
experimentele conditie in een cel aanwezig zijn, te visualiseren en te meten. Messenger 
RNA-moleculen zijn in staat een gen te vertalen naar een eiwit. Met andere woorden, 
de totale verzameling van deze messenger RNA-moleculen weerspiegelt het aantal 
en de hoeveelheid eiwitten die op dat moment aanwezig zijn in de cel onder een 
bepaalde experimentele conditie. Deze verzameling (clustering) van messenger 
RNA-moleculen kan een bepaald patroon weergeven dat gerelateerd kan zijn aan 
een specifieke biologische functie. Door stimulatie van STOX1A in neuronale cellen 
en het toepassen van de bovenstaande techniek, laten voorlopige resultaten nieuwe 
inzichten voor een mogelijke rol voor STOX1A in de ontwikkeling van zenuwcellen 
zien. 
Conclusie
Samenvattend laten de resultaten beschreven in dit proefschrift belangrijke nieuwe 
inzichten zien in de neuronale signaalroutes die STOX1A reguleert. Hierbij hebben 
we ook laten zien dat STOX1A niet alleen betrokken is bij de vorming van het Aβ 
eiwit, maar ook potentieel betrokken is bij de vorming van NFT. Beide zijn belangrijke 
pathologische kenmerken die zich uiten in LOAD. Doordat STOX1A expressie al 
aangetoond kan worden in mensen waar nog geen dementie is geconstateerd maakt 
dit het in de toekomst wellicht mogelijk om therapeutisch in te grijpen in STOX1A 
geassocieerde signaalroutes die beschreven zijn in dit proefschrift. 
Concluderend, het is zeer belangrijk om de werking van STOX1A in neuronale 
signaalroutes te verhelderen vanwege de rol van STOX1A in neurologische 
ziektebeelden.
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